MXPA98005611A - Compositions and methods for the treatment and diagnosis of m cancer - Google Patents

Abstract

Compositions and methods for the detection and therapy of breast cancer are described. Compounds provided include nucleotide sequences that are preferentially expressed in breast tumor tissue, as well as polypeptides encoded by said nucleotide sequences. Vaccines and pharmaceutical compositions comprising said compounds are also provided and may be used, for example, for the prevention and treatment of breast cancer. The polypeptides can also be used for the production of antibodies, which are useful for diagnosing and monitoring the progression of breast cancer in a patient.

Description

COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF BREAST CANCER Technical Field The present invention relates generally to the detection and therapy of breast cancer. The invention relates more specifically to nucleotide sequences that are preferentially expressed in breast tumor tissue and to polypeptides encoded by said nucleotide sequences. The nucleotide and polypeptide sequences can be used in vaccines and pharmaceutical compositions for the prevention and treatment of breast cancer. The polypeptides can also be used for the production of compounds, such as antibodies, useful for the diagnosis and monitoring of the progression of breast cancer in a patient. Background of the Invention Breast cancer is a significant health problem for women in the United States and throughout the world. Although advances have been made in the detection and treatment of the disease, breast cancer remains the second leading cause of cancer-related deaths in women, affecting more than 180,000 women in the United States each year. For women in North America, the chances in their lifetime of contracting breast cancer is now one in eight. Currently there is no vaccine or other universally successful method available for the prevention or treatment of breast cancer. The management of the disease is currently based on a combination of early diagnosis (through routine breast screening procedures) and aggressive treatment, which may include one or more of a variety of treatments such as surgery, radiotherapy, chemotherapy, and therapy. hormones The course of treatment for a particular breast cancer is often selected based on a variety of diagnostic parameters, including an analysis of specific tumor markers. See, for example, Porter-Jordan and Lippman, Breast Cancer 8: 73-100 (1994).

However, the use of established markers often leads to a result that is difficult to interpret and the high mortality observed in patients with breast cancer indicates that improvements are necessary in the treatment, diagnosis and prevention of the disease. 15 Consequently, there is a need in the matter of # Improved methods for therapy and diagnosis of breast cancer. The present invention meets these needs and also provides other related advantages. SUMMARY OF THE INVENTION In summary, the present invention provides compositions and methods for the diagnosis and therapy of breast cancer. In one aspect, isolated DNA molecules are provided, comprising (a) a nucleotide sequence preferentially expressed in breast cancer tissue, relative to normal tissue; (b) a variant of said sequence containing one or more substitutions, deletions, insertions and / or modifications of nucleotides in no more than 20% (preferably not more than 5%) of the nucleotide positions, so that the antigenic and / or immunogenic properties of the polypeptide encoded by the nucleotide sequence are retained; or (c) a nucleotide sequence encoding an epitope of a polypeptide encoded by at least one of the above sequences. In one embodiment, the isolated DNA molecule comprises a human endogenous retroviral sequence as recited in SEQ ID NO: 1. In other embodiments, the isolated DNA molecule comprises a nucleotide sequence recited in any of SEQ ID NO: 3-SEQ ID NO: 77 or SEQ ID NOS: 142, 143, 146-152, 154-166, 168-176, 178-192, 1994-198, 200-204, 206, 207. 209-214, 216, 218, 219, 221-227. In related embodiments, the isolated DNA molecule encodes an epitope of a polypeptide, wherein the polypeptide is encoded by a nucleotide sequence which: (a) hybridizes to a sequence recited in one of SEQ ID NO: 1 or SEQ ID NO: 3 - SEQ ID NO: 77 or SEQ ID NOS .: 142, 143, 146-152, 154-166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216 , 218, 219, 221-227 under strict conditions; and (b) at least 80% identical to a sequence recited in either SEQ ID NO: 1 or SEQ ID NO: 3 -SEC ID NO: 77 or SEQ ID NOS: 142, 143, 146-152, 154- 166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-227; and wherein RNA corresponding to said nucleotide sequence is expressed at a higher level in human breast tumor tissue in normal breast tissue. In another embodiment, the present invention provides an isolated DNA molecule encoding an epitope of a polypeptide, the polypeptide being encoded by (a) a nucleotide sequence transcribed from SEQ ID NO: 141; or (b) a variant of said nucleotide sequence containing one or more substitutions, deletions, insertions and / or nucleotide modifications in no more than 20% of the nucleotide positions, so as to retain the antigenic properties and / or immunogenic of the polypeptide encoded by the nucleotide sequence. Isolated DNA and RNA molecules comprising a nucleotide sequence complementary to a DNA molecule as described above are also provided. In related aspects, the present invention provides recombinant expression vectors comprising a DNA molecule as described above and host cells transformed or transfected with said expression vectors. In additional aspects, polypeptides are provided which comprise an amino acid sequence encoded by a DNA molecule as described above and monoclonal antibodies that bind to said polypeptides. In yet another aspect, methods are provided to determine the presence of breast cancer in a patient. In one embodiment, the method comprises detecting in a biological sample, a polypeptide as described above. In another embodiment, the method comprises detecting, within a biological sample, an RNA molecule encoding a polypeptide as described above. In yet another embodiment, the method comprises (a) injecting intradermally a patient, a polypeptide as described above; and (b) detecting an immune response in the patient's skin and thus detecting the presence of breast cancer in the patient. In additional embodiments, the present invention provides methods for determining the presence of breast cancer in a patient as described above wherein the polypeptide is encoded by a nucleotide sequence selected from the group consisting of SEC I D NO. : 78-86, SEC I D NOS: 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220 and sequences that hybridize to it under strict conditions. In a related aspect, useful diagnostic equipment is provided for the determination of breast cancer. Diagnostic kits generally comprise one or more monoclonal antibodies as described above, or one or more monoclonal antibodies that bind to a polypeptide encoded by a nucleotide sequence selected from the group consisting of sequences provided in SEQ ID NOS: 78-86. and SEQ ID NOS: 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220 and a detection reagent. Within a related aspect, the diagnostic kit comprises a first polymerase chain reaction primer and a second polymerase chain reaction primer, the first and second primers each comprising at least about 10 contiguous nucleotides of a molecule of DNA as described above, or an RNA molecule encoding a polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NOS: 78-86 and SEQ ID NOS: 144, 145, 153, 167, 177, 193 , 199, 205, 199, 205, 208, 215, 217, 220. Within another related aspect, the diagnostic kit comprises at least one oligonucleotide probe, the probe comprising at least about 1 5 contiguous nucleotides of a molecule of DNA as described above, or a DNA molecule selected from the group consisting of SEQ ID NOS: 78-86 and SEQ ID NOS: 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220. In Another related aspect, the present invention provides methods for monitoring the progression of breast cancer in a patient. In one embodiment, the method comprises: (a) detecting an amount, in a biological sample, of a polypeptide as described above at a first point in time; (b) repeating step (a) at a subsequent point in time; and (c) comparing the amounts of polypeptides detected in steps (a) and (b) and of the same monitor the progression of breast cancer in the patient. In another embodiment, the method comprises (a) detecting an amount, within a biological sample, of an AR N molecule that encodes a polypeptide as described above at a first point in time, (b) repeating the step (a ) at a subsequent point in time; and (c) comparing the amounts of RNA molecules detected in steps (a) and (b) and from them monitoring the progression of breast cancer in the patient. In still other embodiments, the present invention provides methods for monitoring the progression of breast cancer in a patient, as described above wherein the polypeptide is encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78 -86, SEQ ID NOS: 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220 and sequences that hybridize thereto under strict conditions. In yet other aspects, pharmaceutical compositions are provided comprising a polypeptide as described above in combination with a physiologically acceptable carrier and vaccines, comprising a polypeptide as described above in combination with an enhancer or immune response helper. In still other aspects, the present invention provides pharmaceutical compositions and vaccines comprising a polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86, SEQ ID NOS: 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220 and sequences that hybridize thereto under stringent conditions. In related aspects, the present invention provides methods for inhibiting the development of breast cancer in a patient, comprising administering to a patient a pharmaceutical composition or vaccine as described above.

These and other aspects of the present invention will be apparent by reference to the following detailed description and accompanying drawings. All references described herein are incorporated herein by reference in their entirety as if each were incorporated individually. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 shows the differentially spread PCR products, separated by gel electrophoresis, obtained from cDNA prepared from normal breast tissue (lines 1 and 2) and from cDNA prepared from breast tumor tissue thereof. patient (lines 3 and 4) . The arrow indicates the band corresponding to B18Ag 1. Figure 2 is one of Northern blots comparing the level of B18Ag1 mRNA in breast tumor tissue (line 1) with the level in normal tissue. Figure 3 shows the mRNA level of B18Ag 1 in breast tumor tissue compared to that of several normal and non-breast tumor tissues as determined by the RNase protection analysis. Figure 4 is a genomic clone map showing the location of additional retroviral sequences obtained from the ends of Xbal constraints and restrictions (provided in SEC i D NO: 3 - SEC I D NO: 10) in relation to B 18Ag 1. Figures 5A and 5B show sequencing strategy, genomic organization and open reading frame provided for the retroviral element containing B 18Ag1.

% Figure 6 shows the nucleotide sequence of B18Ag1 of cDNA specific for representative breast tumor. Figure 7 shows the nucleotide sequence of B17Ag 1 of cDNA specific for representative breast tumor. Figure 8 shows the nucleotide sequence of B17Ag2 of cDNA specific for representative breast tumor. Figure 9 shows the nucleotide sequence of B13Ag2a * ^ ff cDNA specific for representative breast tumor. Figure 10 shows the nucleotide sequence of B13Ag 1 b 10 of cDNA specific for representative breast tumor. Figure 11 shows the nucleotide sequence of B 13Ag 1 a cDNA specific for breast tumor representative. Figure 12 shows the nucleotide sequence of B1 1 Ag 1 of cDNA specific for representative breast tumor. 15 Figure 13 shows the nucleotide sequence of B3CA3c 4 cDNA specific for representative breast tumor. Figure 14 shows the nucleotide sequence of representative B9CG 1 cDNA for breast tumor. Figure 15 shows the nucleotide sequence of representative B9CG3 20 cDNA for breast tumor. Figure 16 shows the nucleotide sequence of B2CA2 of representative breast tumor-specific cDNA. Figure 17 shows the nucleotide sequence of representative B3CA 1 cDNA for breast tumor.

% Figure 18 shows the nucleotide sequence of B3CA2 of cDNA specific for representative breast tumor. Figure 19 shows the nucleotide sequence of B3CA3 of representative breast tumor-specific cDNA. Figure 20 shows the nucleotide sequence of B4CA1 of cDNA specific for representative breast tumor. Figure 21A, describes PCR-TI analysis of breast tumor W genes in breast tumor tissues (lines 1-8) and normal breast tissues (9-13) and H20 (line 14). Figure 21B, describes RT-PCR analysis of breast tumor genes in prostate tumors (lines 1, 2), colon tumors (line 3), lung tumor (line 4), normal prostate (line 5), normal colon (line 6), normal kidney (line 7), normal liver (line 8), normal lung (line 9), normal ovary (lines 10, 18), pancreas 15 normal (lines 11, 12), normal skeletal muscle (line 13), skin * normal (line 14), normal stomach (line 15), normal testicles (line 16), normal small bowel (line 17), HBL-100 (line 19). MCF-12A (line 20), breast tumors (lines 21-23), H20 (line 24) and colon tumor (line 25). Detailed Description of the Invention As noted above, the present invention is generally directed to compositions and methods for the diagnosis, monitoring and therapy of breast cancer. The compositions described herein, include polypeptides, nucleic acid sequences and antibodies. The polypeptides of the present invention generally comprise at least a portion of a protein that is expressed at a higher level in human breast tumor tissue than in normal tumor tissue (i.e., the level of RNA encoding the polypeptide is at least 2 times higher in tumor tissue). Said polypeptides are referred to herein as polypeptides specific for breast tumor and the cDNA molecules encoding said polypeptides are referred to herein as cDNAs specific for breast tumor. The nucleic acid sequences of the present invention generally comprise a A DNA or RNA sequence that encodes an entire portion of a polypeptide as described above, or that is complementary to said sequence. Antibodies are generally proteins of the immune system, or fragments thereof, which are capable of binding to a portion of a polypeptide as described above. The Antibodies can be produced by cell culture techniques, including the generation of monoclonal antibodies as described herein, or via transfection of antibody genes in suitable bacteria or mammalian host cells, in order to allow the production of recombinant antibodies. Polypeptides within the scope of this invention include, but are not limited to, polypeptides (and epitopes thereof) encoded by a human endogenous retroviral sequence, such as the sequence designated B18AG1 (Figure 5 and SEQ ID NO: 1). Also within the scope of the present invention are polypeptides encoded by other sequences within the retroviral genome containing B18Ag1 (SEQ ID NO: 141). Such sequences include, but are not limited to, the sequences recited in SEQ ID NO: 3 -SEC ID NO: 10. B18Ag1 has homology to the gag p30 gene of the endogenous retroviral element S71, as described in Werner et al., Virology 1744 : 225-238 (1990) and also shows homology to approximately thirty with approximately thirty other retroviral gag genes. As discussed in more detail below, the present invention also includes a number of additional breast tumor-specific polypeptides, such as those encoded by the nucleotide sequences recited in SEQ ID NO: 1-SEQ ID NO: 77 and SEC ID NOS: 142, 143, 146-152, 154-166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-227. As used herein, the term "polypeptide" embraces chains of amino acids of any length, including full-length proteins containing the sequences recited herein. A polypeptide comprising an epitope of a protein containing a sequence as described herein may consist entirely of the epitope, or may contain additional sequences. The additional sequences may be derived from the native protein or they may be heterologous, and said sequences may (but not necessarily) have immunogenic or antigenic properties. An "epitope", as used herein, is a portion of a polypeptide that is recognized (i.e., specifically bound) by a surface antigen receptor of B cells and / or T cells. Epitopes can generally be identified using well-known techniques, such as those summarized in Paul, Fundamental Immunology, 3a. ed. , 243-247 (Raven Press, 1993) and references cited therein. Such techniques include screening polypeptides derived from a native polypeptide for the ability to react with antiserum specific for antigen and / or T cell lines or clones. An epitope of a polypeptide is a portion that reacts f with said antiserum and / or T cells at a level that is similar to the reactivity of full-length polypeptide (e.g., in an analysis ELISA and / or T cell reactivity). Such sieves may be snowed out generally using methods well known to those of ordinary skill in the art, such as those described in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988. Epitopes of B cells and 15 T cells can also be predicted via computer analysis. Polypeptides comprising an epitope of a polypeptide that is preferentially expressed in a tumor tissue (with or without additional amino acid sequence) are within the scope of the invention. The compositions and methods of the present invention also encompass variants of the above polypeptides and nucleic acid sequences encoding said polypeptides. As used herein a "variant" of polypeptides, is a polypeptide that differs from the native polypeptide in substitutions and / or modifications, so that the antigenic and / or immunogenic properties of polypeptides are retained. Said variants can generally be identified by modifying one of the above polypeptide sequences and evaluating the reactivity of the modified polypeptide with antiserum and / or T cells as described above. The nucleic acid variants may contain one or more substitutions, deletions, insertions and / or modifications so that the antigenic and / or immunogenic properties of the encoded polypeptide are retained. A preferred variant of the polypeptides described herein is a variant containing substitutions, deletions, insertions and / or nucleotide modifications in no more than 20% of the nucleotide positions. Preferably, a variant contains conservative substitutions. A "conservative substitution" is one in which an amino acid is substituted by another amino acid having similar properties, so that one skilled in the art of peptide chemistry could hope that the secondary structure and hydropathic nature of the amino acid will not be substantially changed. poly peptide. In general, the following amino acid groups represent conservative changes: (1) ala, pro, gly, glu, asp, gln, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his. The variants also (or alternatively) can be modified, for example, by deletion or addition of amino acids that have minimal influence on the immunogenic or antigenic properties, secondary structure or hydropathic nature of the polypeptide. For example, a polypeptide can be conjugated to a signal sequence (or leader) at the N-terminus of the protein which directs co-translational or post-translational transfer of the protein. The polypeptide can also be conjugated to a linker or other sequence for ease of synthesis, purification or identification of polypeptides (e.g., poly-His), or to increase the binding of the polypeptide to a solid support. For example, a polypeptide can be conjugated to an Fc region of immunoglobulin. In general, nucleotide sequences that encode all or a portion of the polypeptides described herein can be prepared using any of several techniques. For example, the cDNA molecules encoding said polypeptides can be cloned on the basis of breast tumor specific expression of the corresponding mRNAs, using differential deployment PCR. This technique compares the amplified products of RNA standard prepared from normal and tumor breast tissue. The cDNA can be prepared by reverse transcription of RNA using a (dT) 1 2AG primer. After the amplification of the AD Nc using a random primer, a band corresponding to a specific amplified product for the tumor RNA of a silver-stained gel can be cut and subcloned into a suitable vector (e.g. vector T, N ovagen, Madison, Wl). The nucleotide sequences encoding a whole portion of the polypeptides specific for breast tumors described herein can be amplified from cDNA prepared as described above using the random primers shown in SEQ ID NO: 87-125. Alternatively, a gene encoding a polypeptide as described herein (or a portion thereof) can be amplified from a human genomic DNA, or from a breast tumor cDNA, via a polymerase chain reaction. For this approach, sequence-specific primers of B18Agl can be designed based on the sequence provided in SEC I D NO: 1, and can be purchased or synthesized. A pair of primers suitable for the amplification of breast tumor cDNA is (5 'ATG GCT ATT TTC GGG GGC TGA CA) (SEQ ID NO: 126) and (5' CCG GTA TCT CCT CGT GGG TAT T) (SEC ID NO.: 127). an amplified portion of B18Ag 1 can then be used to isolate the full length gene from a human genomic DN A bank or from a breast tumor cDNA bank, using well known techniques, such as that described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY (1989). Other sequences within the retroviral genome of which B 18Ag 1 is a part, can similarly be prepared by screening human genomic libraries using sequences specific for B 18Ag 1 as probes. Nucleotides translated into retroviral genome proteins shown in SEQ ID NO: 141 can be determined by cloning the corresponding cDNAs, predicting open reading frames and cloning the appropriate cDNAs in a vector containing a viral promoter, such as T7. The resulting constructs can be employed in a translation reaction, using techniques known to those skilled in the art, to identify nucleotide sequences that result in the expressed protein. Similarly, the specific primers for the remaining breast tumor-specific polypeptides described herein may be designed based on the nucleotide sequence provided in SEQ ID NO: 1-SEQ ID NO: 86 and SEQ ID NO: 142-SEQ ID NO: 226 The recombinant polypeptides encoded by the DNA sequences described above can be easily prepared from DNA sequences. For example, supernatants from suitable host / vector systems that secrete recombinant protein or polypeptide in culture medium can be first concentrated using a commercially available filter. After concentration, the concentrate can be applied to a suitable purification matrix such as an affinity matrix or an ion exchange resin. Finally, one or more reverse phase HPLC steps can be employed to further purify a recombinant polypeptide. In general, any of a variety of expression vectors known to those of ordinary skill in the art can be used to express recombinant polypeptides of this invention. Expression can be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a DNA molecule encoding a recombinant polypeptide. Suitable host cells include prokaryotes, yeasts and higher eukaryotic cells. Preferably, the host cells employed are E. coli, yeast or a mammalian cell line such as COS or CHO. Such techniques can also be used to prepare polypeptides comprising native epitopes or variants of polypeptides. For example, variants of a native polypeptide can generally be prepared using standard mutagenesis techniques, such as site-specific mutagenesis directed to oligonucleotides and DNA sequence sections can be removed to allow the preparation of truncated polypeptides. Portions and other variants having less than about 100 amino acids and generally less than about 50 amino acids, can also be generated by synthetic means using techniques well known to those of ordinary skill in the art. For example, such polypeptides can be synthesized using any of the commercially available solid phase techniques, such as the Merrifield solid phase synthesis method, wherein the amino acids are sequentially added to a growing chain of amino acids. See Merrifield, J. Am. Chem. Soc. 85: 2149-2146 (1963). The equipment for automatic synthesis of polypeptides is commercially available from suppliers such as Applied BioSystems, Inc., Foster City, CA, and can be operated in accordance with the manufacturer's instructions. In specific embodiments, the polypeptides of the present invention encompass amino acid sequences encoded by a * DNA molecule having a sequence recited by anyone, of SEQ ID NO: 1 or SEQ ID NO: 3 - SEQ ID NO: 77 or SEQ ID NOS.142, 143, 146-152, 154-166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-227, variants of said polypeptides that are encoded by DNA molecules containing one or more substitutions, deletions, insertions and / or modifications of nucleotides in no more than 20% of the nucleotide and epitope positions of the above polypeptides. The polypeptides within the scope of the present invention also include polypeptides (and epitopes thereof) encoded by DNA sequences that hybridize to a DNA molecule having a sequence recited in one of SEQ ID NO: 1 or SEQ ID NO: 3 - SEQ ID NO: 77 or SEC ID NOS: 142, 143, 146-152, 154-166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-227 under stringent conditions, wherein the DNA sequences are at least 80% identical in overall sequence to a recited sequence and wherein the RNA corresponding to the nucleotide sequence is expressed at a higher level in tumor tissue of human breast, in normal breast tissue. How it is used in the present "stringent conditions" refers to a prewash in a solution of 6X SSC, 0.2% SDS; hybridizing at 65 ° C, 6X SSC, 0.2% SSC, 0.2% SDS overnight; followed by two washes of 30 minutes each in 1X SSC, 0.1% SDS at 65 ° C and two washes of 30 minutes each in 1X SSC, 0.1% SDS at 65 ° C. The # DNA molecules according to the present invention include molecules that encode any of the above polypeptides. In another aspect of the present invention, antibodies are provided. Said antibodies can be prepared by any of a variety of techniques known to those of ordinary skill in the art. See, for example Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor ^ p. Laboratory, 1988. In said technique, an immunogen comprising the polypeptide is initially injected to any of a wide variety of mammals (e.g., mice, rats, rabbits, sheep or goats). In this step, the polypeptides of this invention can serve as the immunogen without modification. Alternatively, particularly for relatively short polypeptides, a superior immune response can be produced if the polypeptide is binds to a carrier protein, such as bovine serum albumin or boundary limpet hemocyanin. The immunogen is injected into an animal host, preferably according to a predetermined schedule incorporating one or more booster immunizations and the animals are bled periodically. Antibodies Polyclonal, specific for the polypeptide can then be purified from said antiserum, for example, by affinity chromatography using the polypeptide coupled to a suitable solid support. Monoclonal antibodies specific for the polypeptide Antigen of interest can be prepared, for example, using the technique of Kohler and Milstein, Eur. J. Immunol. 6:51 1 -519 (1976) and improvements in it. In summary, these methods involve the preparation of immortal cell lines capable of producing antibodies having the desired specificity (i.e., reactivity with the polypeptide of interest). Said cell lines can be produced, for example, from cells of the vessel obtained from an immunized animal as described above. The cells of the vessel are then immortalized, for example, by fusion with a pair of myeloma cell fusion cells, preferably one that is syngeneic with the immunized animal. A variety of fusion techniques can be employed. For example, vessel cells and myeloma cells can be combined with a non-ionic detergent for a few minutes and then plated at low density in a selective medium that supports the growth of hybrid cells, but not myeloma cells. One technique uses HAT selection (hypoxanthine, aminopterin, thymidine). After a sufficient time, usually about 1 or 2 weeks, colonies of hybrids were observed. The colonies alone are selected and their culture supernatants are tested for binding activity against the polypeptide. Hybridomas that have high reactivity and specificity are preferred. Monoclonal antibodies can be isolated from the supernatants of growth hybridoma colonies. further, several techniques can be expanded to enhance the redemption, such as injection of the hybridoma cell line into the cavity * of a host of suitable vertebrates such as a mouse. The monoclonal antibodies can then be cultured from ascites fluid or blood. The contaminants can be removed from the antibodies by conventional techniques, such as chromatography, filtration, precipitation and extraction. The polypeptides of this invention can be used in purification processes, for example, in an affinity chromatography step. ** ß For example, antibodies can be used in methods to detect breast cancer in a patient. These methods involve using an antibody to detect the presence or absence of a breast tumor-specific polypeptide as described herein in a suitable biological sample. As used herein, suitable biological samples include biopsy samples of normal or tumor tissue, mastectomy, blood, nodes lymphatic, serum or urine, or other tissue, homogenate, or extract thereof obtained from a patient. There is a variety of assay formats known per se from ordinary experience in the art to use an antibody in order to detect polypeptide markers in a sample. See for Example, Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988. For example, the analysis can be carried out in a Western blot format, wherein a protein preparation of the biological sample is subjected to to gel electrophoresis, it is transferred to a suitable membrane and lets react with the antibody. The presence of the antibody in the membrane can then be detected using a suitable detection reagent, as described below. In another embodiment, the assay involves the use of immobilized antibody on a solid support to bind to the polypeptide and remove it from the rest of the sample. The bound polypeptide can then be detected using a second antibody or reagent containing a reporter group. Alternatively, a competitive analysis can be used, in which the polypeptide is labeled with a group # reporter and let bind the immobilized antibody after the incubation of the antibody with the sample. The degree to which the components of the sample inhibit the binding of the labeled polypeptide to the antibody indicates the reactivity of the sample with the immobilized antibody, and as a result, indicates the concentration of the polypeptide in the sample. 15 The solid support can be of any material known by * those of ordinary experience in the subject to which the antibody can be attached. For example, the solid support can be a test on a microtitre plate or nitrocellulose filter or other suitable membrane. Alternatively, the support may be a bead or disk. such as glass, fiberglass, latex or a plastic material such as polystyrene or polyvinyl chloride. The support can also be a magnetic particle or a fiber optic sensor, such as that described, for example, in the Patent of E. U.A. number 5, 359,681.

The antibody can be immobilized on the solid support using a variety of techniques known to those skilled in the art, which are widely described in the patent and scientific literature. In the context of the present invention the term "immobilization" refers to the non-covalent association, such as adsorption, and covalent binding (which may be a direct ligation between the antigen and functional groups on the support or it may be a ligation). way of entanglement agent). Immobilization by adsorption to a well in the microtiter plate or membrane is preferred. In such cases, adsorption can be achieved by contacting the antibody in a buffer solution of suitable pH, with the solid support for an appropriate amount of time. The contact time varies with the temperature, but it is not normally between 1 hour and 1 day. In general, to have in contact a well of a plastic microtiter plate (such as polystyrene or polyvinyl chloride) with an amount of antibody ranging from 10 ng to about 1 μg, and preferably 1 00-200 ng, it is sufficient to immobilize an adequate amount of polypeptides. The covalent attachment of antibody to a solid support can also generally be achieved by first reacting the support with a bifunctional reagent that will react with the support and a functional group, such as a hydroxyl or amino group., in the antibody. For example, the antibody can be covalently attached to supports that have a suitable polymer coating "using benzoquinone or by condensation of a group of aldehydes in the support with an amine and an active hydrogen in the binding partner (see, for example, Pierce Immunotechnology Catalog and Handbook (1991) in A12-A 13). In certain embodiments, the polypeptide detection assay in a sample is a sandwich analysis of two antibodies. This analysis can be carried out by first contacting an antibody that has been immobilized on a solid support, commonly the well of a microtiter plate, with the biological sample, so that the polypeptide within the sample is allowed to bind to the immobilized antibody. The unbound sample is then removed by the immobilized polypeptide-antibody complexes and a second antibody (containing a reporter group) capable of binding to a different site of the polypeptide is added.

The amount of the second antibody that remains attached to the support »Solid is then determined using the appropriate method for the ific reporter group. More ifically, once the antibody is immobilized on the support as described above, the binding sites of The remaining protein on the support is normally blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin or Tween 20 ™ (Sigma Chemical Co., St. Louis, MO). The immobilized antibody is then incubated with the sample and the The polypeptide is allowed to bind to the antibody. The sample can be diluted with # a suitable diluent, such as saline with pH regulated with phosphate solution (PBS) before incubation. In general, the appropriate contact time (i.e., incubation time) is the period that is sufficient to detect i the presence of polypeptides within a sample obtained from an individual with breast cancer. Preferably, the contact time is sufficient to achieve a binding level that is at least 95% of that achieved in equilibrium between the bound and unbound polypeptide. Experts in the field will recognize that time necessary to achieve the balance to be easily determined by analyzing the level of union that occurs over a period of time. At room temperature, an incubation time of about 30 minutes is generally sufficient. The unbound sample can then be removed by washing the solid support with an appropriate pH buffer solution, such % as PBS containing 0.1% Tween 20 ™. The second antibody, which contains a reporter group, can then be added to the solid support. Preferred reporter groups include enzymes (such as horseradish peroxidase), substrates, cofactors. inhibitors, dyes, radionuclides, luminescent groups, fluorescent groups and biotyping. The conjugation of antibody to reporter group can be achieved using normal methods known to those of ordinary skill in the art. The second antibody is then incubated with the complex Antibody-polypeptide immobilized for a sufficient time to detect the bound polypeptide. An appropriate amount of time can usually be determined by analyzing the level of binding that occurs over time. The unbound second antibody is then removed and the second bound antibody is detected using the reporter group. The method used to detect the reporter group depends on the nature of the reporter group. For radioactive groups, scintillation or autoradiographic counting methods are generally appropriate. troscopic methods can be used to detect dyes, luminescent groups and fluorescent groups. Biotin can be detected using avidin, coupled to a different reporter group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups can usually be detected by the addition of substrate (usually for a ific time), followed by troscopic or other analysis of the reaction products. To determine the presence or absence of breast cancer, the signal detected from the reporter group that remains attached to the solid support is generally compared to a signal corresponding to a predetermined established cutoff value of non-tumor tissue. In a preferred embodiment, the cut-off value is the average average signal obtained when the immobilized antibody is incubated with samples from patients without breast cancer. In general, a sample that generates a signal that is three normal deviations above the predetermined cutoff value can be considered positive for breast cancer. In an alternative preferred embodiment, the cutoff value is determined using the receiver operator curve, according to the method of Sackett et al., Clinical Epidemiology: A Basic Science for Clinical Medicine, p. 106-7 (Little Brown and Co., 1985). In summary, in this modality, the cut-off value can be determined from a graph of pairs of real positive regimes (ie, sensitivity) and false positive regimes (100% specificity) that corresponds to each possible cut-off value for the result of Diagnostic test, the cutoff value in the graph is closest to the upper left corner (that is, the value that covers the largest area) is the most accurate cutoff value and a sample that generates a signal that is higher The cut-off value determined by this method can be considered positive. Alternatively, the cut-off value can be changed to the left along the graph, to minimize the false positive regime or to the right to minimize the false negative regime. In general, a sample that generates a sample that is greater than the cut-off value determined by this method is considered positive for breast cancer. In a related embodiment, the analysis is carried out in a flow or separation test format, wherein the antibody is immobilized on a membrane, such as nitrocellulose. In the next flow test, the polypeptide within the sample binds to the immobilized antibody as the sample passes through the membrane. A second labeled antibody that binds to the antibody-polypeptide complex as a solution containing the second antibody flows through the membrane. The detection of the second bound antibody can then be carried out as described above. In the separation test format, one end of the membrane to which the antibody binds is immersed in a solution containing the sample. This sample migrates along the membrane through a region that contains a second antibody and the area of immobilized antibody. The concentration of the second antibody and the area of immobilized antibody indicates the presence of breast cancer. Normally, the concentration of the second antibody in that site generates a pattern, such as a line, that can be read visually. The absence of such pattern indicates a negative result. In general, the amount of antibody immobilized on the membrane is selected to generate a visually discernible pattern when the biological sample contains a level of polypeptide that could be sufficient to generate a positive signal in the sandwich analysis of two antibodies, in the treated format before. Preferably, the amount of antibody immobilized on the membrane varies from about 25 ng to about 1 μg and more preferably from about 50 ng to about 1 μg. Such tests can usually be carried out with a very small amount of biological sample. The presence or absence of breast cancer in a patient can also be determined by evaluating the level of mRNA that encodes a breast tumor-specific polypeptide as described herein within the biological sample (e.g., a biopsy, mastectomy and / or blood sample of a patient) in relation to a predetermined cut-off value. Such evaluation can be accomplished using any of a variety of methods known to those of ordinary skill in the art such as, for example, in situ hybridization and polymerase chain reaction amplification. For example, the chain reaction of I »polymerase can be used to amplify cDNA sequences prepared from RNA that is isolated from one of the biological samples previous Sequence-specific primers for use in said amplification can be designed based on the sequences provided in one of SEQ ID NO: 1 or SEQ ID NO: 1 1 - SEQ ID NO: 86 and SEQ ID NO: 142 - SEQ ID NO.226 and can be purchased or synthesized. In the case of B18Ag1, as noted here, a pair of suitable primer is B 18Ag 1 -2 (5 'ATG GCT ATT TTC GGG GGC • TGA CA) (SEQ ID NO.126) and B18Ag 1 -3 (5 'CCG GTA TCT CCT CGT GGG TAT T) (SEC I D NO .: 127). The PCR reaction products can then be separated by gel electrophoresis and visualized according to methods well known to those of experience ordinary in the matter. Normally amplification is carried out in samples obtained from even pairs of tissue (tumor and non-tumor tissue from the same individual) or from unmatched pairs of tissue (tumor and non-tumor tissue from different individuals). The amplification reaction was preferably carried out in several dilutions of cDNA expanding two orders of magnitude. A double or greater increase in expression in several dilutions of the tumor sample compared to the same dilution of the non-tumor sample is considered positive. Conventional PCR-TI protocols using agarose and ethidium bromide tinsión while it is important to define the specificity of genes does not lead to the development of diagnostic equipment due to the time and effort required to make them quantitative (ie, construction of curves). of saturation and / or titration) and its passage of the samples. This problem is overcome by the development of procedures such as real-time PCR-IT that allows the analysis to be carried in single tubes and in turn can be modified to be used in 96-well plate formats. The instrumentation to carry out said methodologies is available from ABI / Perkin Elmer. Alternatively, other higher-pass assays using labeled probes (eg, digoxigenin) in combination with labeled antibodies (eg, fluorescent, radioactive enzyme) for such probes can also be used in the development of plaque analysis. 96 wells In yet another method for determining the presence or absence of breast cancer in a patient, one or more polypeptides specific for breast tumor described in the skin test may be used. As used herein, a "skin test" is any test performed directly on a patient in which the delayed-type hypersensitivity reaction (HTR) (such as swelling, redness or dermatitis) is measured after intradermal injection of one or more polypeptides as described above. Such an injection can be accomplished using any device sufficient to contact the polypeptide or polypeptides with the skin cells of the patient, such as a tuberculin syringe or a 1 mL syringe. Preferably, the reaction was measured at least 48 hours after injection, more preferably 48-72 hours. The HTR reaction is a cell-mediated immune response that is higher in patients, who have previously been exposed to a test antigen (i.e., an immunogenic portion of a polypeptide employed, or a variant thereof). The answer can be measured visually, using a rule. In general, a response that is greater than about 0.5 cm in diameter, preferably greater than about 5.0 cm in diameter, is a positive response indicating breast cancer. The breast tumor specific polypeptides described herein are preferably formulated for use in a skin test, such as pharmaceutical compositions containing at least one polypeptide and a physiologically acceptable carrier, such as water, saline, alcohol or buffer solution. pH. Said compositions typically contain one or more of the above polypeptides in an amount ranging from about 1 μg to 100 μg, preferably from about 10 μg to 50 μg in a volume of 0.1 mL.Preferably, the carrier employed in said pharmaceutical compositions is in a saline solution with appropriate preservatives, such as phenol and / or Tween 80 ™. In other aspects of the present invention, the progression and / or breast cancer treatment response can monitored carrying out any of the above analyzes for a time and evaluating the previous analysis change for a while and V evaluating the change in the level of response (i.e., the amount of polypeptide or mRNA detected or, in the case of skin test, the degree of immune response detected). For example, month-by-month analyzes can be carried out over a period of 1 to 2 years. In general, breast cancer progresses in those patients in whom the level of response increases with time. In contrast, breast cancer does not progress when the signal detected by either of the two remains constant or decreases with time. In additional aspects of the present invention, the compounds described herein may be used for the immunotherapy of breast cancer. In these aspects, the compounds (which may be polypeptides, antibodies or nucleic acid molecules) are preferably incorporated in pharmaceutical compositions or vaccines. The pharmaceutical compositions comprise one or more of said compounds and a physiologically acceptable carrier. Vaccines can include one or more polypeptides and an immune response enhancer, such as an assistant or a liposome (in which the compound is incorporated). The pharmaceutical compositions and vaccines may additionally contain a delivery system, such as biodegradable microspheres which are described, for example, in the U.A. Nos. 4,897,268 and 5,075, 109. Pharmaceutical compositions and vaccines within the scope of the present invention may also contain other compounds, including one or more separate polypeptides. Alternatively, a vaccine may contain DNA encoding one or more of the polypeptides as described above, such that the polypeptide is generated in situ. In such vaccines, DNA can be present within a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacteria and viral expression systems. Suitable nucleic acid expression systems contain the DNA sequences necessary for expression in the patient (such as the promoter and suitable termination signal). Bacterial delivery systems involve the administration of a bacterium (such as Bacillus-Calmette-Guerrin) that expresses an immunogenic portion of the polypeptide on its cell surface. In a preferred embodiment, the DNA can be introduced using a viral expression system. (V. gr., Vaccine or other pox virus, retrovirus, or adenovirus), which may involve the use of a competent non-pathogenic (defective) replication virus. The techniques for incorporating DNA into said expression systems are well known to those of ordinary skill in the art. The DNA can also be "pure", as described, for example, in Ulmer et al., Science 259: 1745-1749 (1993), and was reviewed by Cohen, Science 2559: 1691-1692 (1993). DNA adsorption can be increased by coating the DNA in biodegradable beads, which are transported efficiently in the cells. While any suitable vehicle known to someone skilled in the art can be employed in the pharmaceutical compositions of this invention, the type of vehicle will vary depending on the mode of administration. For parenteral administration, such as subcutaneous injection, and vehicle preferably comprises water, saline, alcohol, a fat, a wax or a buffer solution. For oral administration, any of the vehicles or a solid vehicle, such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose and magnesium carbonate, can be used. Biodegradable microspheres (e.g., polylactate polyglycolate) can also be employed as carriers for the pharmaceutical compositions of this invention. Any of a variety of auxiliaries can be employed in the vaccines of this invention to nonspecifically increase the immune response. Most auxiliaries contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, proteins * derived from Bortadella pertussis or Mycobacterium tuberculosis. Suitable auxiliaries are commercially available, e.g., as Incomplete Auxiliary and Freund's Complete Auxiliary (Difco Laboratories, Detroit, Ml), Auxiliary 65 from Merck (Merck and 5 Company, Inc., Rahway, NJ), alume, biodegradable microspheres, Monophosphoryl lipid A and quil A. Cytokines such as GM-CSF or interleukin-2, -7, or -12 can also be used as auxiliaries. The above pharmaceutical compositions and vaccines can used, for example, for the therapy of breast cancer in a patient. As used herein, a "patient" refers to any warm-blooded animal, preferably a human being. A patient may or may not suffer from breast cancer. Consequently, the pharmaceutical compositions and vaccines can be used to prevent the development of breast cancer or to * Treat a patient suffering from breast cancer. To prevent the development of breast cancer, a pharmaceutical composition or vaccine comprising one or more polypeptides as described herein can be administered to a patient. Alternatively, the Pure DNA or plasmid or viral vector encoding the polypeptide can be administered. To treat a patient with breast cancer, the pharmaceutical composition or vaccine may comprise one or more polypeptides, antibodies or nucleotide sequences complementary to the A DN encoding a polypeptide as described herein (e.g., antisense RNA or deoxyribonucleotide antisense oligonucleotides). The routes and frequency of administration, as well as the dose, will vary from individual to individual. In general, the pharmaceutical compositions and vaccines can be administered by injection (eg, intracutaneous, intramuscular, intravenous or subcutaneous), intranasally (e.g., by aspiration) or orally. Between 1 and 10 doses can be administered over a period of 52 weeks. Preferably, 6 doses are administered, at intervals of 1 month and then booster vaccines can be given periodically. Alternative protocols may be appropriate for individual patients. A suitable dose is an amount of a compound that, when administered as described above, is capable of promoting an anti-tumor immune response. Said response can be monitored by measuring the anti-tumor antibodies in a patient or in a generation dependent on a vaccine of cytolytic effector cells capable of killing the tumor cells of the patient in vitro. Such vaccines may also be capable of eliciting an immune response that leads to improved clinical progress (eg, more frequent remissions, complete or partial or longer disease-free survival) in vaccinated patients compared to unvaccinated patients. In general, for pharmaceutical compositions and vaccines comprising one or more polypeptides, the amount of each polypeptide present in a dose ranges from about 100μg to 5mg. The appropriate dose sizes will vary with the size of the patient, but will usually vary from 0.1 mL to about 5 mL. The following Examples are offered by way of illustration and not by way of limitation. EXAMPLES Example 1 Preparation of cDNAs Specific for Breast Tumor Using *? M-Differential Deployment RCP-TI This example illustrates the preparation of cDNA molecules that encode breast tumor-specific polypeptides using a differential display screen. A. Preparation of B18Ag 1 cDNA and mRNA Expression Characterization Samples of breast tumor tissue and normal tissue from a patient with breast cancer were prepared and confirmed by pathology after removal of the patient. Normal RNA and tumor RNA was extracted from the samples and the m RNA was isolated and converted to cDNA using a 3 '(dT) 12AG-anchored initiator (SEQ ID NO: 130). The differential display PCR was executed using a randomly chosen primer (CTTCAACCTC) (SEC I D NO .: 103). the amplification conditions were normal pH buffer containing 1.5 mM MgCl2, 20 pmoles of primer, 500 pmoles of dNTP and one unit of Taq DNA polymerase (Perkin-El mer, Branchburg, NJ). Forty-five amplification cycles were carried out using denaturation at 94 ° C for * 30 seconds annealing at 42 ° C for 1 minute and extension at 72 ° C for 30 seconds. An RNA fingerprint containing 76 amplified products was obtained. Although the RNA fingerprint of the breast tumor tissue was more than 98% identical to normal breast tissue, a specific band for the fingerprint pattern of tumor RNA was repeatedly observed. This band was cut from a silver-stained gel, subcloned into the T vector (Novagen, Madison, Wl) and sequenced. '* The sequence of the cDNA, designated as B18Ag1, is provided in SEC I D NO: 1. A database investigation of GEN BANK and EMBL revealed that the initially cloned B 18Ag 1 fragment is 77% identical to the endogenous human retroviral element S71, which is a truncated retroviral element homologous to the Simian Sarcoma Virus (SSV) . S71 contains a gag gene, a portion of the gene of pol and a structure similar to LTR at the 3 'end (see Werner et al., Virology 174: 225-238 (1990)). B18Ag 1 is also 65% identical to the SSV in the region corresponding to the P30 site (gag). B 18Ag 1 contains three separate and incomplete reading frames covering a region that shares considerable homology to a wide variety of retrovirus gag proteins that infect mammals. In addition, the homology to S71 is not only within the gag gene, but extends several kb of sequence including an LTR. The PCR primers specific for B18Ag 1 are synthesized using computer analysis guidelines. The PCR-TI amplification (94 ° C, 30 seconds, 60 ° C, 42 ° C, 30 seconds, 72 ° C, 30 seconds, for 40 cycles) confirmed that B 18Ag 1 represents a real ARMm sequence present at levels Relatively high breast tumor tissue in the patient The primers used in the amplification were B 18Ag-1 (CTG CCT GAG CCA CAA ATG) (SEQ ID NO: 128) and B 18Ag 1-4 (CCG GAG GAG GAA GCT AGA GGA ATA) (SEQ ID NO: 129) at a magnesium concentration of 3.5 mM and a pH of 8.5 and B 18Ag 1-2 (ATG GCT ATT TTC GGG GCC TGA CA) (SEQ ID NO: 12β) and B18Ag1 -3 (CCG GTA TCT CCT CGT GGT TATT) (SEQ ID NO: 127) to 2mM magnesium at pH 9.5. The same experiments showed excessively low at the non-existent levels of expression in this patient's normal breast tissue (see Figure 1). The PCR-TI experiments were then used to show that B 18Ag 1 mRNA is present in nine breast tumor samples (from Brazilian and American patients) but were absent, or at excessively low levels, in normal breast tissue that corresponds to each patient with cancer. PCR-TI analyzes also showed that transcription of B18Ag 1 is not present in several normal tissues (including lymph node, myocardium and liver) and present at relatively low levels of PBMC and lung tissue. The presence of B18Ag1 mRNA in breast tumor samples and its absence of normal breast tissue has been confirmed by Northern blot analysis, as shown in Figure 2. "jl Differential expression of B18IAg1 in breast tumor tissue was also confirmed by RNase protection analysis Figure 3 shows the level of B18Ag1 mRNA in various tissue types as determined in four RNase 5 protection analyzes Lines 1-12 represent normal breast tissue samples, lines 13-25 represent several breast tumor samples: lines 26-27 represent normal prostate samples, lines 28-29 represent tumor samples of prostate; * lines 30-32 represent samples of colon tumor; line 33 represents normal aorta; line 34 represents normal small intestine; line 35 represents normal skin; line 36 represents normal lymph node; line 37 represents normal ovary; line 38 represents normal liver; line 39 represents normal skeletal muscle; line 40 represents a first sample of normal stomach, line 41 represents a second normal stomach sample; line 42 represents a normal lung; line 43 represents normal kidney; and line 44 represents normal pancreas. The inter-experimental comparison was facilitated by including a positive control RNA of message abundance of B-actin in each analysis and normalizing the results of different analyzes with respect to this control. The PCR-TI and analysis of Southern spots has shown that the site of B18Ag1 is present in human genomic DNA in a single copy of the endogenous retroviral element. A genomic clone of approximately 12-18 kb was isolated using the B 1 8Ag 1 sequence as a probe. Four subclones were also isolated * additional by digestion of Xbal. The additional retroviral sequences obtained from the ends of the Xbal digestions of these clones (localized as shown in Figure 4) are shown as SEQ ID NO: 3 - SEQ ID NO: 10, wherein SEQ ID NO: 3 shows the location of the sequence marked 10 in Figure 4, SEQ ID NO: 4 shows the location of the sequence marked 1 1 -29, SEQ ID NO: 5 shows the location of the sequence marked 3, SEQ ID NO: 6 shows the location of the sequence marked 6, SEQ ID NO: 7 shows the location of the sequence marked 12, SEQ ID NO: 8 shows the location of the sequence marked 13, SEQ ID NO: 9 shows the location of the sequence marked 15 and SEQ ID NO: 10 shows the location of the marked sequence 1 1 -22. Subsequent studies showed that the genomic clone of 12-18 kb contains a retroviral element of approximately 7.75 kb, as shown in Figures 5A and 5B. The sequence of * this retroviral element is shown in SEC I D NO: 141. The line numbered in the upper part of Figure 5A represents the sequence of the yarn direction of the retroviral genomic clone. The box of this line shows the position of the selected restriction sites. The arrow describes the different overlap clones used to sequence the retroviral element. The direction of the arrow shows whether the sequence of the one-step subclone corresponded to the direction or sense of the thread. Figure 5B is a schematic diagram of the retroviral element containing one of viral genes within the element. The open boxes correspond to predicted reading frames, starting with a methionine, found through the element. Each of the six similar reading frames is shown, as indicated to the left of the boxes, with frames 1 -3 corresponding to those found in the direction of the thread. Using the cDNA of SEQ ID NO: 1 as a probe, a longer cDNA was obtained (SEQ ID NO: 227) which contains difference in * minor nucleotides (less than 1%) compared to the sequence genomics shown in SEC I D NO: 141. B. Preparation of cDNA Molecules Encoding Other Breast Tumor Specific Polypeptides Normal RNA and tumor RNA were prepared and mRNA was isolated and converted to cDNA using a 30 'anchor (dT)? 2AG primer, as described above. The differential display PCR was then executed using randomly chosen primers SEC I D NO. : 87-125 The amplification conditions were as noted above, and the observed bands specific for the fingerprint pattern of tumor RNA were cut from a dyeing gel with silver, were subcloned into the vector T (Novagen, Madison, Wl) or the vector pCR I l (Invitrogen, San Diego, CA) and sequenced. The sequence is provided in SEC I D NO: 1 1 - SEQ ID NO: 86. Of the 79 isolated sequences, 67 were found to be novel (SEC I D NO: 1 1 -77) (see also Figures 6-20). Subsequent studies identified that 84 additional sequences (SEQ ID NOS: 142-226) of which 72 appeared to be novel (SEQ ID NOS: 142, 143, 146-152, 154-166, 168-176, 178-192, 194-198 , 200-204, 206, 207, 209-214, 219, 218, 219, 221-227). To the best of the inventors' knowledge none of the previously identified sequences has thus been shown to be expressed at a higher level in the h breast tumor tissue than in normal breast tissue. Table 1 shows the level of specific transcripts for representative breast tumors in normal breast tissue * (columns BN I-BN7), samples of breast tumors (columns BTI-10 BT12) and normal prostate, kidney, liver, lung, small intestine, stomach, myocardium, lymph node, pancreas, skeletal muscle, ovary and normal aorta , as determined by PCR-IT analysis. A scale of 0-3 for the abundance of messages was used, with 0 denoting no detectable message and 3 a level of message comparable to the control message (glyceraldehyde 3-phosphate dehydrogenase). The lack of data in a given box * indicates that the tissue has not been tested for the presence or absence of that specific antigen. -iritis 4*". s > • Example 2 Preparation of B18Ag1 DNA from Human Genomic DNA This Example illustrates the preparation of B18Ag1 DNA by amplification of genomic DNA. B 18Ag 1 DNA can be prepared from 250 ng of DNA * human genomic using 20 pmoles of specific primers of 10 B18Ag1, 500 pmoles of dN ITPS and 1 unit of Taqf DNA polymerase (Perkin Elmer, Branchburg, NJ) using the following amplification parameters: 94 ° C for 30 seconds of denaturation , 30 seconds at 60 ° C at 42 ° C of descent annealing at 2 ° C increased every two cycles and extension at 15 72 ° C for 30 seconds. The last increment (at an annealing temperature of 42 ° C) should rotate 25 times. The primers were selected using a computer analysis. The primers synthesized were B18Ag 1 -1, B18Ag 1 -2, B18Ag 1 -3 and B18Ag1 -4. The primer pairs that can be used are 1 +3, 1 +4, 2 + 3 and 2 + 4.

After gel electrophoresis, the band corresponding to B18Ag1 DNA can be excised and cloned into a suitable vector. Example 3 Preparation of B18Ag 1 DNA from Breast Tumor cDNA This Example illustrates the preparation of B18Ag1 DNA by the amplification of human breast tumor cDNA. The first cDNA strand was synthesized from RNA prepared from human breast tumor tissue in a reaction mixture containing 500 ng of poly A + RNA, 200 pmoles of the primer (T) 12AG (ie, TTT TTT TTT TTT AG) (SEQ ID NO: 130), 1X of the first strand of reverse transcriptase pH buffer, 6.7 mM of DDT, 500 mmoles of dNTP and 1 unit of AMV reverse transcriptase or Hr MMLV (from a provider, such as Gibco-BRL (Grand Island, NY)) in a final volume of 30 μl. After the synthesis of the first thread, the CDNA was diluted approximately 25-fold and 1 μl was used for the amplification as described in Example 2. While some pairs of primers may result in a heterogeneous population of transcripts, the primers B18Ag1-2 (5 'ATG GCT ATT TTC GGG GGC TGA CA) (SEQ ID NO: 126) and B18Ag1-3 (5 'CCG GTA TCT CCT CGT GGG TAT T) (SEQ ID NO: 127) produced a single amplification product of 151 bp. Example 4 Identification of B-Cell and B-cell Epitopes of B18Aq1 This Example illustrates the identification of B18Ag1 epitopes. The sequence of B18Ag1 can be screened using a variety of computer algorithms. To determine B-cell epitopes, the sequence can be screened for hydrophobicity and hydrophilicity values using the method of Hopp, Prog.

Clin. Biol. Res. 172B: 367-77 (1985) or, alternatively, Cease et al. J. Exp. Med 164: 1779-84 (1986) or Spouge et al., J. Immunol 138: 204-12 (1987). Additional MHC Class II epitopes (antibodies or B-cells) can be predicted using programs such as AM PH I (see, Margalit et al., J. Immunol., 138: 2213 (1987)) or the methods of Rothbard and Taylor (e.g., EMBO J. 7:93 (1988)). Once the peptides (15-20 amino acids long) were identified using these techniques, individual peptides can be synthesized using automatic equipment for peptide synthesis (available from manufacturers such as Applied Biosystems, Inc., Foster City, CA) and techniques such as the Merrfield synthesis. After the synthesis, the peptides can be used to screen cultured serum from normal patients and with breast cancer to determine if breast cancer patients have antibodies reactive with the peptides. The presence of said antibodies in patients with breast cancer could confirm the immunogenicity of the specific B-cell epitope in question. Also peptides can be tested for their ability to generate a serological or humoral immune response in animals (mice, rats, rabbits, chimpanzees, etc.) following immunization in vivo. The generation of a specific antiserum for peptides after immunization further confirms the immunogenicity of the specific B-cell epitope in question. To identify T-cell epitopes, the B18Ag1 sequence can be screened using different computer algorithms * that can be useful to identify 8-10 amino acid motifs within the B18Ag1 sequence that are capable of binding to M HC molecules Class I of HLA. (See, for example, Ramme nsee et al., Immunogenetics 41: 178-228 (1995)). After synthesis, said peptides can be tested for their ability to bind to MHC Class I using normal binding assays (eg, Sette et al., J. Immunol., 153: 5586-92 (1994)) and more. importantly they can be tested for their capacity in order to generate reactive cytotoxic T-cells for antigens after the In vitro stimulation of the patient or normal peripheral mononuclear cells using, for example, the methods of Bakker et al. Cancer Res. 55: 5330-34 (1995); Visseren et al., J. Immunol 154: 3991-98 (1995); Kawakami et al., J. Immunol. 154: 3961-68 (1995). and Kast et al., J. Immunol. 152: 3904-12 (1994). The successful in vitro generation of T-cells capable of killing autologous tumor cells (which have the same Class I M HC molecules) after stimulation of in vitro peptides, further confirms the immunogenicidas of the B18Ag1 antigen. In addition, said peptides can be used to generate murine peptides and reactive cytotoxic T-cells of B 18Ag1 after in vivo immunization of mice converted to transgenic for the expression of a particular human MHC Class I haplotype (Vitiello et al., J. Exp. Med. 173: 1007-15 (1991 ).

A representative list of B-cell epitopes and predicted B18Ag1 T-cells, interrupted according to the expected HLA Class I MHC binding antigen, is shown below. Predicted Th motives (epitopes of B-cells) (SEQ ID 5 NOS .: 131-133) SSGGRTFDDFHRYLLVGI QGAAQKPINLSKXIEVVQGHDE SPGVFLEHLQEAYRIYTPFDLSA * Reasons A2.1 HLA Expected (epitopes of T-cells) (SEQ ID 10 NOS..134-140) YLLVGIQGA GAAQKPINL NLSKXIEVV EVVQGHDES 15 HLQEAYRIY NLAFVAQAA FVAQAAPDS Example 5 Characterization of Breast Tumor Genes Discovered by Differential Deployment RCP 20 The specificity and sensitivity of the breast tumor genes discovered by the differential deployment PCR was determined using RCP-TI. This procedure allowed rapid evaluation of mRNA expression of breast tumor genes semiquantitatively without using large amounts of RNA.

Utilizing specific gene primers, the levels of mRNA expression in a variety of tissues was examined, including 8 breast tumors, 5 normal mammals, 2 prostate tumors, 2 colon tumors, 2 lung tumors and 14 different tissues normal human adults, including prostate, colon, kidney, liver, lung, ovary, pancreas, skeletal muscle, skin, stomach and normal testicles. To ensure the semiquantitative nature of the TI-PCR, β-actin was used as an internal control for each of the tissues examined. Several dilutions of the first cDNA strand were prepared and PCR-TI analysis was carried out and specific β-actin primers were used. A dilution was then selected that allowed amplification of the linear scale of the β-actin pattern and that was sufficiently sensitive to reflect the difference in the initial copy number. Using this condition, β-actin levels were determined for each reverse transcription reaction of each tissue. DNA contamination was reduced by DNase treatment ensuring a negative result when using the first cDNA strand that was prepared without addition to reverse transcriptase. Using gene-specific primers, mRNA expression levels were determined in a variety of tissues. To date 32 genes have been successfully examined by RT-PCR, three of which exhibited good specificity and sensitivity for breast tumors. Figures 21 A and 21 B describe the results * for these three genes: B15AG-1 (SEQ ID NO: 27), B31GA1b (SEQ ID NO: 148) and B38GA2a (SEQ ID NO: 157). From the foregoing, it will be appreciated that, although the specific embodiments of the invention have been described herein for the purpose of illustration, various modifications may be made without departing from the spirit and scope of the invention.

* * SEQUENCE LIST (1) GENERAL INFORMATION (I) APPLICANT: Corixa Corporation. (ii) TITLE OF THE INVENTION: COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF BREAST CANCER (iii) NUMBER OF SEQUENCES: 227 (v) ADDRESS OF CORRESPONDENCE (TO) RECIPIENT: DEED and BERRY LLP (B) STREET: 6300 Columbia Center, 701 Fifth Avenue (C) CITY: Seattle (D) STATE: Washington (E) COUNTRY: E.U.A. (F) ZP: 98104-7092 (v) COMPUTER LEADABLE FORM: (A) TYPE OF MEDIUM: soft disk (B) COMPUTER: IBM compatible PC (C) OPERATING SYSTEM: PC-DOS / MS-DOS (D) SOFTWARE: Patentln Reléase # 1.0- Version # 1.30 (vi) CURRENT REQUEST DATA: (A) APPLICATION NUMBER: (B) DATE OF SUBMISSION: 10-JANUARY 1996 (C) CLASSIFICATION: (viii) EMPLOYEE / AGENT INFORMATION: (A) NAME: Maki, David J .. (B) REGISTRATION NUMBER: 31,392 * (C) REFERENCE / NUMBER: 210121.419PC (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (206) 622-4900 (B) TELEFAX: (206) 682-6031 5 (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 363 base pairs (B) TYPE: nucleic acid * (C) THREAD FORM : simple 10"(D) TOPOLOGY: linear (ix) FEATURE: (A) NAME / KEY: CDS (B) LOCATION: 1.363 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1 fifteen # twenty # TTA GAG ACC CAG TTG GGA CCT AAT TGG GAC CCA AAT TTC TGA AGT GGA 48 Leu Glu Thr Gln Leu Gly Pro Asn Trp Asp Pro Asn Phe Ser Ser Gly 1 5 10 15 GGG AGA ACT TTT GAC GAT TTC CAC CGG TAT CTC CTC GTG GGT ATT CAG% Gly Arg Thr Phe Asp Asp Phe His Arg Tyr Leu Leu Val Gly He Gln 20 25 30 GGA GCT GCC CAG AAA CCT ATA AAC TTG TCT AAG GCG ATT GAA GTC GTC 144 Gly Ala Wing Gln Lys Pro He Asn Leu Ser Lys Wing He Glu Val Val 35 40 45 * CAG GGG CAT GAT GAG TCA CCA GGA GTG TTT TTA GAG CAC CTC CAG GAG 192 Gln Gly His Asp Glu Ser Pro Gly Val Phe Leu Glu His Leu Gln Glu 50 55 60 GCT TAT CGG Ap TAC ACC CCT TTT GAC CTG GCA GCC CCC GAA AAT AGC 240 Wing Tyr Arg He Tyr Thr Pro Phe Asp Leu Wing Wing Pro Glu Asn Ser 65 70 75 80 15 CAT GCT Cp AAT pG GCA TTT GTG GCT CAG GCA GCC CCA GAT AGT AAA 288 # His Ala Leu Asn Leu Ala Phe Val Ala Ala Ala Ala Pro Asp Ser Lys 85 90 95 AGG AAA CTC CAA AAA CTA GAG GGA Tp TGC TGG AAT GAA TAC CAG TCA 336 Arg Lys Leu Gln Lys Leu Glu Gly Phe Cys Trp Asn Glu Tyr Gln Ser 20 100 105 110 GCT TTT AGA GAT AGC CTA AAA GGT T 363 Wing Phe Arg Asp Ser Leu Lys Gly Phe 115 120 (2) INFORMATION FOR SEQ ID NO: 2: 25 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 121 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 2: Leu Glu Thr Gln Leu Gly Pro Asn Trp Asp Pro Asn Phe Ser Ser Gly 1 5 10 15 Gly Arg Thr Phe Asp Asp Phe His Arg Tyr Leu Leu Val Gly lie G n 20 25 30 Gly Ala Ala G n Lys Pro He Asn Leu Ser Lys Ala He Glu Val Val 35 40 45 Gln Gly His Asp Glu Ser Pro Gly Val Phe Leu Glu His Leu Gln Glu 50 55 60 Ala Tyr Arg He Tyr Thr Pro Phe Asp Leu Ala Wing Pro Glu Asn Ser 65 70 75 80 His Ala Leu Asn Leu Ala Phe Val Ala Ala Gln Ala Ala Pro Asp Ser Lys 85 90 95 Arg Lys Leu Glp Lys Leu Glu Gly Phe Cys Trp Asn Glu Tyr Gln Ser 100 105 110 Wing Phe Arg Asp Ser Leu Lys Gly Phe 115 120 (2) INFORMATION FOR SEQ ID NO: 3: # (i) SEQUENCE CHARACTERISTICS: (A) LONGITU D: 1 101 base pairs (B) TYPE: nucleic acid ( C) FOR HI LO: Simple 5 (D) TOPOLOGY: line l (xi) DESCR I SEQUENCE PICTURE: SEQ ID NO: 3: TCpAGAATC pCATACCCC GAACTCTTGG GAAAACTpA ATCAGTCACC TACAGTCTAC 60 CACCCATHA GGAGGAGCAA AGCTACCTCA GCTCCTCCGG AGCCGTpTA AGATCCCCCA 120 * 10 TCpCAAAGC CTAACAGATC AAGCAGCTCT CCGGTGCACA ACCTGCGCCC AGGTAAATGC 180 CAAAAAAGGT CCTAAACCCA GCCCAGGCCA CCGTCTCCAA GAAAACTCAC CAGGAGAAAA 240 GTGGGAAAp GACTITACAG AAGTAAAACC ACACCGGGCT GGGTACAAAT ACCpCTAGT 300 ACTGGTAGAC ACCTTCTCTG GATGGACTGA AGCATpGCT ACCAAAAACG AAACTGTCAA 360 TATGGTAGp AAGppTAC TCAATGAAAT CATCCCTCGA CGTGGGCTGC CTGpGCCAT 420 AGGGTCTGAT AATGGAACGG CCpCGCCp GTCTATAGp TAATCAGTCA GTAAGGCGp 480 AAACApCAA TGGAAGCTCC ApGTGCCTA TCGACCCAGA GCTCTGGGCA AGTAGAACGC 540 ATGAACTGCA CCCTAAAAAA ACACTCpAC AAAApAATC pAAAAACCG GTGpAApG 600 TGpAGTCTC CpCCCpAG CCCTACTTAG AGpAAGGTG CACCCCTTAC TGGGCTGGGT 660 TCpTACCp pGAAATCAT NTTTGGAAG GGGCTGCCTA TCpTNCpA ACTAAAAAAN 720 AAAAATCTNC TGCCCTpTC AAGGAACCAT CCCATCCAp CCTNAACAAA AGGCCTGCCN 840 TTCpCCCCC AGpAACTNT ppTNpAA AApCCCAAA AAANGAACCN CCTGCTGGAA 900 AAACNCCCCC CTCCAANCCC CGGCCNAAGN GGAAGGpCC CpGAATCCC NCCCCCNCNA 960 ANGGCCCGGA ACCNpAAAN TNGpCCNGG GGGTNNGGCC TAAAAGNCCN ATpGGTAAA 1020 CCTANAAAp ppcppN TAAAAACCAC NpTNNpT pCTTAAACA AAACCCTNp 1080 TNTAGNANCN TATpCCCNC C 1101 (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1087 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 4: TCTAGAGCTG CGCCTGGATC CCGCCACAGT GAGGAGACCT GAAGACCAGA GAAAACACAG 60 CAAGTAGGCC CpTAAACTA CTCACCTGTG pGTCTTCTA ATTTApCTG TpTATpTG 120 pTCCATCAT pTAAGGGGT TAAAATCATC pßpCAGAC CTCAGCATAT AAAATGACCC 180 ATCTGTAGAC CTCAGGCTCC AACCATACCC CAAGAGpGT CTGGTpTGT pAAApACT 240 GCCAGGpTC AGCTGCAGAT ATCCCTGGAA GGAATApCC AGApCCCTG AGTAGTTTCC 300 2 ooieíonu opioB -Odll (a) seseq ep sejed 0101- On lONO "! (V) • VI0N3n03S 30 SV0llSJt_J310VdV0 (!) • 9-ON 0103S VUVd NÓlOVI? JdOdNI (z) 03 0801 1V1WWN133U1L31VD 31NWW3333N1Í131LLL 1131333333333131ULU. 0201 W333319NV 33333N33199933NW33311199999¡V1N1N1N33333133N1LLL » 096 NV33333NNN Nlllllllll 1VN33VW1L 11333JUL1L9993NN1W91131NV991N1 91. 006 31LLLWVN11V331331LL 1L9NN9N33333333V1L399NV1NN99N11N1WN3133 0fr8 39N31333331N31VN1N3333V9131NNV 333991V99V p9VlLLL91331LL9993V 08 ¿WWV19V1L n milB LLL 13993333333333N 3333399VNV 11W99133V UL 11W99NN3333V33133V333IIMI33N 33V11WW3331N3913N1 WNW39113 01- 099 3N13933131 W33991LLL NLLU.W999139NV3319119331391131NV993WW * 009 U1LL1NN13 INlNllllNN JL133N3N313131LWV1V9 VN31V3331111VÍV1LL19 OW 19W9W91131L91WJJLL 31131W9V1199199111191VW331LV V1333V1L9V 9 08! 7 31LLV33913 WV1LV99V99V3JJ.3011V WVHWV9V 919V11913V 19VW1LL39 02 * V13333V1311LLWWWV V1V1393WV 9191L391W 1LL3W1LLL 1V99LU1V9 09C 1V3VWW9V 9V3191331L 9V9W99V911L191311311399V1V1331WW1L99V # 09 * (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: TCTAGACCAA GAAATGGGAG GATpTAGAG TGACTGATGA TpCTCTATC ATCTGCAGp 60 AGTAAACAp CTCCACAGp TATGCAAAAA GTAACAAAAC CACTGCAGAT GACAAACACT 120 AGGTAACACA CATACTATCT CCCAAATACC TACCCACAAG CTCAACAAp pAAACTGp 180 AGGATCACTG GCTCTAATCA CCATGACATG AGGTCACCAC CAAACCATCA AGCGCTAAAC 240 # AGACAGAATG pTCCACTCC TGATCCACTG TGTGGGAAGA AGCACCGAAC pACCCACTG 300 GGGGGCCTGC NTCANAANAA AAGCCCATGC CCCCGGGTNT NCC rTNAAC CGGAACGAAT 360 NAACCCACCA TCCCCACANC TCCTCTGpC NTGGGCCCTG CATCTTGTGG CCTCNTNTNC 420 TTTNGGGGAN ACNTGGGGAA GGTACCCCAT pCNpGACC CCNCNANAAA ACCCCNGTGG 480 CCCTTTGCCC TGApCNCNT GGGCCTpTC TCTpTCCCT TTTGGGpGT pAAApCCC 540 • AATGTCCCCN GAACCCTCTC CNTNCTGCCC AAAACCTACC TAAATTNCTC NCTANGNNp 600 pCTTGGTGT TNCT? TCAA AGGTNACCTT NCCTGpCAN NCCCNACNAA AATrTrípCC 660 NTATNNTGGN CCCNNAAAAA NNNATCNNCC CNAApGCCC GAApGGpN GGppTCCT 720 NCTGGGGGAA ACCCpTAAA pTCCCCCp GGCCGGCCCC CCl II 11 ICC CCCCpTNGA 780 # AGGCAGGNGG pCTTCCCGA ACTTCCAAp NCAACAGCCN TGCCCApGN TGAAACCCp 840 pCCTAAAAT TAAAAAATAN CCGGpNNGG NNGGCCTCp TCCCCTCCNG GNGGGNNGNG 900 AAANTCCTTA CCCCNAAAAA GGpGCpAG CCCCCNGTCC CCACTCCCCC NGGAAAAATN 960 AACCTiTTCN AAAAAAGGAA TATAANpTN CCACTCCTTN GpCTCpCC 1010 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 950 base pairs 10 (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: TCTAGAGCTC GCGGCCGCGA GCTCTAATAC GACTCACTAT AGGGCGTC6A CTCGATCTCA 60 GCTCACTGCA ATCTCTGCCC CCGGGGTCAT GCGApCTCC TGCCTCAGCC pCCAAGTAG_120_* CTGGGApAC AGGCGTGCAA CACCACACCC GGCTAATTp GTATppAA TAGAGATGGG 180 GTTpCCCp GpGGCCANN ATGGTCTCNA ACCCCTGACC TCNNGTGATC CCCCCNCCCN 240 NGANCTCNNA CTGCTGGGGA TNNCCGNNNN NNNCCTCCCN NCNCNNNNNN NCNCNNTCCN 300 TNNTCCTTNC TCNNNNNNNN CNNTCNNTCC NNCTTCTCNC CNNNTNpNT CNNCNNCCNN 360 CNNNCCNCNT NCCCNCNNNT TCNCNTNCNN TNTCCNNCNN NNTCNNCNNN CNNNNCNTNN 420 CCNNTACNTC NTNNNCNNNT CCNTCTNTNN CCTCNNCNNT CNCTNCNCNT TNTCTCCTCN 480 NTNNNNNNCT CCNNNNNTCT CNTCNCNNCN TNCCTCNNTN NCCNCNCCCC NCCTCNCNNC 540 CTNNTTTNNN CNNCNNNTCC NTNCCNpCN NNTCCNNTNN CNNCNTCNCN NNCNpMTC 600 CCNCCNNpC CpNCNCNTN NNNTNTCNNN CNCNTCNNTC NTpNCTCCT NNNTCCCNNC 660 -10 TCNNpCNCC CNNNTCCNCC CCCCNCCTNT CTCTCNCCCN NNTNNNTNTN NNNCNTCCNC 720 TNTCNCNpC NTCNNTNCNT TNCTNTCNNC NNCNNTNCNC TNCCNTNTNT CTNNNTCNCN 780 TCNCNTNTCN CCNTCCNpN CTNTCTCCTN TNTCCpCCC CTCNCCTNCT CNpCNCCNC 840 CCNNTNTNTN TNNCNCCNNT NCTNNNCNNC CNTCNTTTCN TCTCTNCTNN NNNTNNCCTC 900 NNCCCNTNCC CTNNTNCNCT NCTNNTACCN TNCTNCTCCN TCTTCCTTCC 950 (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1086 base pairs (B) TYPE: nucleic acid 0 (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7 TCTAGAGCTC GCGGCCGCGA GCTCAApAA CCCTCACTAA AGGGAGTCGA CTCGATCAGA 60 CTGpACTGT GTCTATGTAG AAAGAAGTAG ACATAAGAGA pCCAppG pCTGTACTA 120 5 AGAAAAAApC pCTGCCTTG AGATGCTGp AATCTGTAAC CCTAGCCCCA ACCCTGTGCT 180 CACAGAGACA TGTGCTGTGT TGACTCAAGG pCAATGGAT pAGGGCTAT GCTpGpAA 240 AAAAGTGCTT GAAGATAATA TGCTTGTTAA AAGTCATCAC CApCTCTAA TCTCAAGTAC 300 CCAGG6ACAC AATACACTGC GGAAGGCCGC AGGGACCTCT GTCTAGGAAA GCCAGGTAp 360 GTCCAAGAp TCTCCCCATG TGATAGCCTG AGATATGGCC TCATGGGAAG GGTAAGACCT 420 GACTGTCCCC CAGCCCGACA TCCCCCAGCC CGACATCCCC CAGCCCGACA CCCGAAAAGG 480 GTCTGTGCTG AGGAAGApA NTAAAAGAGG AAGGCTCTp GCApGAAGT AAGAAGAAGG 540 CTCTGTCTCC TGCTCGTCCC TGGGCAATAA AATGTCTTGG TGpAAACCC GAATGTATGT 600 TCTACTTACT GAGAATAGGA GAAAACATCC pAGGGCTGG AGGTGAGACA CCCTGGCGGC 660 ATACTGCTCT pAATGCACG AGATGTTTGT NTAApGCCA TCCAGGGCCA NCCCCTUCC 720 pAAcprp ATGANACAAA AAcprGpc NcppccTG CGAACCTCTC CCCCTA? AN 780 CCTApGGCC TGCCCATCCC CTCCCCAAAN GGTGAAAANA TGpCNTAAA TNCGAGGGAA 840 TCCAAAACNT pTCCCGpG GTCCCCTpC CAACCCCGTC CCTGGGCCNN pTCCTCCCC 900 AACNTGTCCC GGNTCCTTCN pCCCNCCCC CTTCCCNGAN AAAAAACCCC GTNTGANGGN 960 GCCCCCTCAA ApATAACCT pCCNAAACA AANNGGpCN AAGGTGGTp GNpCCGGTG 1020 CGGCTGGCCT TGAGGTCCCC CCTNCACCCC AATTTGGAAN CCNGppp pApGCCCN 1080 NTCCCC 1086 * (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1177 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: NCCNpTAGA TGpGACAAN NTAAACAAGC NGCTCAGGCA GCTGAAAAAA GCCACTGATA 60 AAGCATCCTG GAGTATCAGA GTTTACTGp AGATCAGCCT CATpGACTT CCCCTCCCAC 120 ATGGTGpTA AATCCAGCTA CACTACTTCC TGACTCAAAC TCCACTApC CTGpCATGA 180 CTGTCAGGAA CTGpGGAAA CTACTGAAAC TGGCCGACCT GATCTTCAAA ATGTGCCCCT 240 AGGAAAGGTG GATGCCACCG TGpCACAGA CAGTACCNCC pCCTCGAGA AGGGACTACG 300 AGGGGCCGGT GCANCTGpA CCAAGGAGAC TNATGTGpG TGGGCTCAGG CTpACCANC 360 * AAACACCTCA NCNCNNAAGG CTGAApGAT CGCCCTCACT CAGGCTCTCG GATGGGGTAA 420 GGGATApAA CGpAACACT GACAGCAGGT ACGCCpTGC TACTGTGCAT GTACGTGGAG 480 CCATCTACCA GGAGCGTGGG CTACTCACTC GGCAGGTGGC TGTNATCCAC TGTAAANG6A 540 twenty # CATCAAAAGG AAAACNNGGC TGpGCCCGT GGTAACCANA AANCTGATCN NCAGCTCNAA 600 GATGCTGTGT TGACTTTCAC TCNCNCCTCT TAAACpGCT GCCCACANTC TCCTpCCCA 660 ACCAGATCTG CCTGACAATC CCCATACTCA AAAAAAAAAN AANACTGGCC CCGAACCCNA 720 ACCAATAAAA ACGGGGANGG TNGGTNGANC NNCCTGACCC AAAAATAATG GATCCCCCGG 780 GCTGCAGGAA pCAApCAN CCpATCNAT ACCCCCAACN NGGNGGGGGG GGCCNGTNCC 840 CApNCCCCT NTATTNApC pTNNCCCCC CCCCCGGCNT CCTTTpNAA CTCGTGAAAG 900 GGAAAACCTG NCTTACCAAN pATCNCCTG GACCNTCCCC pCCNCGGTN GNpANAAAA 960 AAAAGCCCNC ANTCCCNTCC NAAApTGCA CNGAAAGGNA AGGAApTAA CCpTApp 1020 pNNTCCTTT ANTpGTNNN CCCCCTpTA CCCAGGCGAA CNGCCATCNT pAANAAAAA 1080 AAANAGAANG pTATppC CpNGAACCA TCCCAATANA AANCACCCGC NGGGGAACGG 1140 GGNGGNAGGC CNCTCACCCC CTTTNTGTNG GNGGGNC 1177 (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1146 base pairs 20 (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: NCCNNpNNT GATGpGTCT piTGGCCTC TCTpGGATA CpTCCCTCT CpCAGAGGT 60 GAAAAGGGTC AAAAGGAGCT GpGACAGTC ATCCCAGGTG GGCCAATGTG TCCAGAGTAC 120 AGACTCCATC AGTGAGGTCA AAGCCTGGGG CTTpCAGAG AAGGGAGGAT TATGGGTTp 180 CCAApATAC AAGTCAGAAG TAGAAAGAAG GGACATAAAC CAGGAAGGGG GTGGAGCACT 240 CATCACCCAG AGGGACTTGT GCCTCTCTCA GTGGTAGTAG AGGGGCTACT TCCTCCCACC 300 ACGGpGCAA CCAAGAGGCA ATGGGTGATG AGCCTACAGG GGACATANCC GAGGAGACAT 360 GGGATGACCC TAAGGGAGTA GGCTGGTpT AAGGCGGTGG GACTGGGTGA GGGAAACTCT 420 CCTCpcpC AGAGAGAAGC AGTACAGGGC GAGCTGAACC GGCTGAAGGT CGAGGCGAAA 480 ACACGGTCTG GCTCAGGAAG ACCTTGGAAG TAAAApATG AATGGTGCAT GAATGGAGCC 540 ATGGAAGGGG TGCTCCTGAC CAAACTCAGC CApGATCAA TGpAGGGAA ACTGATCAGG 600 GAAGCCGGGA ApTCApAA CAACCCGCCA CACAGCpGA ACApGTGAG GpCAGTGAC 660 CCpCAAGGG GCCACTCCAC TCCAACTpG GCCApCTAC pTGCNAAAT pCCAAAACT 720 TCCTTppA A GCCGAATC CNTANTCCCT NAAAAACNAA AAAAAATCTG CNCCTApCT 780 GGAAAAGGCC CANCCCpAC CAGGCTGGAA GAAATTpNC Cl l l l l l l l l ppTGAAGG 840 93 09e 1331393V33 39V19V9199 V9139133V3 39V3V11V99 19V3VU133 191V9111L3 OO? 31L1L91933 9V3W39993 V33V1L9913 1LL39W1W 9139139V91 131V3913V3 0 * 2 V319VW913 V919399V9V U19W39V3 9991913V9V 99WV99191 399131V9V3 03 081 99V3191LV9 99391V19V9 1L91311311 31LLL9V339 9V9131L9V9 1313991LV1 021 liliV91331 133W33V33 W9W9DVD1 9V9V131L9V 13V331V999 9_ 30_VD91 09 331LW931V 1V91139W1 V931V1993V 93199V9313 33339993V1 9991LV31L3 • O μON 01 03S: VI0N3n03S 30 NQIOdl _.OS30 (¡x) 91. | BTU || : Vj9010d01 (?) OÜÜOUTS:? TI H 30 VlAI ^ Od (O) ooj? | Onu opioe:? D ll (a) seseq ap saied g ^ g: a nil 9N01 (v): VI 0N3 n03S 30 SVOilSj _. 310V_. VO (!) 01-: O I.: ON 01 03S VdVd NQI OVWdOd N I (Z) 9 * 11 NV9V1V 0 * 11 1LL1NN133. NWWV999N 99N1N91LLN WVWNN331 JJ11V33WV 331133W3N 0801 VNJ1V9N3J-9 9N1LLLJJ13 33N33NW99 VN3NV3331L 1LL3WVN33 UJLÍV33333 0201 3333331119 NN1V9N13N9 9N33111W3 333339WN1 V9V9V999V1 1WLLL131L 096 N1333N331L 33311NJ133 3N333WWV 3WWW30V 1133311WN 3WWV33JJ. 006 1V99099999 9N33N333W WVWW333 3333N3J1W N133W911V W1LN1LLN3 89 • GGTAGATGGC TCCACGTACA TGCACAGTAG CAAAGGCGTA CCTGCTGTCA GTGpAACGT 420 TAATATCCTT ACCCCATCGG AGAGCCTGAG TGAGGGCGAT CAApCAGCC CTpTGTGCT 480 GAGGTGpTG CTGGpAAGC CCTGAACCCA CAACACATCT GTCTCCATGG TAACAGCTGC 540 ACCGG 545 (2) INFORMATION FOR SEQ ID NO: 1 1: (i) SECTION CHARACTERISTICS: (A) LONGITU D: 196 base pairs 10 (B) TI PO: nucleic acid (C) THREAD FORM: single ( D) TOPOLOGY: line l (xi) DESCR IPTION OF SEQUENCE: SEQ ID NO: 1 1: TCTCCTAGGC TGGGCACAGT GGCTCATACC TGTAATCCTG ACCGTpCAG AGGCTCAGGT 60 15 GGGGGGGATCG CpGAGCCCA AGApTCAAG ACTAGTCTGG GTAACATAGT GAGACCCTAT 120 # CTCTACGAAA AAATAAAAAA ATGAGCCTGG TGTAGTGGCA CACACCAGCT GAGGAGGGAG 180 AATCGAGCCT AGGAGA 196 (2) INFORMATION FOR SEQ ID NO: 12: 20 (i) SEQUENCE CHARACTERISTICS: (A) LONGITU D: 388 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear 25 • (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: TCTCCTAGGC TTGGGGGCTC TGACTAGAAA pCAAGGAAC CTGGGApCA AGTCCAACTG 60 TGACACCAAC pACACTGTG GNCTCCAATA AACTGCpCT pCCTApCC CTCTCTApA 120 AATAAAATAA GGAAAACGAT GTCTGTGTAT AGCCAAGTCA GNTATCCTAA AAGGAGATAC 180 TAAGTGACAT TAAATATCAG AATGTAAAAC CTGGGAACCA GGpCCCAGC CTGGGApAA 240 ACTGACAGCA AGAAGACTGA ACAGTACTAC TGTGAAAAGC CCGAAGNGGC AATATGpCA 300 • CTCTACCGp GAAGGATGGC TGGGAGAATG AATGCTCTGT CCCCCAGTCC CAAGCTCACT 360 TACTATACCT CCTITATAGC CTAGGAGA 388 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 337 base pairs 15 (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: twenty 93 081 V1_3_13V3V 1111133119933V1LLLL999V931393V 1U1V1V3J11V1V31WW 0Z 021 33WV1LLV31L313911L3 V3V99W1W 3WV1913V11LU19199139V31L919V 09 913VW1V3993W9133V33333W1LLV JLLLV331LL33919V3V1V3391L9V19V1: *? N 0103S: VI0N3fl03S 30 NOlOdlídOSSO (.x) * | B? Ui | : V) 9010d01 (?) G OIÜOUTS: 0 IH 30 VI? IyOd (O) oo? E | onu opioB:? Dll (a) seseq ep seied (.g: anil9NO "l (v): VI0N3n03S 30 svoiisjasiovy VO (!): f! ON Ql O? s V_JVd NOlOVI? Id OdNI (3) 0l Ee V13V13V V3999111V1 13199V9V91 00 £ 3V9V99919319199V99V11L3V391LLV 131V399V3313131V313913V3V9131L * 2 39V19131LL 9V3991LLL9 V9V9V9W311L9LL139V1 W191W9319999191199 9 81 3111VI.IIU 33HLV1U91331113311131391V9V31V3V13H1V 91V1V9W3V 21 31V9HW1V 9V3JLL91W399V999V3W V91V1V1VW 999V91V1W WV91333V1 9 11913111W 33WJJ.VJLÍ11V3V31L1LV 11V3131U91V31W1V1339119V19V1 # l-Z # AAACAGpp TAAGTCGTp GGAACAAGAT ATTTTpcp TCCTGGCAGC TpTAACAp 240 ATAGCAAAp TGTGTCTGGG GGACTGCTGG TCACTGTpC TCACAGpGC AAATCAA6GC 300 ATpGCAACC AAGAAAAAAA AAl 11111 IG ppApTGA AACTGGACCG GATAAACGGT 360 GpTGGAGCG GCTGCTGTAT ATAGTpTAA ATGGTTTAp GCACCTCCTT AAGpGCACT 420 TATGTGGGGG GGGGNTpTG NATAGAAAGT NTHANTCAC ANAGTCACAG GGACTpTNT 480 CpiTGGNNA CTGAGCTAAA AAGGGCTGNT TfTCGGGTGG GGGCAGATGA AGGCTCACAG 540 GAGGCCTTTC TCpAGAGGG GGGAACTNCT A 571 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 548 base pairs 15 (B) TYPE: nucleic acid - k (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: TATATAGGTA ATAAcpAM TATAT? TGA TCACCCACTG GGGTGATAAG ACAATAGATA 60 TAAAAGTAp TCCAAAAAGC ATAAAACCAA AGTATCATAC CAAACCAAAT TCATACTGCT 120 TCCCCCACCC GCACTGAAAC pCACCTTCT AACTGTCTAC CTAACCAAAT TCTACCCpC 180 AAGTCpTGG TGCGTGCTCA CTACTCTHl 111 III i ilf I? INIIIIGG AGATGGAGTC 240 TGGCTGTGCA GCCCAGGGGT GGAGTACAAT GGCACAACCT CAGCTCACTG NAACCTCCGC 300 CTCCCAGGp CATGAGApC TCCTGNpCA GCCTTCCCAG TAGCTGGGAC TACAGGTGTG 360 CATCACCATG CCTGGNTAAT pTNGGGTAG AGATGGGGGT TpACATGp 420 GGCCAGGNTG GTNTCGAACT CCTGACCTCA AGTGATCCAC CCACCTCAGG CTCCCAAAGT 480 GCTAGGApA CAGACATGAG CCACTGNGCC CAGNCCTGGT GCATGCTCAC pCTCTAGGC 540 AACTACTA 548 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 638 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 16: # pcCGTTATG CACATGCAGA ATApCTATC GGTACpCAG CTATTACTCA TTpGATGGC 60 GCAATCCGAG CCTATCCTCA AGATGAGTAT pAGAAAGAA pGApTAGC GATAGACCAA 120 GCTGGTAAGC ACTCTGACTA CACGAAApG pCAGATGTG ATGGApTAT GACAGpGAT 180 CpTGGAAGA GApApAAG TGApApp AAAGGGAATC CApAApCC AGAATATCp 240 GGpTAGCTC AAGATGATAT AGAAATAGAA CAGAAAGAGA CTACAAATGA AGATGTATCA 300 CCAACTGATA pGAAGAGCC TATAGTAGAA AATGAApAG CTGCATTTAT TAGCCpACA 360 CATAGCGAp pCCTGATGA ATCTTATAp CAGCCATCGA CATAGCApA CCTGATGGGC 420 AACCTTACGA ATAATAGAAA CTGGGTGCGG GGCTApGAT GAApCATCC NCAGTAAAp 480 TGGATATNAC AAAATATAAC TCGApGCAT pGGATGATG GAATACTAAA TCTGGCAAAA 540 GTAACpTGG AGCTACTAGT AACCTCTCTT TpGAGATGC AAAAppCT pTAGGGTp 600 CpApCTCT ACpTACGGA TApGGAGCA TAACGGGA 638 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 286 base pairs 20 (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: ACTGATGGAT GTCGCCGGAG GCGAGGGGCC pATCTGATG CTCGGCTGCC TGTTCGTGAT 60 GTGCGCGGCG ApGGGCTGT pATCTCAAA CACCGCCACG GCGGTGCTGA TGGCGCCTAT 120 TGCCpAGCG GCGGCGAAGT CAATGGGCGT CTCACCCTAT CCTTTTGCCA TGGTGGTGGC 180 GATGGCGGCT TCGGCGGCGT pATGACCCC GGTCTCCTCG CCGGpAACA CCCTGGTGCT 240 TGGCCCTGGC AAGTACTCAT pAGCGAHT TGTCAAAATA GGCGTG 286 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 262 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 18: TCGGTCATAG CAGCCCCTTC pCTCAATTT CATCTGTCAC TACCCTGGTG TAGTATCTCA 60 TAGCCpACA ppTATAGC CTCCTCCCTG GTCTGTCTp TGATprCCT GCCTGTAATC 120 CATATCACAC ATAACTGCAA GTAAACATp CTAAAGTGTG GpATGCTCA TGTCACTCCT 180 GTGNCAAGAA ATAGpTCCA pACCGTCp AATAAAApC GGApTGpC pTCTAp 240 TCACTCTTCA CCTATGACCG AA 262 (2) INFORMATION FOR SEQ ID NO: 19 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 261 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: TCGGTCATAG CAAAGCCAGT GGTpGAGCT CTCTACTGTG TAAACTCCTA AACCAAGGCC 60 ApTATGATA AATGGTGGCA GGAppTAT TATAAACATG TACCCATGCA AATpCCTAT 120 AACTCTGAGA TATApCTTC TACATTTAAA CAATAAAAAT AATCTATpT TAAAAGCCTA 180 ATpGCGTAG pAGGTAAGA GTGpTAATG AGAGGGTATA AGGTATAAAT CACCAGTCAA 240 CGTpCTCTG CCTATGACCG A 261 (2) INFORMATION FOR SEQ ID NO: 20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 294 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 20: TCGGTCATAG CAGCCCCpC pCTCAATp CATCTGTCAC TACCCTGGTG TAGTATCTCA 60 TAGCCpACA TTTpATAGC CTCCTCCCTG GTCTGTCpr TGATTpCCT GCCTGTAATC 120 CATATCACAC ATAACTGCAA GTAAACATp CTAAAGTGTG GpATGCTCA TGTCACTCCT 180 GTGNCAAGAA ATAGTpCCA pACCGTCp AATAAAApC GGApTGpC pTNCTApN 240 TCACTCTTCA CCTATGACCG AA 262 (2) INFORMATION FOR SEQ ID NO: 21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 208 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 21: TCGGTCATAG CAAAGCCAGT GGTpGAGCT CTCTACTGTG TAAACTCCTA AACCAAGGCC 60 ApTATGATA AATGGTGGCA GGATprTAT TATAAACATG TACCCATGCA AApTCCTAT 120 AACTCTGAGA TATApCTTC TACApTAAA CAATAAAAAT AATCTATpT TAAAAGCCTA 180 ATITGCGTAG pAGGTAAGA GTGpTAATG AGAGGGTATA AGGTATAAAT CACCAGTCAA 240 CGTpCTCTG CCTATGACCG A 261 (2) INFORMATION FOR SEQ ID NO: 22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 287 base pairs (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22: NCCNpGAGC TGAGTGApG AGATNTGTAA TGGpGTAAG GGTGApCAG GCGGApAGG 60 GTGGCGGGTC ACCCGGCAGT GGGTCTCCCG ACAGGCCAGC AGGATpGGG GCAGGTACGG 120 NGTGCGCATC GCTCGACTAT ATGCTATGGC AGGCGAGCCG TGGAAGGNGG ATCAGGTCAC 180 * GGCGCTGGAG CTTTCCACGG TCCATGNAp GNGATGGCTG pCTAGGCGG CTGpGCCAA 240 GCGTGATGGT ACGCTGGCTG GAGCApGAT pCTGGTGCC AAGGTGG 287 (2) INFORMATION FOR SEQ ID NO: 23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 204 base pairs 15 (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23: pGGGTAAAG GGAGCAAGGA GAAGGCATGG AGAGGCTCAN GCTGGTCCTG GCCTACGACT 60 GGGCCAAGCT GTCGCCGGGG ATGGTGGAGA ACTGAAGCGG GACCTCCTCG AGGTCCTCCG 120 NCGpACTTC NCCGTCCAGG AGGAGGGTCT pCCGTGGTC TNGGAG6AGC GGGGGGAGAA 180 GATNCTCCTC ATGGTCNACA TCCC 204 93 -QZ-OH 0103S: VI0N3n03S 30 NplOdldOSSO (¡x) | B? Ui | : Vj90! Od01 (?) 03 OIÜOUTS -OllH 30 VI? JdOd () ooiepnu opioe:? Dll (a) seseq ep S? JBd 9Z3: an l9N01 (V): VI0N3D03S 30 SV0I1SI _J310V_1V0 (!): 9:? N 0103S VÜVd NOlüVlAli OdNl (3) 91.

Z V33V 9191V19V1139V1V11V3V 0 * 2 9JJ19V9119 J_lLV199_.il 11W31V1V11VJL1N119911VW9V91L1 V991LWV1L 081 V1LL11V13N 1LV91W1L9131L1LV1L3 V9V1L91V3V 991V3931W 33U 3W11 01. 021 1LL1VJ119V 991LV1V1L9 V91V333V91 M3NIIIW 91391L9V1V 91WV13319 i 9 LILVIIVV WW311V1V 9999V91LV33V39919V9V 199939V99V 3199J1V991 Jfß ' • * 3ON 0103S: VI0N3n03S 30 NOlOdlcdOSSO (ix) | BTU.i | : V | 9010d01 (?) OIMOUTS: oilH 30 VllüOd (O) S ooi? | Onu opioe -Odll (a) s? SBq ep S? JBd] 793: anil9N01 (V): VI0N3n03S 30 SV0I1SI_.310V._IV0 (0; -? N a? 03S yvd NOiovi? IaodNi (z) 61 ^^ * 9 pACAACGAG GGGAAACTCC GTCTCTACAA AAApAAAAA ApAGCCAGG T6TGGTGGTG 60 TGCACCCGCA ATCCCAGCTA CpGGGAGGT TGAGACACAA GANTCACCTA NATGTGGGAG 120 GTCAAGGpG CATGAGTCAT GApGTGCCA CTGCACTCCA GCCTGGGTGA CAGACCGAGA 180 CCCTGCCTCA ANAGANAANG AATAGGAAGT TCAGAAATCN TGGNTGTGGN GCCCAGCAAT 240 CTGCATCTAT NCAACCCCTG CAGGCAANGC TGATGCAGCC TANGpCAAG AGCTGCTGp 300 TCTGGAGGCA GCAGpNGGG CpCCATCCA GTATCACGGC CACACTCGCA CNAGCCATCT 360 GTCCTCCGTN TGTNAC 376 (2) INFORMATION FOR SEQ ID NO: 26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 372 base pairs (B) TYPE: nucleic acid 15 (C) THREAD FORM: simple * (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26: pACAACGAG GGGAAACTCC GTCTCTACAA AAApAAAAA ApAGCCAGG TGTGGTGGTG 60 TGCACCTGTA ATCCCAGCTA CpGGGCGGC TGAGACACAA GAACCACCTA AATGTGGGAG 120 GGTCAAGGp GCATGAGTCA TGATCGCGCC ACTGCACTCC AGCCTGGGTG ACAGACTGAG 180 ACCCTGCCTC AAAAGAAAAA GAATAGGAAG pCAGAAACC CTGGGTGTGG NGCCCAGCAA 240 TCTGCATpA AACAATCCCT GCAGGCAATG CTGATGCAGC CTAAGpCAA GAGCTGCTGT 300 TCTGGAGGCA GNAGTAAGGG CpCCATCCA GCATCACGGN CAACACTGCA AAAGCACCTG 360 TCCTCGpGG TA 372 (2) INFORMATION FOR SEQ ID NO: 27: 5 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 477 base pairs (B) TYPE: nucleic acid 4 - (C) THREAD FORM: single (D) TOPOLOGY: linear 10 (xi) DESCRIPTION OF SEQUENCE CIA: SEQ ID NO: 27: pCTGTCCAC ATCTACAAGT pTATTTAp pGTGGGTp TCAGGGTGAC TAAGppTC 60 CCTACApGA AAAGAGAAGT TGCTAAAAGG TGCACAGGAA ATCAIIMII TAAGTGAATA 120 TGATAATATG GGTCCGTGCT TAATACAACT GAGACATAp TGpCTCTGT TppTAGAG 180 TCACCTCpA AAGTCCAATC CCACAATGGT GAAAAAAAAA TAGAAAGTAT pGpCTACC 240 pTAAGGAGA CTGCAGGGAT TCTCCpGAA AACGGAGTAT G6AATCAATC pAAATAAAT 300 ATGAAApGG pGGTCTTCT GGGATAAGAA ApCCCAACT CAGTGTGCTG AAApCACCT 360 GACMIIIII GGGAAAAAAT AGTCGAAAAT GTCAATpGG TCCATAAAAT ACATGpACT 420 ApAAAAGAT ApTAAAGAC AAApcpTC AGAGCTCTAA GApGGTGTG GACAGAA 477 (2) IN FORMATION FOR SEQ ID NO: 28 (i) SEQUENCE CHARACTERISTICS: 25 (A) LENGTH: 438 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28: TCTNCAACCT CpGANTGTC AAAAACCpN TAGGCTATCT CTAAAAGCTG ACTGGTApC 60 ApCCAGCAA AATCCCTCTA GTppGGAG pTCC pA CTATCTGGGG CTGCCTGAGC 120 CACAAATGCC AAApAAGAG CATGGCTAp pCGGGGGCT GACAGGTCAA AAGGGGTGTA 180 AATCCGATAA GCCTCCTGGA GGTGCTCTAA AAACACTCCT GGTGACTCAT CATGCCCCTG 240 GACGACpCA ATCGNCpAG ACAAGpTAT AGGTTTCTGG GCAGCTCCCT GAATACCCAC 300 GAGGAGATAC CGGTGGAAAT CGTCAAAAGT TCTCCCTCCA CpGAGAAAT pGGGTCCCA 360 ApAGGTCCC AApGGGTCT CTAATCACTA pCCTCTAGC TTCCTCCTCC GGNCTApGG 420 pGATGTGAG GpGAAGA 438 (2) INFORMATION FOR SEQ ID NO: 29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 620 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 29 'AAGAGGGTAC CAGCCCCAAG CCpGACAAC pCCATAGGG TGTCAAGCCT GTGGGTGCAC 60 AGAAGTCAAA AApGAGpT TGGGATCCTC AGCCTAGAp TCAGAGGATA TAAAGAAACA 120 CCTAACACCT AGATApCAG ACAAAAGpT ACTACAGGGA TGAAGCpTC ACGGAAAACC 180 TCTACTAGGA AAGTACAGAA GAGAAATGTG GGTpGGAGC CCCCAAACAG AATCCCCTCT 240 AGAACACTGC CTAATGAAAC TGTGAGAAGA TGGCCACTGT CATCCAGACA CCAGAATGAT 300 AGACCCACCA AAAACpATG CCATApGCC TATAAAACCT ACAGACACTC AATGCCAGCC 360 CCATGAAAAA AAAACTGAGA AGAAGACTGT NCCCTACAAT GCCACCGGAG CAGAACTGCC 420 CCAGGCCATG GAAGCACAGC TCTTATATCA ATGTGACCTG GATGpGAGA CATGGAATCC 480 NANGAAATCN TTpAANACT TCCACGGpN AATGACTGCC CTApANAp CNGAACTTAN 540 ATCCNGGCCT GTGACCTCp TGCpTGGCC ApCCCCCp pTGGAATGG 600 CCCATGCCTG TNCCCTCpA 620 (2) INFORMATION FOR SEQ ID NO: 30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 100 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 30: * pACAACGAG GGGGTCAATG TCATAAATGT CACAATAAAA CAATCTCTTC IMIIMIII 60 1111 H 1111 1111111111 IIIHHin 100 (2) INFORMATION FOR SEQ ID NO: 31: 5 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 762 base pairs (B) TYPE: nucleic acid ^ (C) THREAD FORM: single (D) TOPOLOGY: linear 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31: fifteen twenty TAGTCTATGC GCCGGACAGA GCAGAApAA ApGGAAGp GCCCTCCGGA CpTCTACCC 60 ACACTCpCC TGAAAAGAGA AAGAAAAGAG GCAGGAAAGA GGpAGGAp TCATpTCAA 120 GAGTCAGCTA ApAGGAGAG CAGAGpTAG ACAGCAGTAG GCACCCCATG ATACAAACCA 180 TGGACAAAGT CCCTGTpAG TAACTGCCAG ACATGATCCT GCTCAGGTp TGAAATCTCT 240 CTGCCCATAA AAGATGGAGA GCAGGAGTGC CATCCACATC AACACGTGTC CAAGAAAGAG 300 TCTCAGGGAG ACAAGGGTAT CAAAAAACAA GApCTTAAT GGGAAGGAAA TCAAACCAAA 360 AAApAGAp pTCTCTACA TATATATAAT ATACAGATAT pAACACAp ApCCAGAGG 420 TGGCTCCAGT CCpGGGGCT TGAGAGATGG TGAAAACTp TGpCCACAT TAACTTCTGC 480 TCTCAAApC TGAAGTATAT CAGAATGGGA CAGGCAATGT pTGCTCCAC ACTGGGGCAC 540 AGACCCAAAT GGpCTGTGC CCGAAGAAGA GAAGCCCGAA AGACATGAAG GATGCpAAG 600 GGGGGpGGG AAAGCCAAAT TGGTANTATC TTITCCTCCT GCCTGTGpC CNGAAGTCTC 660 CNCTGAAGGA ApCTTAAAA CCCpTGTGA GGAAATGCCC CCpACCATG ACAANTGGTC 720 CCApGCpT TAGGGNGATG GAAACACCAA GGGTpTGAT CC 762 (2) INFORMATION FOR SEQ ID NO: 32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 276 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) DESCRIPTION OF SECU ENC IA: SEQ ID NO: 32: TAGTCTATGC GTGTApAAC CTCCCCTCCC TCAGTAACAA CCAAAGAGGC AGGAGCTGp 60 ApACCAACC CCApTTACA GATGCATCAA TAATGACAGA GAAGTGAAGT GACpGCGCA 120 CACAACCAGT AAApGGCAG AGTCAGATp GAATCCATGG AGTCTGGTCT GCACTpCAA 180 TCACCGAATA CCCTITCTAA GAAACGTGTG CTGAATGAGT GCATGGATAA ATCAGTGTCT 240 # ACTCAACATC pTGCCTAGA TATCCCGCAT AGACTA 276 (2) INFORMATION FOR SEQ ID NO: 33: (i) SEQUENCE CHARACTERISTICS: (A) LONGITU D: 477 base pairs (B) TYPE: nucleic acid 15 (C) THREAD FORM: simple A (D) TOPOLOGY : line l (xi) DESCRIPTION OF SECU ENC IA: SEQ ID NO: 33: TAGTAGpGC CAAATATpG AAAApTACC CAGAAGTGAT TGAAAACTp pGGAAACAA 60 AAACAAATAA AGCCAAAAGG TAAAATAAAA ATATCTpGC ACTCTCGpA pACCTATCC 120 ATAACTpp CACCGTAAGC TCTCCTGCp GpAGTGTAG TGTGGpATA pAAACTTp 180 TAGpApAT prpApcA cppccACT AGAAAGTCAT TApGApTA GCACACATGT 240 TGATCTCAp ppTATAGG CAAAApTGA TGCTATGCAA CAAAAATACT 300 CAAGCCCAp ATCTppTC CCCCCGAAAT CTGAAAApG CAGGGGACAC AGGGAAGpA 360AApGTAAA TATGpCAGT pATGpTAA AAATGCACAA AACATAAGAA 420 AApGTGTp ACpGAGCTG CTGApGTAA GCAGTpTAT CTCAGGGGCA ACTACTA 477 (2) INFORMATION FOR SEQ ID NO: 34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 631 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 34: TAGTAGpGC CAApCAGAT GATCAGAAAT GCTGCTpCC TCAGCApGT CTTGpAAAC 60 CGCATGCCAT pGGAACTp GGCAGTGAGA AGCCAAAAGG AAGAGGTGAA TGACATATAT 120 ATATATATAT ApCAATGAA AGTAAAATGT ATATGCTCAT ATACpTCTA GpATCAGAA 180 TGAGpAAGC pTATGCCAT TGGGCTGCTG CATATTÍTAA TCAGAAGATA AAAGAAAATC 240 TGGGCAGGGT TAGAATGTGA TACATGT? T pTAAAACTG pAMTApA prcGATAp 300 TGTCTAAGAA CCGGAATGp CpAAAApT ACTAAAACAG TApGpTGA GGAAGAGAAA 360 ACTGTACTGT pGCCApAT TACAGTCGTA CAAGTGCATG TCAAGTCACC CACTCTCTCA 420 (2) INFORMATION FOR SEQ ID NO: 35: (i) SEQUENCE CHARACTERISTICS: (A) LONGITU D: 578 base pairs (B) TI PO: nucleic acid (C) FORM OF H ILO : simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35: TAGTAGpGC CATCCCATAT TACAGAAGGC TCTGTATACA TGACTTATp GGAAGTGATC 60 TGTpTCTCT CCAAACCCAT pATCGTAAT pCACCAGTC pGGATCAAT CTTGGpTCC 120 ACTGATACCA TGAAACCTAC pGGAGCAGA CApGCACAG piTCTGTGG TAAAAACTAA 180 AGGTpApT GCTAAGCTGT CATCpATGC pAGTAp l i l i l lACAG TGGGGAApG 240 CTGAGApAC AppGpAT TCApAGATA cprGGGATA ACTTGACACT GTcpcpp 300 TpCGCTpT AApGCTATC ATCATGCTp TGAAACAAGA ACACApAGT CCTCAAGTAT 360 TACATAAGCT TGCTTGpAC GCCTGGTGGT pAAAGGACT ATCTTTGGCC TCAGGpCAC 420 AAGAATGGGC AAAGTGTpC CTTATGpCT GTAGpCTCA ATAAAAGAp GCCAGGGGCC 480 GGGTACTGTG GCTCGCACTG TAATCCCAGC ACTpGGGAA GCTGAGGCTG GCGGATCATG 540 pAGGGCAGG TGpCGAAAC CAGCCTGGGC AACTACTA 578 (2) INFORMATION FOR SEQ ID NO: 36: (i) SEQUENCE CHARACTERISTICS: _ (A) LENGTH: 583 base pairs 5 (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear fr (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36: 1Q TAGTAGpGC CTGTAATCCC AGCAACTCAG GAGGCTGGGG CAGGAGAATC AGpGAACCT 60 GGGAGGCAGA AGTTGTAAp AGCAAAGATC GCACCApGC ACTTCAGCCT GGGCAACAAG 120 AGTGAGApC CATCTCAAAA ACAAAAAAAA GAAAAAGAAA AGAAAAGGAA AAAACGTATA 180 AACCCAGCCA AAACAAAATG ATCApCpR TAATAAGCAA GACTAATpA ATGTGpTAT 240 pAATCAAAG CAGpGAATC pCTGAGTTA pGGTGAAAA TACCCATGTA GpAApTAG_300_GGpcpACT TGGGTGAACG pTGATGpC ACAGGpATA AAATGGpAA CAAGGAAAAT "360 GATGCATAAA GAATCTTATA AACTACTAAA AATAAATAAA ATATAAATGG ATAGGTGCTA 420 TGGATGGAGT TpTGTGTAA TTTAAAATCT TGAAGTCAp pGGATGCTC ApGGpGTC 480 TGGTAATpC CApAGGAAA AGGpATGAT ATGGGGAAAC TGTpCTGGA AApGCGGAA 540 TGpTCTCAT CTGTAAAATG CTAGTATCTC AGGGCAACTA CTA 583 (2) INFORMATION FOR SEQ ID NO: 37: 25 (i) SEQUENCE CHARACTERISTICS: (A) ITU D LENGTH: 716 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37: GATCTACTAG TCATNTGGAT TCTATCCATG GCAGCTAAGC CTTTCTBAAT GGApCTACT 60 GCTpCTTGT TCpTAATCC AGACCCTTAT ATATGTpAT GpCACAGGC AGGGCAATGT 120 pAGTGAAAA CAApCTAAA TppTATp TGCATpTCA TGCTAATpC CGTCACACTC 180 CAGCAGGCp CCTGGGAGAA TAAGGAGAAA TACAGCTAAA GACApGTCC CTGCpACTT 240 ACAGCCTAAT GGTATGCAAA ACCACpCAA TAAAGTAACA GGAAAAGTAC TAACCAGGTA 300 GAATGGACCA AAACTGATAT AGAAAAATCA GAGGAAGAGA GGAACAAATA TTTACTGAGT 360 CCTAGAATGT ACAAGGCTp pAApACAT ATpTATGTA AGGCCTGCAA AAAACAGGTG 420 AGTAATCAAC ATpGTCCCA TpTACATAT AAGGAAACTG AAGCTTAAAT TGAATAATTT 480 AATGCATAGA pTTATAGp AGACCATGp CAGGTCCCTA TGpATACp ACTAGCTGTA 540 TGAATATGAG AAAATAATp TGpAppC pGGCATCAG TATTITCATC TGCAAAATAA 600 AGCTAAAGp ApTAGCAAA CAGTCAGCAT AGTGCCTGAT ACATAGTAGG TGCTCCAAAC 660 ATGApACNC TANTApNGG TApANAAAA ATCCAATATA GGCNTGGATA AAACCG 716 (2) FOUNDATION FOR SEC ID NO: 38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 688 base pairs (B) TYPE: nucleic acid (C) FORM OF H ILO: simple 5 (D) ) TOPOLOGY: line l (xi) DESCRIPTION OF SEC U IN C IA: SEQ ID NO: 38: pCTGTCCAC ATATCATCCC ACpTAApG pAATCAGCA AAACpTCAA TGAAAAATCA 60 CCAGGATCAC ACCAGGAAAC TGAAGGTGTA l i l i l I I M? CCTTAAAAAA 120 AAAAAAAAAA ACCAAACAAA CCAAAACAGA pAACAGCAA AGAGpCTAA AAAApTACA 180 pTCTCTTAC AACTGTCAp CAGAGAACAA TAGpcpAA GTCTGpAAA TCpGGCAp 240 AACAGAGAAA CpGATGAAN AGpGTACTT GGAATApGT GGAI I I I I U ppGTCTAA 300 TCTCCCCCTA pGppGCC AACAGTAAp TAAGTTTGTG TGGAACATCC CCGTAGp &A 360 AGTGTAAACA ATGTATAGGA AGGAATATAT GATAAGATGA TGCATCACAT ATGCApACA 420 # TGTAGGGACC pCACAACp CATGCACTCA GAAAACATGC pGAAGAGGA GGAGAGGACG 480 GCCCAGGGTC ACCATCCAGG TGCCTTGAGG ACAGAGAATG CAGAAGTGGC ACTGpGAAA 540 TTTAGAAGAC CATGTGTGAA TGGTpCAGG CCTGGGATGT pGCCACCAA GAAGTGCCTC 600 CGAGAAATp CpTCCCAp TGGAATACAG GGTGGCTTGA TGGGTACGGT GGGTGACCCA 660 ACGAAGAAAA TGAAApCTG CCCTpCC 688 (2) I NFORMATION FOR S EC ID NO: 39: (i) SEQUENCE CHARACTERISTICS: (A) LONGITU D: 585 base pairs (B) TI PO: nucleic acid (C) FORM OF HI LO: simple (D) ) TOPOLOGY: linear (xi) DESCR I SECU ENC AI PCIÓ N: SEC ID NO: 39: TAGTAGpGC CGCNNACCTA AAANpGGAA AGCATGATGT CTAGGAAACA TANTAAAATA 60 GGGTATGCCT ATGTGCTACA GAGAGATGp AGCApTAAA GTGCATANp pATGTATp 120 TGACAAATGC ATATNCCTCT ATAATCCACA ACTGApACG AAGCTATTAC AApAAAAAG 180 HTGGCCGGG CGTGGTGGGC GGTGGCTGAC GCCTGTAATC CCAGCACTTT GGGAGGCCGA 240 GGCACGCGGA TCACGAGGTC GGGAGpCAA GACCATCCTG GCTAACACGG TGAAAGTCCA 300 TCTCTACTAA AAATACGAAA AAATTACCCC GGCGTGGTGG CGGGCGCCTG TAGTCCCAGC 360 TACTCCGGAG GCTGAGGCAG GAGAATGGCG TGAACCCAGG ACACGGAGCT TGCAGTGTGC 420 CAACATCACG TCACTGCCCT CCAGCCTGGG GGACAGGAAC AAGANTCCCG TCCTCANAAA 480 AGAAAAATAC TACTNATANT pCNACpTA T TAApA CACAGAACTN CCTCpGGTA 540 CCCCCTTACC ApCATCTCA CCCACCTCCT ATAGGGCACN NCTAA 585 OI? OUTS: oilH 30 VI? Idid (O) 93 ooi? pnu opioB -Odll (a) s? seq? p s? jed ZZ: anil9N01 (V): VI0N3lT03S 30 SV0llSjd310Vd VO 0): |. *: 0N 0103S VidVd NOlOVI? od OdNI (3) 03 SZ * V9V3V 99191V9V191L3WW1W V1WW3V333WW91333 V319V1L3W 02 * VW999V191 W3111L313 U3W3991L 1133V3919133U1V91W WVW1L3V3 09S 1LV1V01V11 V1V333V993 V39WJ1V19119V313191 V1WV3W9V 9V3VWWW 91- 00e 1313V9199V 9W1113V991LV999Í911 V33V31LU11Í1LV133113V1VW3W9 0 * 2 V199WV1L331319V3913331W9V99V V3111L93313V1V331LV91LV9W1LLV 081 1LLV1V3111 W33W33V9 W9V3331V1131L1W9991L9V913V3V 39V3111W9 021 199V319WV VW33UIH 1913V931LL 1V3V911VW 33V991VU11V191V3W1 01 09 9V1W1LLL31V1VW1LL319L11W9W W913139W 9V1L31W33 V3V3319131: 0 * -ON I heard 03S: VI N3fl03S 30 Npl0dl-J0S30 (! X) | B? Ui | -VjOOlOdOl (O) OIMOUTS: 01IH 30 VlAi-JOd () oo¡? | Onu oppB:? Dll (a) s? Seq? P S? JBd g¿: aflll9N01 (V): VI0N3n03S 30 svousjasiova VO (!): 0 * ON 01 G3S VidVd NQIOVI? I-JOdNI (Z) eß # # (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41: TAAGAGGGTA CATCGGGTAA GAACGTAGGC ACATCTAGAG CpAGAGAAG TCTGGGGTAG_60_GAAAAAAATC TAAGTATTTA TAAGGGTATA GGTAACATp AAAAGTAGGG CTAGCTGACA 120 pApTAGAA AGAACACATA CGGAGAGATA AGGGCAAAGG ACTAAGACCA GAGGAACACT 180 AATATpAGT GATCACTTCC ApCTTGGTA AAAATAGTAA CTpTAAGp AGCpCAAGG 240 AAGATTpTG GCCATGApA GpGTCAAAA GpAGpCTC pGGGpTAT ApACTAAp 300 pGppAAG ATCCpGpA GTGCpTMT AAAGTCATGT TATATCAAAC GCTCTAAAAC 360 ApGTAGCAT GpAAATGTC ACAATATACT TACCATpGT TGTATATGGC TGTACCCTCT 420 CTA 423 (2) IN FORMATION FOR SEQ ID NO: 42: jk (i) SECU ENC AL CHARACTERISTICS: (A) LONGITU D: 527 base pairs (B) TI PO: nucleic acid (C) FORM OF HI LO: simple 2Q (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42: TCTCCTAGGC TAATGTGTGT GTpCTGTAA AAGTAAAAAG pAAAAApT TAAAAATAGA 60 AAAAAGCpA TAGAATAAGA ATATGAAGAA AGAAAATAp pTGTACAp TGCACAATGA 120 GpTATGTp TAAGCTAAGT GpApACAA AAGAGCCAAA AAGGppAA AAApAAAAC 180 GpTGTAAAG pACAGTACC CTTATGpAA pTATAApG AAGAAAGAAA AACIHUII 240 TATAAATGTA GTGTAGCCTA AGCATACAGT ApTATAAAG TCTGGCAGTG pCAATAATG 300 TCCTAGGCCT TCACApCAC TCACTGACTC ACCCAGAGCA ACTTCCAGTC CTGTAAGCTC 360 CApCGTGGT AAGTGCCCTA TACAGGTGCA CCATTTATp TACAGTATp pACTGTACC 420 pCTCTATGT pCCATATGT pCGATATAC AAATACCACT GGpACTATN GCCCNACAGG 480 TAApCCAGT AACACGGCCT GTATACGTCT GGTANCCCTA GNGAAGA 527 (2) INFORMATION FOR SEQ ID NO: 43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 331 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 43: 93 03 **: 0N 01 03S: VION3D03S 30 NplOdldOSSO (jx) IB? Uü: VI9010d01 (?) Gl OI? OUTS: 01IH 30 VIAldOd (O) or iepnu opioe:? Dll (a) s? Seq? P S? JBd 369 : anil9N01 (V) VI0N3n03S 30 SV0llSjd310VídV0 (!): **: 0N 01 03S VÜVd N lOVI? i andOdNI (Z) 0 | - iee 3 W1W1WV1 WIVIVJIVI 3V13V13311 # OOe 3W1LV1L9V 33W9V9V3V 3W991L391911V1W19119W9WW31L990V11LV 0 * 2 1V9131LV311V99V9W999133331W31L9131139V V1LV3WV191L3V3VW31 9 081 1VW3V31V9 V3JU1V1L9191LLLW1U.1L91V31WV 9V9V1LWW 991L9V1313 021 3113131119 W3V331U13W9VWWV 9W9WVWV VWV9W1LL 3113339139 09 91L33V13V1199V1LU1V 13V399913391V1V31313 W3V99V193133W31L31 93 : 9 ON 01 03S: V10N3fl03S 30 NOI0d 0S30 (? X) | e? Ui | : vj9010dO! (?) OI I IDUTS: oi l H 30 V yOd (O) 03 oo '? nu op e:? dll (a) s? seq? p S? JBd Z99: a nil9N0"l (V): VI0N3D03S 30 SVOllSJdSlOVy VO (!): 9 * -0N 01 03S VÜVd NplOVI? iyOdNI (3) 91. 269 W 13V13W399 3991V9191L 1V991WV93 91U393W3 3V911333V3 0 * S V1V9W9V33 1999V99913 9V333_tr1333 V133V9H91L 13V31991LV 991XV89913 08 * 91V991LNV9 V999V1LL9V VW331V999 W99V9V191 WJJ19V313 13131V9133 02 * 91VW99139 W39V91913 V333991V9V VW1V991V1 WV9139V11 991L39111V 0. 098 H19V1W13 1L991W11L 199WWW1 19V999V313 9V391L91V9 1LLL39131L 00C V9V9V19W1 3V333W911 1V91LV1L3V 991399V31V 991L9V9V1V 1W99W993 0 * 2 991W1V9V9 191999WU V1V991W99 V1V319V9W 9V99131VW 9V39W1V1V 081 11LW131U 1 £ M) 113913 VV9WW9V1 3V3V139191 V9V99V91L3 33V919V9V3 021 JJL99W) 199V 9V13333V9V 39V33319W V13V9V133V 1V133V9V13 1L391LL913 09 33DV3W333:) 3V039V93V 313013J1V9 1L93MV1VW V399V3391L 9V19VJ1399 Z6 F GGCpAGTAG pGCCApGC GAGTGCTTGC TCAACGAGCG pGAACATGG CGGApGTCT 60 AGApCAACG GApTGAGp pACCAGCAA AGCGAACCAA GCGCGGCCCA GAGAApATG 120 GGpGGpGG CpTGAAAAG ATGGAAATCC TGTAGGCCTA GTCAGAAAAG CCTTCTTGCA 180 GAACAGpGG pCTCGGGCG AACGCTCATC AAGATGCCCA pGGAAAGGC TAGCGTGTAT 240 pGGGAGAGC CTGATAGCGT GTCTTCTGAT GATGTpGTG CTTGGACAGT GACAAAAGAT 300 ATGCAAAGCA AGTCCGAACT AGACGTCAAG CTTCGTGAGC AAApApGT AGACTCCTAC 360 pATACTGTG AGGAATGATA GCCAAGGGTG GGGACTpAA GACTAAGGTG GTpGTACTT 420 GCGCCGATGA TCCCAGGCAG AAAGAMCTGA TCGCTAGTp TATACGGGCA ACTACTAAGC 480 CGAATTCCAG CACACTGGCG GCCGpACTA ApGGATCCG ANCTCGGTAC CAGCpGATG 540 CATASCpGA GpWTCTATA NTGTCNC 567 (2) INFORMATION FOR SEQ ID NO: 46: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 908 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 46: 93: Z * - ON 01 03S V Vd NOI OVI? J dOd NI (Z) 806 19VW1V3 006 W99339V93 V1V33V3333 331LW3331 39331VÜ91 1VW919191 331LL9139V 0 * 8 1V31991V31 V119399133 9V1VW13V3 1919V1V131 V19V91L39V 1V391V91L3 oz 08 ¿9W33V1993 139V9331V9 91W13V119 399939913V 3V39V331LV V93339W13 2Z V13W39991 V1V33V3V91 9W9V31319 1V191V1LV1 V9199W9V9 99191L9V39 99 139V331919 V31W9V339 VW9V91999 V91L31W91 W99VW399 W913331W 91-09 1V9V991311 W39V991W 1U1V3911L V193W1V1V 13313331V3 19191W119 * 9 1V19V9V913 V11W11V9V 39V39V1V91 V99V1V9133 1W11VW1V 931VM3V991 8 * 3913111V11 33939V3133 191V9V1LV3 V131LL13ÍV 191LWV1LV 3V313V3133 2 * 9V13331331? 9V9133V1V V9V1399V13 3V13919V99 1V33V93391 19V19V1L39 01. 9C 931LW9919 1919V33933 993W19V13 V331V9931L 9V933V1991 139W31V39 00e 1V1L9W313 W1W9V1V1 1V3V9199V1 1LV139W33 93V1LV91V3 3V91V139V3 0 * 2 VW99V3V3V 31LLW3W1 V9939V9191 1W9991991 91V1991L99 931139W11 081 1V3WU399 9333V39V1L V311V3399V 19V9191W1 1W39W393 9999V39939 021 9W991V933 31LL99V3V9 9V99199V39 9W1LV31LV 9339199999 9333311139 09 33W39WW V33999V9V9 939W9NV93 9N9NV1NN9N 9V3999V933 V9VW339V9 66 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 480 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple 5 (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47: TGCCAACAAG GAAAGTpTA AATGTCCCCT TGAGGApCT TGCTGATCAT CAAApCAGT 60 GGTTTpAAG GpßppCT GTCAAATAAC TCTAACTpA AGCCAAACAG TATATGGAAG 120 CACAGATAKA ATApACACA GATAAAAGAG GAGpGATCT AAAGTARAGA TAGpGGGGG 180 CpTAATpC TGGAACCTAG GTCTCCCCAT CpcpCTGT GCTGAGGAAC pcpGGAAG 240 CGGGGApCT AAAGpcpT GGAAGACAGT pGAAAACCA CCATGpGp CTCAGTACCT 300 pAppTAA AAAGTAGGTG AACATpTGA GAGAGAAAAG GGCpGGpG AGATGAAGTC 360 # CCCCCCCCCC CH 11 lll II ppAGCTGA AATAGATACC CTATGpNAA RGAARGGAp 420 APApTACC ATGCCAYTAR SCACATGCTC TpGATGGGC NYCTCCSTAC CCTCCpAAG 480 (2) INFORMATION FOR SEQ ID NO: 48: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 591 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single 25 (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48: AAGAGGGTAC CGAGTGGAAT pCCGCTTCA CTAGTCTGGT GTGGCTAGTC GGTFTCGTGG 60 TGGCCAACAT TACGAACTTC CAACTCAACC CTTCTTGGAC GpCAAGCGG GAGTACCGGC 120 GAGGATGGTG GCGTGAApC TGGCCpTCT pGCCGTGGG ATCGGTAGCC GCCATCATCG 180 GTATGpTAT CAAGATCTTC TpACTAACC CGACCTCTCC GATpACCTG CCCGAGCCGT 240 GGpTAACGA GGGGAGGGGG ATCCAGTCAC GCGAGTACTG GTCCCAGATC TTCGCCATCG 300 TCGTGACAAT GCCTATCAAC pCGTCGTCA ATAAGpGTG GACCTTCCGA ACGGTGAAGC 360 ACTCCGAAAA CGTCCGGTGG CTGCTGTGCG GTGACTCCCA AAATCpGAT AACAACAAGG 420 TAACCGAATC GCGCTAAGGA ACCCCGGCAT CTCGGGTACT CTGCATATGC GTACCCCpA 480 AGCCGAApC CAGCACACTG GCGGCCGpA CTAApGGAT CCGAACTCCG TAACCAAGCC 540 TGATGCGTAA CpGAGpAT TCTATAGTGT CCCTAAAATA ACCTGGCGp A 591 (2) INFORMATION FOR SEQ ID NO: 49: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 454 ares base (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 49: AAGAGGGTAC CTGCCpGAA ATpAAATGT CTAAGGAAAR TGGGAGATGA pAAGAGpG 60 GTGTGGCYTA GTCACACCAA AATGTATpA pACATCCTG CTCCTpCTA GpGACAGGA 120 AAGAAAGCTG CTGTGGGGAA AGGAGGGATA AATACTGAAG GGApTACTA AACAAATGTC 180 CATCACAGAG TpTCCTTp AGACAGAGTC pGCTCTGTC ACCCAGGCTG 240 GAATGAAGWG GTATGATCTC AGpGAATGC AACCTCTACC TCCTAGGpc AAGCGApCT 300 CATGCCTCAG CCTCCTGAGC AGCTGGGACT ATAGGCGCAT GCTACCATGC CAGGCTAAp 360 pTATATpT TApAGAGAC GGGGTGpGC CATGpGGCC AGGCAGGTCT CGAACTCCTG 420 GGCCTCAGAT GATCTGCCCC ACCGTACCCT CTTA 454 (2) INFORMATION FOR SEQ ID NO: 50: (i) SEQUENCE CHARACTERISTICS: 15 (A) LENGTH: 463 base pairs # (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50: twenty AAGAGGGTAC CAAAAAAAAG AAAAAGGAAA AAAAGAAAAA CAACpGTAT AAGGCTpCT 60 GCTGCATACA GCI II I HU pTAAATAAA TGGTGCCAAC AAATGTpp GCApCACAC 120 CAApGCTGG pTTGAAATC GTACTCpCA AAGGTATpG TGCAGATCAA TCCAATAGTG 180 ATGCCCCGTA GGTpTGTGG ACTGCCCACG pGTCTACCT TCTCATGTAG GAGCCApGA 240 GAGACTGTp GGACATGCCT GTGpCATGT AGCCGTGATG TCCGGGGGCC GTGTACATCA 300 TGpACCGTG GGGTGGGGTC TGCApGGCT GCTGGGCATA TGGCTGGGTG CCCATCATGC 360 CCATCTGCAT CTGCATAGGG TApGGGGCG pTGATCCAT ATAGCCATGA pGCTGTGGT 420 AGCCACTGp CATCApGGC TGGGACATGC TGpACCCTC pA 463 (2) INFORMATION FOR SEQ ID NO: 51: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 399 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 51: 93 OOe 91399WV19 VW31911ÍV 3133931991 1399911393 V3V133133V W1919U11 0 * 2 991LV9139V 33W13V331 1333913331 9W131V991 V333V99J19 3W9V139V1 081 13V313WV9 W9339V31V 19V19V31W 9939WW31 1W1W91LL V1V99W911 021 31W9V3131 3JJ1V39113 WV11V9WV 919919VWV WW9V9131 V1LW1W39 03 09 91W1V1V91 3H13WJ13 V31V31WW 1V91LW199 1L33W31W 3133W3113 : 29: 0N 01 03S: VI ON3n? 3S 30 NOlOdl dOSSO (¡x) oupu? ooi? pnu op B .'Odll (a) S? seq? p S? JBd 368: a nil 9N01 (V): VI 0N3 n03S 30 svousjysiovy VO (!): 3: 0N 01 03S V? dVd NÓlOVI? HdOd NI (3) 0 66C 91L99V911 13191V91V3 1V1V1LW1L 1V19V3V333 09C 39VW1913V V319LLV1D1 91W91V3V1 V1V1399VW V1LLL13V11 V139V9H33 002 V133W13W lilVlUlVl 93V1V13V3V 91V19V39V9 1319V11V13 13H33V91L 0 * 2 131V3H1W 9W1LÍ1V31 1L39V91VW 9V1L3V1L3V 991V19V9W 1LV1LW1V3 9 081 3H991L91V 39V1L331LL 1LW3W1LV V1LV1LLV9V 1L3W991W 1W3V11V91 021 1LW3919V3 9V9WV1399 99V91V919V 3V33V131V9 39W131333 V13V31LLLL 09 31339W133 9V31393V33 V339V913V9 9V3V1LV999 13919VW33 3133W31L3 * ÍH F * AAATAGGAAG ATAATGAACC GTGTCTlTp GGTCTCTpT CCATCCApA CTCTGATTp 360 ACAAAGAGGC CTGTApCCC CTGGTGAGGT TG 392 (2) INFORMATION FOR SEQ ID NO: 53: 5 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 179 base pairs (B) TYPE: nucleic acid F (C) THREAD FORM: single (D) TOPOLOGY: linear 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53: pCGGGTGAT GCCTCCTCAG GCTACAGTGA AGACTGGAp ACAGAAAGGT GCCAGCGAGA 60 TpCAGApC CTGTAAACCT CTAAAGAAAA GGAGTCGCGC CTCAACTGAT GTAGAAATGA 120 CTAGpCAGC ATACNGAGAC ACNTCTGACT CCGApCTAG AGGACTGAGT GACCTGCAN 179 (2) INFORMATION FOR SEQ ID NO: 54: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 112 base pairs (B) TYPE: nucleic acid 20 (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54: pCGGGTGAT GCCTCCTCAG GCTACATCAT NATAGAAGCA AAGTAGAANA ATCNNGpTG 60 TGCAT? TCC CACANACAAA ApCAAATGA NTGGAAGAAA pGGGANAGT AT 112 (2) INFORMATION FOR SEQ ID NO: 55: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 225 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 55: TGAGCpCCG CpCTGACAA CTCAATAGAT AATCAAAGGA CAACpTAAC AGGGApCAC 60 AAAGGAGTAT ATCCAAATGC CAATAAACAT ATAAAAAGGA ApCAGCTTC ATCATCATCA 120 GAAGWATGCA AApAAAACC ATAATGAGAA ACCACTATGT CCCACTAGAA TAGATAAAAT 180 CpAAAAGAC TGGTAAAACC AAGTGpGGT AAGGCAAGAG GAGCA 225 (2) INFORMATION FOR SEQ ID NO: 56: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 175 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: line! (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56: 92 : 89ON 0103S: VI0N3í) 03S 30 NOIOdl_.OS30 (¡x) ÍTTU? : Vj9010d01 (?) OIIPUTS: oilH 30 VI? IdOd (O) ooi? Pnu oppe:? Dll (a) s? Seq? P S? JBd nz OnilONOl (V) 03: VI0N3fl03S 30 SVOllSj _.310V? DV0 (! ): 89-ON 0103S V Vd NplOVI? JÍdOdNI (3) E22 VW VWVWWW 3913V3313911313131991L1199V119 081 9V313W191131LL91131913V1LV339 V1V1LL33313V31991331391L9V3331 9 021 919V99WV199V9991V1V 991LV3V1V3 V3VW91913 II II 191191 HLW1L9J1 09 1W9191L11 V191L9139V 101LW191L 1LV991W91 V991V333V33V1LLV339V JS ON 0103S: VI0N3n03S 30 NOlOdlUOSSO (! X) | B? Ui | : vj9010d01 (?) 01- onpu? s: oilH 30 VIAlidOd (O) ooi? pnu oppe:? dll (a) # s? seq? p S? JBd e33 On lONOl (V): VI0N3H03S 30 SVOIISI-OIOVH VO ( !) • Z9: 0N 0103S VHVd NQIOVI? J-.OdNI (Z) S_I V3JLD9 W9939W9V 319JU.919W. DJL31V999V9999V993V91333V1VD399 021 9V9919W91 WWV33V191V1L91V9W V1V1331913333VU11V9991LV13.il 09 9133131LV39W13319V9 V119103WV W3JL3J1V3V 3W33V113391L3133139 ZOl. F * GpCGAAGGT GAACGTGTAG GTAGCGGATC TCACAACTGG GGAACTGTCA AAGACGAAp 60 AACTGACTTG GATCAATCAA ATGTGACTGA GGAAACACCT GAAGGTGAAG AACATCATCC 120 AGTGGCAGAC ACTGAAAATA AGGAGAATGA ACTTGAAGAG GTAAAAGAGG AGGGTCCAAA 180 (2) INFORMATION FOR SEQ ID NO: 59: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 208 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single 10 (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59: GCTCCTCpG CCpACCAAC pTGCACCCA TCATCAACCA TGTGGCCAGG pTGCAGCCC 60 AGGCTGCACA TCAGGG6ACT GCCTCGCAAT ACpCATGCT GpGCTGCTG ACTGATGGTG 120 CTGTGACGGA TGTGGAAGCC ACACGTGAGG CTGTGGTGCG TGCCTCGAAC CTGCCCATGT 180 * CAGTGATCAT TATGGGTGGT AAATGGCT 208 (2) INFORMATION FOR SEQ ID NO: 60: 20 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 171 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear 25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60: AGCCApTAC CACCCATACT AAApCTAGT TCAAACTCCA ACTTCTTCCA TAAAACATCT 60 AACCACTGAC ACCAGpGGC AATAGCTTCT TCCTTCpTA ACCTCTTAGA GTATpATGG 120 TCAATGCCAC ACATpCTGC AACTGAATAA AGpGGTAAG GCAAGAGGAG C 171 (2) INFORMATION FOR SEQ ID NO: 61: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 134 base pairs (B) TYPE: nucleic acid 10 (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61: CGGGTGATGC CTCCTCAGGC pTGGTGTGT CCACTCNACT CACTGGCCTC pCTCCAGCA 60 ACTGGTGAAN ATGTCCTCAN GAAAANCNCC ACACGCNGCT CAGGGTGGGG TGGGAANCAT 120 j CANAATCATC NGGC 134 (2) INFORMATION FOR SEQ ID NO: 62: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 145 base pairs 20 (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION 'SEC ID NO'62' AGAGGGTACA TATGCAACAG TATATAAAGG AAGAAGTGCA CTGAGAGGAA CTTCATCAAG 60 GCCATpAAT CAATAAGTGA TAGAGTCAAG GCTCAACCCA GGTGTGACGG ApCCAGGTC 120 CCAAGCTCCT TACTGGTACC CTCTT 145 (2) INFORMATION FOR SEQ ID NO: 63: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 297 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single 10 (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63: TGCACTGAGA GGAApCAAA GGGpTATGC CAAAGAACAA ACCAGTCCTC TGCAGCCTAA 60 CTCApTGp TpGGGCTGC GAAGCCATGT AGAGGGCGAT CAGGCAGTAG ATGGTCCCTC 120 CCACAGTCAG CGCCATGGTG GTCCGGTAAA GCATpGGTC AGGCAGGCCT CGTpCAGGT 180 AGACGGGCAC ACATCAGCp TCTGGAAAAA CTpTGTAGC TCTGGAGCp TGTTpTCCC 240 AGCATAATCA TACACTGTGG AATCGGAGGT CAGTpAGp GGTAAGGCAA GAGGAGC 297 (2) INFORMATION FOR SEQ ID NO: 64: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 300 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single 25 (D) TOPOLOGY: linear CIA: SEC ID NO: 64: GCACTGAGAG GAACTTCCAA TACTATGpG AATAGGAGTG GTGAGAGAGG GCATCCTTGT 60 CTTGTGCCGG TTpCAAAGG GAATGCpCC AGCTTTTGCC CApCAGTAT AATApAAAG 120 AATGTTpAC CAppcTGT cpGccTGp prcTGTGp TpGpGGTc TcpcApcT? ßo CCAppTAG GCCpTACAT GpAGGAATA TATrTCTpT AATGATACp CACCpTGGT 240 ATCTpTGTG AGACTCTACT CATAGTGTGA TAAGCACTGG GpGGTAAGG CAAGAGGAGC 300 (2) INFORMATION FOR SEQ ID NO: 65: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 203 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single 15 (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65: GCTCCTCpG CCpACCAAC TCACCCAGTA TGTCAGCAAT TITATCRGCT pACCTACGA 60 AACAGCCTGT ATCCAAACAC pAACACACT CACCTGAAAA GpCAGGCAA CAATCGCCp 120 CTCATGGGTC TCTCTGCTCC AGpCTGAAC CTITCTCTH TCCTAGAACA TGCATTTARG 180 TCGATAGAAG pCCTCTCAG TGC 203 (2) INFORMATION FOR SEQ ID NO: 66: (i) SEQUENCE CHARACTERISTICS: 25 (A) LENGTH: 344 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66: TACGGGGACC CCTGCApGA GAAAGC6AGA CTCACTCTGA AGCTGAAATG CTGpGCCCT 60 TGCAGTGCTG GTAGCAGGAG pCTGTGCTT TGTGGGCTAA GGCTCCTGGA TGACCCCTGA 120 CATGGAGAAG GCAGAGpGT GTGCCCCpC TCATGGCCTC GTCAAGGCAT CATGGACTGC 180 CACACACAAA ATGCCGTpT TApAACGAC ATGAAApGA AGGAGAGAAC ACAApCACT 240 GATGTGGCTC GTAACCATGG ATATGGTCAC ATACAGAGGT GTGApATGT AAAGGpAAT 300 TCCACCCACC TCATGTGGAA ACTAGCCTCA ATGCAGGGGT CCCA 344 (2) INFORMATION FOR SEQ ID NO: 67: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 157 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 67: GCACTGAGAG GAACpCGTA GGGAGGpGA ACTGGCTGCT GAGGAGGGGG AACAACAGGG 60 TAACCAGACT GATAGCCAp GGATGGATAA TATGGTGGp GAGGAGGGAC ACTACpATA 120 GCAGAGGGp GTGTATAGCC TGAGGAGGCA TCACCCG 157 (2) INFORMATION FOR SEQ ID NO: 68: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 137 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68: GCACTGAGAG GAACpCTAG AAAGTGAAAG TCTAGACATA AAATAAAATA AAAAT? AAA 60 ACTCAGGAGA GACAGCCCAG CACGGTGGCT CACGCCTGTA ATCCCAGAAC pTGGGAGCC 120 TGAGGAGGCA TCACCCG 137 (2) INFORMATION FOR SEQ ID NO: 69: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 137 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 69: CGGGTGATGC CTCCTCAGGC TGTATpTGA AGACTATCGA CTGGACpCT TATCAACTGA 60 AGAATCCGp AAAAATACCA GpGTApAT pCTACCTGT CAAAATCCAT pCAAATGp 120 GAAGpCCTC TCAGTGC 137 (2) INFORMATION FOR SEQ ID NO: 70: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 220 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 70: AGCATGpGA GCCCAGACAC GCAATCTGAA T6AGTGTGCA CCTCAAGTAA ATGTCTACAC 60 GCTGCCTGGT CTGACATGGC ACACCATCNC GTGGAGGGCA CASCTCTGCT CNGCCTACWA 120 CGAGGGCANT CTCATWGACA GGpCCACCC ACCAAACTGC AAGAGGCTCA NNAAGTACTR 180 CCAGGGTMYA SGGACMASGG TGGGAYTYCA YCACWCATCT 220 (2) INFORMATION FOR SEQ ID NO: 71: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 353 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 71: CGpAGGGTC TCTATCCACT GCTAAACCAT ACACCTGGGT AAACAGGGAC CATpAACAT 60 TCCCANCTAA ATATGCCAAG TGACpCACA TGpTATCp AAAGATGTCC AAAACGCAAC 120 TGATTpCTC CCCTAAACCT GTGATGGTGG GATGApAAN CCTGAGTGGT CTACAGCAAG 180 pAAGTGCAA GGTGCTAAAT GAANGTGACC TGAGATACAG CATCTACAAG GCAGTACCTC 240 TCAACNCAGG GCAACTTTGC pCTCANAGG GCATpAGCA GTGTCTGAAG TAATpCTGT 300 - f ApACAACTC ACGGGGCGGG GGGTGAATAT CTANTGGANA GNAGACCCTA ACG 353 (2) INFORMATION FOR SEQ ID NO: 72: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 343 base pairs (B) TYPE: nucleic acid (C) HI FORM: simple 15 (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72: GCACTGAGAG 6AACTTCCAA TACYATKATC AGAGTGAACA RGCARCCYAC AGAACAGGAG 60 AAAATGpYG CAATCTCTCC ATCTGACAAA AGGCTAATAT CCAGAWTCTA AWAGGAACp 120 AAACAAApT ATGAGAAAAG AACARACAAC CTCAWCAAAA AGTGGGTGAA GGAWATGCTS 180 AAARGAAGAC ATYTApCAG CCAGTAAACA YATGAAAAAA AGGCTCATSA TCACTGAWCA 240 pAGAGAAAT GCAAATCAAA ACCACAATGA GATACCATCT YAYRCCAGp AGAAYGGTGA 300 # TCApAAAAR STCAGGAAAC AACAGATGCT GGACAAGGTG TCA 343 (2) INFORMATION FOR SEQ ID NO: 73: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 321 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single 15 (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 73: GCACTGAGAG GAACTTCAGA GAGAGAGAGA GAGpCCACC CTGTACpGG GGAGAGAAAC 60 AGAAGGTGAG AAAGTCTpG GpCTGAAGC AGCTTCTAAG ATCTpTCAT pGCTTCAp 120 twenty TCAAAGpCC CATGCTGCCA AAGTGCCATC CTpGGGGTA CTGTpTCTG AGCTCCAGTG 180 ATAACTCAp TATACAAGGG AGATACCCAG AAAAAAAGTG AGCAAATCp AAAAAGGTGG 240 CTTGAGpCA GCCpAAATA CCATCpGAA ATGACACAGA GAAAGAANGA TGpGGGTGG 300 GAGTGGATAG AGACCCTAAC G 321 (2) INFORMATION FOR SEQ ID NO: 74: # (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 321 base pairs 10 (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74: GCACTGAGAG GAACpCAGA GAGAGAGAGA GAGpCCACC CTGTACpGG GGAGAGAAAC 60 # AGAAGGTGAG AAAGTCTpG GpCTGAAGC AGCpCTAAG ATCTpTCAT pGCTTCAp 120 TCAAAGpCC CATGCTGCCA AAGTGCCATC CTpGGGGTA CTGTpTCTG AGCTCCAGTG 180 ATAACTCAp TATACAAGGG AGATACCCAG AAAAAAAGTG AGCAAATCp AAAAAGGTGG 240 CpGAGpCA GYCpAAATA CCATCpGAA ATGAMACAGA GAAAGAAGGA TGpGGGTGG 300 GAGTGGATAG AGACCCTAAC G 321 (2) INFORMATION FOR SEQ ID NO: 75: (i) SEQUENCE CHARACTERISTICS: 25 • (A) LENGTH: 317 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 75: GCACTGAGAG GAACTTCCAC ATGCACTGAG AAATGCATGT TCACAAGGAC TGAAGTCTGG 60 AACTCAGTp CTCAGpCCA ATCCTGApC AGGTGTTTAC CAGCTACACA ACCpAAGCA 120 AGTCAGATAA CCpAGCTTC CTCATATGCA AAATGAGAAT GAAAAGTACT CATCGCTGAA 180 pGppGAG GApAGAAAA ACATCTGGCA TGCAGTAGM ApCAApAG TApCATTp 240 CApcpCTA AApAAACAA ATAGGATGGT TAGTGGTGGA AOTCAGACA CCAGAAATGG 300 GAGTGGATAG AGACCCT 317 (2) INFORMATION FOR SEQ ID NO: 76 • (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 244 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76: ^^ CGpAGGGTC TCTATCCACT CCCACTACTG ATCAAACTCT A? TA? GAA pAppTAT 60 CATACpTAA GpCTGGGAT ACACGTGCAG CATGCGCAGG TpGpGCAT AGGTATACAC 120 pGCCATGGT GGTpGCTGC ACCCATCAGT CCATCATCTA CApAGGTAT pCTCCTAAT 180 GCTATCCCTC CCCTAGCCCC pACACCCCC AACAGGCTCT AGTGTGTGAA GpCCTCTCA 240 GTGC 244 * (2) INFORMATION FOR SEQ ID NO: 77: 10 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 254 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear 15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 77: TCTATCCACT GAAATCTGAA GCACAGGAGG AAGAGAAGCA GTYCTAGTGA 60 GATGGCAAGT TCWpTACCA CACTCTpAA CApTYG AGTpTAACC mATITATG 120 GATAATAAAG GpAATApA ATAATGATp AppAAGGC ApCCCRAAT pGCATAAp 180 CTCCTpTGG AGATACCCp pATCTCCAG TGCAAGTCTG GATCAAAGTG ATASAKAGAA 240 GpCCTCTCA GTGC 254 (2) INFORMATION FOR SEQ ID NO: 78: (i) SEQUENCE CHARACTERISTICS: 25 (A) LENGTH: 355 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 78: pCGATACAG GCAAACATGA ACTGCAGGAG GCTGGTGACG ATCATGATGT TGCCGATGGT 60 CCGGATGGNC ACGAAGACGC ACTGGANCAC GTGCTTACGT CCTpTGCTC TGpGATGGC 120 CCTGAGGGGA CGCAGGACCC pATGACCCT CAGAATCTTC ACAACGGGAG ATGGCACTGG 180 ApGANTCCC ANTGACACCA GAGACACCCC AACCACCAGN ATATCANTAT ApGATGTAG_240_pCCTGTAGA NGGCCCCCp GTGGAGGAAA GCTCCATNAG pGGTCATCT TCAACAGGAT 300 CTCAACAGp TCCGATGGCT GTGATGGGCA TAGTCATANT TAACCNTGTN TCGAA 355 (2) INFORMATION FOR SEQ ID NO: 79: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 406 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 79: TAAGAGGGTA CCAGCAGAAA GGpAGTATC ATCAGATAGC ATCpATACG AGTAATATGC 60 CTGCTApTG AAGTGTAAp GAGAAGGAAA ATpTAGCGT GCTCACTGAC CTGCCTGTAG_120_CCCCAGTGAC AGCTAGGATG TGCApCTCC AGCCATCAAG AGACTGAGTC AAGpGpCC 180 pAAGTCAGA ACAGCAGACT CAGCTCTGAC ApCTGApc GAATGACACT GpCAGGAAT 240 CGGAATCCTG TCGApAGAC TGGACAGCTT GTGGCAAGTG AATrTGCCTG TAACAAGCCA 300 * GAIHIIIAA AApTATAp GTAAATAATG TGTGTGTGTG TCTGTGTATA TATATATATA 360 TGTACAGpA TCTAAGpAA pTAAAAGp GpTGGTACC CTCTTA 406 (2) INFORMATION FOR SEQ ID NO: 80: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 327 base pairs (B) TYPE: nucleic acid 15 (C) THREAD FORM: single (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 80. twenty ^ w ppppp pTACTCGGC TCAGTCTAAT CCTT? TGTA GTCACTCATA GGCCAGACTT eo AGGGCTAGGA TGATGApAA TAAGAGGGAT GACATAACTA pAGTGGCAG GpAGpGp 120 TGTAGGGCTC ATGGTAGGGG TAAAAGGAGG GCAATpCTA GATCAAATAA TAAGAAGGTA 180 ATAGCTACTA AGAAGAATp TATGGAGAAA GGGACGCGGG CGGGGGATAT AGGGTCGAAG 240 CCGCACTCGT AAGGGGTGGA ppTCTATG TAGCCGpGA GpGTGGTAG TCAAAATGTA 300 ATAApApA GTAGTAAGCC TAGGAGA 327 (2) INFORMATION FOR SEQ ID NO: 81: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 318 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single 15 (D) TOPOLOGY: linear F- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 81: TAGTCTATGC GGpGApCG GCAATCCAp ApTGCTGGA TpTGTCATG TGTpTGCCA 60 twenty ApGCApCA TAATpApA TGCATpATG CTTGTATCTC CTAAGTCATG GTATATAATC 120 CATGCTTTp ATGTpTGTC TGACATAAAC TCpATCAGA GCCCTpGCA CACAGGGAp 180 CAATAAATAT TAACACAGTC TACATpAp TGGTGAATAT TGCATATCTG CTGTACTGAA 240 AGCACApAA GTAACAAAGG CAAGTGAGAA GAATGAAAAG CACTACTCAC AACAGpATC 300 ATGApGCGC ATAGACTA 318 (2) INFORMATION FOR SEQ ID NO: 82: (i) SEQUENCE CHARACTERISTICS (A) LENGTH: 338 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 82: TCpCAACCT CTACTCCCAC TAATAGCTp pGATGACTT CTAGCAAGCC TCGCTAACCT 60 CGCCpACCC CCCACTApA ACCTACTGGG AGAACTCTCT GTGCTAGTAA CCACGpCTC 120 CTGATCAAAT ATCACTCTCC TACpACAGG ACTCAACATA CTAGTCACAG CCCTATACTC 180 CCTCTACATA TITACCACAA CACAATGGGG CTCACTCACC CACCACApA ACAACATAAA 240 ACCCTCApC ACACGAGAAA ACACCCTCAT GpCATACAC CTATCCCCCA pCTCCTCCT 300 ATCCCTCAAC CCCGACATCA pACCGGGp pCCTCp 338 (2) INFORMATION FOR SEQ ID NO: 83: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 111 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 83: AGCCATpAC CACCCATCCA CAAAAAAAAA AAAAAAAAAG AAAAATATCA AGGAATAAAA 60 «* ATAGACTGTG AACAAAAAGG AACATGTGCT GGCCTGAGGA GGCATCACCC G lll (2) INFORMATION FOR SEQ ID NO: 84: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 224 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single 15 (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 84:CCTCCTCAGG CCAAGAAGAT AAAGCTTCAG ACCCCTAACA CATGÍCCAAA 60 AAGGAAGAAA GGAGAAAAAA GGGCATCATC CCCGpCCGA AGGGTCAGGG AGGAGGAAAT 120 TGAGGTGGAT TCACGAGpG CGGACAACTC CpTGATGCC AAGCGAGGTG CAGCCGGAGA 180 CTGGGGAGAG CGAGCCAATC AGGTpTGAA GpCCTCTCA GTGC 224 (2) INFORMATION FOR SEQ ID NO: 85: 25 (i) SEQUENCE CHARACTERISTICS: base (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID NO: 85: GCACTGAGAG GAACTTCGp GGAAACGGGT HIIHCATG TAAGGCTAGA CAGAAGAAp 60 CTCAGTAACT TCCTTGTGp GTGTGTApC AACTCACASA GpGAACGAT CCpTACACA 120 GAGCAGACp GTAACACTCT TVTTGTGGAA pTGCAAGTG GAGATTTCAG SCGCpTGAA 180 GTSAAAGGTA GAAAAGGAAA TATCpCCTA TAAAAACTAG ACAGAATGAT TCTCAGAAAC 240 TCCpTGTGA TGTGTGCGp CAACTCACAG AGpTAACCT pCWHTCAT AGAAGCAGp 300 AGGAAACACT CTGTpGTAA AGTCTGCAAG TGGATAGAGA CCCTAACG 348 (2) INFORMATION FOR SEQ ID NO: 86: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 293 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single 20 (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 86: GCACTGAGAG GAACTTCYp GTGWTGTKTG YApCAACTC ACAGAGpGA ASSV'fl p 60 ACABAGWKCA GGCTTKCAAA CACTCTpp GTMGAATYTG CAAGWGGAKA TpSRRCCRC 120 pTGWGGYCW WYSKTMGAAW MGGRWATATC pCWYATMRA AMCTAGACAG AAKSApCTC 180 AKAAWSTYYY YTGTGAWGWS TGCRpCAAC TCACAGAGKT KAACMWTYCT ICYTSATRGAG 240 CAGTTWKGAA ACTCTMTpC pTGGApCT GCAAGTGGAT AGAGACCCTA ACG 293 * (2) INFORMATION FOR SEQ ID NO: 87: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 87: CTCTAGGCT 10 F 10 (2) INFORMATION FOR SEQ ID NO: 88: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) THREAD FORM, single 15 (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 88: AGTAGTTGCC 10 (2) INFORMATION FOR SEQ ID NO: 89: UENCE: (A) LENGTH: 11 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple 5 (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO: 89: TTCCGTTATGC 11 (2) INFORMATION FOR SEQ ID NO: 90: (i) SEQUENCE CHARACTERISTICS: 10 (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 90: 15 TGGTAAAGGG 10 (2) INFORMATION FOR SEQ ID NO: 91: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid 20 (C) THREAD FORM: single (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 91: TCGGTCATAG_10_(2) INFORMATION FOR SEQ ID NO: 92: 25 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear 5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 92: TACAACGAGG 10 (2) INFORMATION FOR SEQ ID NO: 93: IT (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs 10 (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 93: TGGATTGGTC 10 (2) INFORMATION FOR SEQ ID NO: 94: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single 20 (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 94: CTTTCTACCC 10 (2) INFORMATION FOR SEQ ID NO: 95: (i) SEQUENCE CHARACTERISTICS: 25 (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 95: 5 TTTTGGCTCC 10 (2) INFORMATION FOR SEQ ID NO: 96: (i) SEQUENCE CHARACTERISTICS: jttt (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid 10 (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 96:. GGAACCAATC 10 (2) INFORMATION FOR SEQ ID NO: 97: 15 (i) SEQUENCE CHARACTERISTICS: ft (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear 20 (xí) SEQUENCE DESCRIPTION: SEQ ID NO: 97: TCGATACAGG 10 (2) INFORMATION FOR SEQ ID NO: 98: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs 25 (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 98: GGTACTAAGG 10 (2) INFORMATION FOR SEQ ID NO: 99: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) ) THREAD FORM: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 99: AGTCTATGCG 10 (2) INFORMATION FOR SEQ ID NO: 100: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 100: CTATCCATGG 10 (2) INFORMATION FOR SEQ ID NO: 101: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 101: TCTGTCCACA 10 (2) INFORMATION FOR SEQ ID NO: 102: 5 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 102: AAGAGGGTAC 10 (2) INFORMATION FOR SEQ ID NO: 103: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs 15 (B) TYPE: nucleic acid? (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 103: CTTCAACCTC 10 (2) INFORMATION FOR SEQ ID NO: 104: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single 25 (D) TOPOLOGY: linear * (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 104: GCTCCTCTTG CCTTACCAAC 20 (2) INFORMATION FOR SEQ ID NO: 105: (i) SEQUENCE CHARACTERISTICS: 5 (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear * (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 105: 10 GTAAGTCGAG CAGTGTGATG 20 (2) INFORMATION FOR SEQ ID NO: 106: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid 15 (C) THREAD FORM: single (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 106: GTAAGTCGAG CAGTCTGATG 20 (2) INFORMATION FOR SEQ ID NO: 107: 20 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear 25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 107: GACTTAGTGG AAACAATGTA 20 (2) INFORMATION FOR SEQ ID NO: 108: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 108: GTAATTCCGC CAACCGTAGT 20 (2) INFORMATION FOR SEQ ID NO: 109: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) ) THREAD FORM: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 109: ATGGTTGATC GATAGTGGAA 20 (2) INFORMATION FOR SEQ ID NO: 110: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 110: ACGGGGACCC CTGATTGAG 20 (2) INFORMATION FOR SEQ ID NO: 111: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) ) THREAD FORM: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 111: TATTCTAGAC CATTCGCTAC 20 (2) INFORMATION FOR SEQ ID NO: 112: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 112: ACATAACCAC TTTAGCGTTC 20 (2) INFORMATION FOR SEQ ID NO: 113: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) ) THREAD FORM: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 113: CGGGTGATGC CTCCTCAGGC 20 (2) INFORMATION FOR SEQ ID NO: 114: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH : 20 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 114: AGCATGTTGA GCCCAGACAC 20TION FOR SEQ ID NO: 115: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 115: GACACCTTGT CCAGCATCTG 20 (2) INFORMATION FOR SEQ ID NO: 116: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear (x) ) SEQUENCE DESCRIPTION: SEQ ID NO: 116: TACGCTGCAA CACTGTGGAG 20 (2) INFORMATION FOR SEQ ID NO: 117: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 117: CGTTAGGGTC TCTATCCACT 20 (2) INFORMATION FOR SEQ ID NO: 118: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 118: AGACTGACTC ATGTCCCCTA 20 (2) INFORMATION FOR SEQ ID NO: 119: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) ) THREAD FORM: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 119: TCATCGCTCG GTGACTCAAG 20 (2) INFORMATION FOR SEQ ID NO: 120: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs # (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 120: 5 CAAGATTCCA TAGGCTGACC 20 (2) INFORMATION FOR SEQ ID NO: 121: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid 10 (C) THREAD FORM: single (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 121: ACGTACTGGT CTTGAAGGTC 20 (2) INFORMATION FOR SEQ ID NO: 122: 15 (i) SEQUENCE CHARACTERISTICS: # (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear 20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 122: GACGCTTGGC CACTTGACAC 20 (2) INFORMATION FOR SEQ ID NO: 123: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs 25 (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 123: GTATCGACGTAGTGGTCTCC 20 (2) INFORMATION FOR SEQ ID NO: 1244: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) ) THREAD FORM: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 124: TAGTGACATTACGACGCTGG 20 (2) INFORMATION FOR SEQ ID NO: 125: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (x) ) SEQUENCE DESCRIPTION: SEQ ID NO: 125: CGGGTGATGC CTCCTCAGGC 20 (2) INFORMATION FOR SEQ ID NO: 126: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 126: ATGGCTATTT TCGGGGGCTG ACA 23 (2) INFORMATION FOR SEQ ID NO: 127: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 127: CCGGTATCTC CTCGTGGGTA TT 20 (2) INFORMATION FOR SEQ ID NO: 128: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 128: CTGCCTGAGC CACAAATG 20 (2) INFORMATION FOR SEQ ID NO: 129: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 244 base pairs (B) TYPE: nucleic acid (C) ) THREAD FORM: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO.129: CCGGAGGAGGAAGCTAGAGGAATA 20 (2) INFORMATION FOR SEQ ID NO: 130: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO.130: TTTTTTTTTT TTAG_20_ (2) INFORMATION FOR SEQ ID NO: 131: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 amino acids (B) TYPE: amino acids (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 131: Ser Ser Gly Gly Arg Thr Phe Asp Asp Phe His Arg Tyr Leu Leu Val 1 5 10 15 (2) INFORMATION FOR SEC ID N0.132: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH : 22 amino acids (B) TYPE: amino acids (C) THREAD FORM: simple (D) TOPOLOGY: linear (xí) SEQUENCE DESCRIPTION: SEQ ID NO: 132: Gln Gly Wing Wing Gln Lys Pro He Asn Leu Ser Lys Xaa lie Glu Val 1 5 10 15 Van Gln Gly His Asp Glu 20 (2) INFORMATION FOR SEQ ID NO: 133: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 amino acids (B) TYPE: amino acids (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 133: Ser Pro Gly Val Phe Leu Glu His Leu Gln Glu Wing Tyr Arg He Tyr 1 5 10 15 Thr Pro Phe Asp Leu Ser Wing 20 (2) INFORMATION FOR SEQ ID NO: 134: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH : 9 amino acids (B) TYPE: amino acids (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 134: Tyr Leu Leu Val Gly lie Gln Gly Wing 1 5 (2) INFORMATION FOR SEQ ID NO: 135: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acids (C) THREAD FORM: simple (D) TOPOLOGY: linear 5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 135: Gly Ala Ala Gln Lys Pro He Asn Leu 1 5 (2) INFORMATION FOR SEQ ID NO: 136: * (i) SEQUENCE CHARACTERISTICS: 10 (A) LENGTH: 9 amino acids (B) TYPE: amino acids (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 136: Asn Leu Ser Lys Xaa He Glu Val Val 1 5 (2) INFORMATION FOR SEQ ID NO: 137: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids 20 (B) TYPE: amino acids (C) THREAD FORM : simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 137: Glu Val Val Gln Gly His Asp Glu Ser 25 1 5 (2) INFORMATION FOR SEQ ID NO.138: (i) SEQUENCE CHARACTERISTICS : (A) LENGTH: 9 amino acids (B) TYPE: amino acids (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 138: His Leu Gln Glu Ala Tyr Arg He Tyr -c ^^ 1 5 w (2) INFORMATION FOR SEQ ID NO: 139: 10 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acids (C) THREAD FORM: single (D) TOPOLOGY: linear 15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 139: Asn Leu Ala Phe Val Ala Ala Gln Ala Ala 1 5 (2) INFORMATION FOR SEQ ID NO: 140: (i) SEQUENCE CHARACTERISTICS: 20 (A) LENGTH: 9 amino acids (B) TYPE: amino acid two (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 140: Phe Val Ala Gln Ala Ala Pro Asp Ser 1 5: 141: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9388 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 141: GCTCGCGGCC GCGAGCTCAA pAACCCTCA CTAAAGGGAG TCGACTCGAT CAGACTCTTA 60 CTGTGTCTAT GTAGAAAGAA GTAGACATAA GAGApCCAT TpGpCTGT ACTAAGAAAA 120 ApCTTCTGC CpGAGATGC TGpAATCTG TAACCCTAGC CCCAACCCTG TGCTCACAGA 180 GACATGTGCT GTGp &ACTC AAGGpCAAT GGATTTAGGG CTATGCTpG pAAAAAAGT 240 GCpGAAGAT AATATGCTTG pAAAAGTCA TCACCApCT CTAATCTCAA GTACCCAGGG 300 ACACAATACA CTGCGGAAGG CCGCAGGGAC CTCTGTCTAG GAAAGCCAGG TApGTCCAA 360 GATpCTCCC CATGTGATAG CCT6AGATAT GGCCTCATGG GAAGGGTAAG ACCTGACTGT 420 CCCCCAGCCC GACATCCCCC AGCCCGACAT CCCCCAGCCC GACACCCGAA AAGGGTCTGT 480 GCTGAGGAGG ApAGTAAAA GAGGAAGGCC TCTpGCAGT TGAGGTAAGA GGAAGGCATC 540 TGTCTCCTGC TCGTCCCTGG GCAATAGAAT GTCpGGTGT AAAACCCGAT TGTATGpCT 600 0891 1393999193 13V9933V33 19331V3131 1193399333 33391399V3 13V99913W 93 0291 9993993V33 91LV33991L VWS991999 3V3319391L 1133991331 9V991939V3 0991 9V31999V99 1393V9991V 3V99339133 9193V33993 HV1399911 319V313319 00SI V91919W99 919WV3919 9V33133991 99V3913199 1L99W3939 91339W993 03 0 ** I 31LLV33313 3393339W9 9331119339 33991LV333 1L193V31V9 131V3W19V 08CT 1339131913 V993VW991 3391191913 J-131LL3311 93939V913V 91399V9JJLLL 02 i V131933131 WV91399H V331V3V391 33W999V99 191W13991 1V1L31L3V3 092T 9W333399V 199V399V19 1139191391 11139VW99 V39391WW V3939V3311 # 9L 0021 V339V199V3 9939399111 V9ULLVW1 9J1V91999V V33V39V3W V99V3919W Opi V9W33131V W39199133 939V331319 99V999199V 339991V399 V399199933 0801 V31L91991L 319991199V V9V3919919 913V9W3W 3V913931L9 1339V13V1L 01. 020? 1W1W31L3 333V3399V3 9999V99191 99V3V333V1 WV9V93V91 33V331L931 096 31319V3131 JJLL31LL313 1919131319 1U.3V1V131 3111311113 V3139991L3 * 006 3319933939 V913919193 3133199V19 13331919V3 3V9V9V313V V999V913V1 0 * 8 VW1W31V9 1W1V9V9V1 991V9V9331 3D30331V3 V339133991 1V1333V1LV Q8 ¿13V3333131 333V913913 31U193V31 191LL33V9V 9V3V3V91V1 J1V1L3VW1 02Z 133ULL33V3 9V3V399W3 1V3V3919W 1V1911L91V 9V933V391V V1L 1391D 099 V1W399399 1393V3V9V9 199V991399 9V1L331V3V VW9V99V1V 9V913V1L3V 9 * 1. 09Z2 9333999339 V9V9399933 V3193VW9V 99933V3193 WV9V939V3 33399V991L 93 00Z2 1V3V93V199 V3139313W 1313111193 991919VW3 13191HW1 1H3V991W 0 * 92 V1VW139V3 3993991131 31V339V1LV 39V9111LW 9V9V9939V9 V3J131L333 0892 39V131V9W 9WW1V19V W33WV131 1133331333 3133V9V13V V1U1911W 03 02SZ W19131LLV 1113-11391 I U H3W1L 1L331V11ÍV 33W191331 1L3W11V13 09 * 2 W99133V39 133339VW1 131W1W19 1133V31V13 193933339V VW33391V1 00 * 2 1V9LLV9331 V31LW99V9 331L9V3933 1V1V139W3 991913V1V9 W1L913W1 0 * 82 1W391W9V V331V3V39V 33313V9139 W3919113V V113V99W3 1331133339 * 91. 0822 V399DV311 1313991131 V3313V991V 9V33939V9V V139V1L333 1313V911W 02Z2 D133V33111 91L339V133 V31VW1L33 1113331313 V9V1LLLL91 333W13V1L 0912 LLL99133W 33391W191 9V19V1L31V 1V91LL1991 33119 19V V99VW1L11 01. 0012 91LW9911L 9V119V939V 3V399W191 9131L1WV9 99991L31L1 V1V33WW1 0 * 02 V1LL399V31 31L3W3W3 9V1W13319 1U91991LL 19VU I HW 33VW1LW1 0861 3911911911 11W991WV V119V339V3 V99W1V913 131913V991 9V11LV1LV1 026T 91L9V339J1 1LL3V3131V VW3V1L133 W3333V39V W1W1V1L1 91V1191V1L 0981 1991331LV3 ViWWlLVi 99V91199 V39333V919 V999V99913 393V391L91 0081 1LL9199V39 9V13U1V9Í 11L3393VW V1999313V3 339V31L11L 399S93WW 0 * ZI V199WV1LV 9V3313191L V19333V913 133V913311 19V191V913 939913V393 9 * 1- F CTGTGTGCTC CCCCGGAAGG ACAGCCAGCT TGTAGGGGGG AGTGCCACCT GAAAAAAAAA 2820 TpCCAGGTC CCCAAAGGGT GACCGTCTTC CGGAGGACAG CGGATCGACT ACCATGCGGG 2880 TGCCCACCAA AApCCACCT CTGAGTCCTC AACTGCTGAC CCCGGGGTCA GGTAGGTCAG 2940 ATpGACpT GGpCTGGCA GAGGGAAGCG ACCCTGATGA GGGTGTCCCT (T? TGACTC 3000 TGCCCATTTC TCTAGGATGC TAGAGGGTAG AGCCCTGGp pCTGpAGA CGCCTCTGTG 3060 TCTCTGTCTG GGAGGGAAGT GGCCCTGACA GGGGCCATCC GTCAG TCCACATCCC 3120 AGGATGCTGG GGGACTGAGT CCTGGTpCT GGCAGACTGG TCTCTCTCTC TCTCPyTTC 3180 TATCTCTAAT CTTTC TCAGGTpCT TGGAGAATCT CTGGGAAAGA AAAAAGAAAA 3240 ACTGpATAA ACTCTGTGTG AATGGTGAAT GAATGGGGGA GGACAAGGGC pGCG 3300 CCTCCAGTp GTAGCTCCAC GGCGAAAGCT ACGGAGpCA AGTGGGCCCT CACCTGCGGT 3360 TCCGTGGCGA CCTCATAAGG CpAAGGCAG CATCCGGCAT AGCTCGATCC GAGCCGGGGG 3420 # pTATACCGG CCTGTCAATG CTAAGAGGAG CCCAAGTCCC CTAAGGGGGA GCGGCCAGGC 3480 GGGCATCTGA CTGATCCCAT CACGGGACCC CCTCCCpTGTCTAAA AAAAAAAAAA 3540 GAAGAAACTG TCATAACTGT pACATGCCC TAGGGTCAAC TGpTGTpT ATGTTTApG 3600 pCTGpCGG TGTCTApGT TAGT GGpGTCAAG GTpTGCATG TCAGGACGTC 3660 GATApGCCC AAGACGTCTG GGTAAGAACT TCTGCAAGGT CCTTAGTGCT GAIUIUGT 3720 CACAGGAGGT TAAATpCTC ATCAATCAp TAGGCTGGCC ACCACAGTCC TGTCTpTCT 3780 GCCAGAAGCA AGTCAGGTGT TGpACGGGA ATGAGTGTAA AAAAACApC GCCTGApGG 026 3840 * 139V311993 39V31333V9 3133931LLL 91933V9V33 9V91331331 99W33133V 098 * 1LHW1V31 1V33V391V3 13V3313991 V33113333V 39V99V3199 1119V91399 008 * 1W31V91LV 3V13331LL9 V31V913331 339933313V W913V1191 1999399191 0 * Z * 9139W3a9 aW3V3133 W913V3199 9W91L3333 9919V91L9V 9911L9VW3 03 089 * 3991W9V19 VW391313V 3V9913139V V399WWW 113393319V 991V1LV99V 9V3131LL99 029 * 313 131 I I I I W9V391391 V1V19V3313 13339V99U 999W19113 09S * 39V3331331 13V3VW999 WWWWW WWW31L3 3911WVJ1V p31VW311 OOS * 91V131V1V9 1LL9991391 9131913131 1L9V919V99 9V3333339V 3313V1V931 9 0 *** 11311913a V91L91V319 913 a3139 131 1 I I 1991 9a9139Va 1V19919W3 08C * 99191V919V 3V139WVa 31W313331 3313319V13 1339913999 3131V9V99V 028 * 333V913W3 31V9V133V3 W9V9V9V9V V9W9V131V 9V3V1999V1 aV199WW 0 092 * 3V3V9V991V 319V91H33 91J1V139V9 ai999139V WW9WW1 1333W9a3 002 * 313V313139 131399a3V 99V3313193 9V3a9W39 V3V93919V3 31U193131 0 * 1 * 1333339133 31331331st V3V3V3333V 13319919W 331V93WW Va31V3331 080 * 313V139919 13133a913 13V113aV9 V11193a3V ai3913V19 31333V133V 020 * W999V1919 13V0V39V1V W1Ü33919 133.I..I H3W 1913aV319 9ai3133V3 0968 139a33a V9V391333V 339V3WW3 a99919919 913VW13W V13133133V 0068 99 VDa99 V331V3V333 3VlV319aV 9VJHV19a 991V91V33V 39913U1V9 8 * 1 . f CTCACCCAGT CCCACCGCCT 4980 TAAAACCAGC CTACTCCCTT AGGGTCATCC CATGTCTCCT CGGCTATGTC CCCTGTAGGC 5040 TCATCACCCA pGCCTCTTG GpGCAACCG TGGTGGGAGG AAGTAGCCCC TCTACTACCA 5100 CTGAGAGAGG CACAAGTCCC TCTGGGTGAT GACTGCTCCA CCCCCpCCT GGpTATGTC 5160 CCpcpTCT ACpCTGACT TGTATAApG GAAAACCCAT AATCCTCCCT TCTCTGAAAA 5220 GCCCCAGGCT pGACCTCAC TGATGGAGTC TGTACTCTGG ACACApGGC CCACCTGGGA 5280 TGACTGTCAA CAGCTCCTp TGACCCTTp CACCTCTGAA GAGAGGGAAA GTATCCAAAG 5340 AGAGGCCAAA AAGTACAACC TCACATCAAC CAATAGGCCG GAGGAGGAAG CTAGAGGAAT 5400 AGTGApAGA GACCCAApG GGACCTAAp GGGACCCAAA TTTCTCAAGT GGAGGGAGAA 5460 CppGACGA TGTCCACCGG TATCTCCTCG TGGGTApCA GGGAGCTGCT CAGAAACCTA 5520 TAAACpGTC TAAGGCGACT GAAGTCGTCC AGGGGCATGA TGAGTCACCA GGAGTGTpT 5580 # TAGAGCACCT CCAGGAGGCT TATCGGATp ACACCCCHT TGACCTGGCA GCCCCCGAAA 5640 ATAGCCATGC TCpAApTG GCApTGTGG CTCAGGCAGC CCCAGATAGT AAAAGGAAAC 5700 TCCAAAAACT AGAGGGATp TGCTGGAATG AATACCAGTC AGCTpTAGA GATAGCCTAA 5760 AAGGTTpTG ACAGTCAAGA GGpGAAAAA CAAAAACAAG CAGCTCAGGC AGCTGAAAAA 5820 AGCCACTGAT AAAGCATCCT GGAGTATCAG AGTTTACTGT TAGATCAGCC TCATpGACT 5880 TCCCCTCCCA CATGGTGTp AAATCCAGCT ACACTACpC CTGACTCAAA CTCCACTAp 5940 CCTGpCATG ACTCTCAGGA ACTGpGGAA ACTACTGAAA CTGGCCGACC TGATCTTCAA 6000 l \ AATGTGCCCC TAGGAAAGGT GGATGCCACC GTGpCACAG ACAGTAGCAG CpCCTCGAG 6060 AAGGGACTAC GAAAGGCCGG TGCAGCTGp ACCATGGAGA CAGATGTGp GTGGGCTCAG 6120 GCpTACCAG CAAACACCTC AGCACAAAAG GCTGAApGA TCGCCCTCAC TCAGGCTCTC 6180 CGATGGGGTA AGGATApAA CGpAACACT 6ACAGCAGGT ACGCCTpGC TACTGTGCAT 6240 GTACGTGGAG CCATCTACCA GGAGCGTGGG CTACTCACCT CAGCAGGTGG CTGTAATCCA 6300 CTGTAAAGGA CATCAAAAGG AAAACACGGC TGpGCCCGT GGTAACCAGA AAGCTGApC 6360 AGCAGCTCAA GATGCAGTGT GACTÍTCAGT CACGCCTCTA AACpGCTGC CCACAGTCTC 6420 CipCCACAG CCAGATCTGC CTGACAATCC CGCATACTCA ACAGAAGAAG AAAACTGGCC 6480 TCAGAACTCA GAGCCAATAA AAATCAGGAA GGpGGTGGA pcpCCTGA CTCTAGAATC 6540 pCATACCCC GAACTCpGG GAAAACpTA ATCAGTCACC TACAGTCTAC CACCCATTTA 6600 GGAGGAGCAA AGCTACCTCA GCTCCTCCGG AGCCGTpTA AGATCCCCCA TCpCAAAGC 6660 # CTAACAGATC AAGCAGCTCT CCGGTGCACA ACCTGCGCCC AGGTAAATGC CAAAAAAGGT 6720 CCTAAACCCA GCCCAGGCCA CCGTCTCCAA GAAAACTCAC CAGGAGAAAA GTGGGAAAp 6780 GACTTTACAG AAGTAAAACC ACACCGGGCT GGGTACAAAT ACCTTCTAGT ACTGGTAGAC 6840 ACCpCTCTG GATGGACTGA AGCATTTGCT ACCAAAAACG AAACTGTCAA TATGGTAGp 6900 AAGTppAC TCAATGAAAT CATCCCTCGA CGTGGGCTGC CTGpGCCAT AGGGTCTGAT 6960 AATGGACCGG CCpCGCCTT GTCTATAGp TAGTCAGTCA GTAAGGCGp AAACApCAA 7020 TGGAAGCTCC ApGTGCCTA TCGACCCCAG AGCTCTGGGC AAGTAGAACG CATGAACTGC 7080 fil ^ r ACCCTAAAAA ACACTCTTAC AAAApAATC pAGAAACCG GTGTAAApG TGTAAGTCTC 7140 CpCCpTAG CCCTACTGAG AGTAAGGTGC ACCCCpACT GGGCTGGGp CTTACCpp 7200 GAAATCATGT ATGGGAGGGC GCTGCCTATC pGCCTAAGC TAAGAGATGC CCAApGGCA 7260 AAAATATCAC AAACTAATp ApACAGTAC CTACAGTCTC CCCAACAGGT ACAAGATATC 7320 ATCCTGCCAC pGpCGAGG AACCCATCCC AATCCAApC CTGAACAGAC AGGGCCCTGC 7380 cApcApcc CGCCAGGTGA ccTGpG r CTTAAAAAGT TCCAGAGAGA AGGACTCCCT 7440 CCTGCpGGA AGAGACCTCA CACCGTCATC ACGATGCCAA CGGCTCTGAA GGTGGATGGC 7500 ATTCCTGCGT GGApCATCA CTCCCGCATC AAAAAGGCCA ACGGAGCCCA ACTAGAAACA 7560 TGGGTCCCCA GGGCTGGGTC AGGCCCCpA AAACTGCACC TAAGTTGGGT GAAGCCApA 7620 GApAApCT TpTCpAAT pTGTAAAAC AATGCATAGC pCTGTCAAA CpATCTATC 7680 p VAGACTCA ATATAACCCC CTTGpATAA CTGAGGAATC AATGATpGA pCCCCAAAA 7740 # ACACAAGTGG GGAATGTAGT GTCCAACCTG GppTACTA ACCCTGpp TAGACTCTCC 7800 CTpCCpTA ATCACTCAGC CpGHTCCA CCTGAApGA CTCTCCCpA GCTAAGAGCG 7860 CCAGATGGAC TCCATCpGG CTCTpCACT GGCAGCCGCT TCCTCAAGGA CTTAACTTGT 7920 twenty GCAAGCTGAC TCCCAGCACA TCCAAGAATG CAApAACTG ATAAGATACT GTGGCAAGCT 7980 ATATCCGCAG pCCCAGGAA pCGTCCAAT TGApACACC CAAAAGCCCC GCGTCTATCA 8040 CCpGTAATA ATCpAAAGC CCCTGCACCT GGAACTApA ACGpCCTGT AACCApTAT 8100 CCppAACT ppTGCCTA CpTATpCT GTAAAApCT pTAACTAGA CCCCCCCTCT 8160 CCTpCTAAA CCAAAGTATA AAAGCAAATC TAGCCCCTTC pCAGGCCGA GAGAATrTCG 8220 AGCGpAGCC GTCTCTTGGC CACCAGCTAA ATAAACGGAT TCpCATGTG TCTCAAAGTG 8280 TGGCGTpTC TCTAACTCGC TCAGGTACGA CCGTGGTAGT ATpTCCCCA ACGTCpAp 8340 TpAGGGCAC GTATGTAGAG TAACTpTAT GAAAGAAACC ACTTAAGGAG GTpTGGGAT 8400 pCCpTATC AACTGTAATA CTGGTpTGA pApTATp ApTATTTAT I H? I IGAG 8460 AAGGAGTTTC ACTCpGpG CCCAGGCTGG AGTGCAATGG TGCGATCpG GCTCACTGCA 8520 ACpcCGCCT CCCAGGpCA AGCGApCTC CTGCCTCAGC CTCGAGAGTA GCTGGGApA 8580 TAGGCATGCG CCACCACACC CAGCTAATp TGTATTpTA GTAAAGATGG GGTpcpCA 8640 TGpGGTCAA GCTGGTCTGG AACTCCCCGC CTCGGGTGAT CTGCCCGCCT CGGCCTCCGA 8700 AAGTGCTGGG ApACAGGTG TGATCCACCA CACCCAGCCG ATpATATGT ATATAAATCA 8760 CApCCTCTA ACCAAAATGT AGTGpTCCT TCCATCpGA ATATAGGCTG TAGACCCCGT 8820 GGGTATGGGA CApGpAAC AGTGAGACCA CAGCAGTTp TATGTCATCT GACAGCATCT 8880 CCAAATAGCC pCATGGpG TCACTGCpC CCAAGACAAT TCCAAATAAC ACTTCCCAGT 8940 GATGACTTGC TACpGCTAT TGpACpAA TGTGpAAGG TGGCTGpAC AGACACTAp 9000 AGTATGTCAG GAApACACC AAAApTAGT GGCTCAAACA ATCATpTAT TATGTATGTG 9060 GATTCTCATG GTCAGGTCAG GATTTCAGAC AGGGCACAAG GGTAGCCCAC pGTCTCTGT 9120 CTATGATGTC TGGCCTCAGC ACAGGAGACT CAACAGCTGG GGTCTGGGAC CATpGGAGG 9180 CpGpCCCT CACATCTGAT ACCTGGCpG GGATGpGGA AGAGGGGGTG AGCTGAGACT 9240 * (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 143: TGTAAGTCGA GCAGTGTGAT GTCCACTGCA GTGTGpGCT GGGAACAGp AATGAGCAAA 60 pGTATACAA TGGCTAGTAC ApGACCGGG ApTGpGAA GCTGGTGAGT GpATGACTT 120 AGCCTGpAG ACTAGTCTAT GCACATGGCT CTGGTCAACT ACCGCTCTCT CApTCTCCA 180 GATAAATCCC CCATGCpTA TApCTCpC CAAACATACT ATCCTCATCA CCACATAGp 240 ccpTGp TGcprGpc TAGAcprcc cppcTGp pcpApcA AACCTATATC 300 TCHTGCATA GApGTAAAT TCAAATGCCC TCAGGGTGCA GGCAGpCAT GTAAGGGAGG 360 GAGGCTAGCC AGTGAGATCT GCATCACACT GCTCGACpA CA 402 * (2) INFORMATION FOR SEC ID NO: 144: (i) SEQUENCE CHARACTERISTICS. (A) LENGTH: 224 base pairs (B) TYPE: nucleic acid 20 (C) THREAD FORM: single (D) TOPOLOGY: linear (xí) SEQUENCE DESCRIPTION: SEQ ID NO: 144 GAGTGCCTAT ATGTAGTGp TCCATATGGC CTTGACTTCC pACAGCCTG GCAGCCTCAG 9300 GGTAGTCAGA ApCTTAGGA GGCACAGGGC TCCAGGGCAG ATGCTGAGGG CTCTTpATG 9360 AGGTAGCACA GCAAATCCAC CCAGGATC 9388 (2) INFORMATION FOR SEQ ID NO: 142: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 419 base pairs ^ F- (B) TYPE: nucleic acid (C) THREAD FORM: single 10 (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 142: TGTAAGTCGA GCAGTGTGAT GGAAGGAATG GTCpTGGAG AGAGCATATC CATCTCCTCC 60 TCACTGCCTC CTAATGTCAT GAGGTACACT GAGCAGAAp AAACAGGGTA GTCpAACCA 120 CACTATpp AGCTACCGTG TCAAGCTAAT GGpAAAGAA CACppGGT pACACpGT 180 TGGCTCATAG AAGpGCpT CCGCCATCAC GCAATAAGp TGTGTGTAAT CAGAAGGAGT 240 TACCpATGG TTTCAGTGTC ApcpTAGT TAACpGGGA GCTGTGTAAT pAGGCpTG 300 CGTApApT CACpCTGp CTCCACpAT GAAGTGApG TGTGpCGCG TGTGTGTGCG 360 TGCGCATGTG CpCCGGCAG pAACATAAG CAAATACCCA ACATCACACT GCTCGACp 419 (2) INFORMATION FOR SEQ ID NO: 143: (i) SEQUENCE CHARACTERISTICS. (A) LENGTH: 402 base pairs TCGGGTGATG CCTCCTCAGG CCAAGAAGAT AAAGCTTCAG ACCCCTAACA CATiTCCAM 60 AAGGAAGAAA GGAGAAAAAA GGGCATCATC CCCGpCCGA AGGGTCAGGG AGGAGGAAAT 120 TGAGGTGGAT TCACGACTTG CGGACAACTC CpTGATGCC AAGCGAGGTG CAGCCGGAGA 180 CTGGGGAGAG CGAGCCAATC AGGTpTGAA GpCCTCTCA GTGC 224 (2) INFORMATION FOR SEQ ID NO: 145: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 111 base pairs 10 (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 145: AGCCATpAC CACCCATCCA CAAAAAAAAA AAAAAAAAAG AAAAATATCA AGGAATAAAA 60G AACAAAAAGG AACATpGCT GGCCTGAGGA GGCATCACCC G 111 (2) INFORMATION FOR SEQ ID NO: 146: (i) SEQUENCE CHARACTERISTICS: 20 (A) LENGTH: 585 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 146: TAGCATGpG AGCCCAGACA CpGTAGAGA GAGGAGGACA GpAGAAGAA GAAGAAAAGT .60 TpTAAATGC TGAAAGpAC TATAAGAAAG CTTTGGCpT GGATGAGACT pTAAAGATG 120 CAGAGGATGC pTGCAGAAA CpCATAAAT ATATGCAGGT GApCCTTAT pCCTCCTAG_180_AAApTAGTG ATATpGAAA TAATGCCCAA ACpAApp CTCCTGAGGA AAACTApCT 240 ACApACpA AGTAAGGCAT TATGAAAAGT pcpHTAG GTATAGTTp TCCTAApGG 300 GpTGACAp GCpCATAGT GCCTCTGTTT pGTCCATAA TCGAAAGTAA AGATAGCTGT 360 GAGAAAACTA pACCTAAAT pGGTATGp GTpTGAGAA ATGTCCpAT AGGGAGCTCA 420 CCTGGTGGp pTAAApAT TGpGCTACT ATAApGAGC TAApATAAA AACCppTG 480 AGACATATGT TAAApGTCT TpCCTGTAA TACTGATGAT GATGTTpCT CATGCATpT 540 CpCTGAAp GGGACCApG CTGCTGTGTC TGGGCTCACA TGCTA 585 (2) INFORMATION FOR SEQ ID NO.147: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 579 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO.R47: TAGCATGpG AGCCCAGACA CTGGGCAGCG GGGGTGGCCA CGGCAGCTCC TGCCGAGCCC 60 AAGCGTGTp GTCTGTGAAG GACCCTGACG TCACCTGCCA GGCTAGGGAG GGGTCAATGT 120 GGAGTGAATG pCACCGACT pCGCAGGAG TGTGCAGAAG CCAGGTGCAA CpGGpTGC 180 pGTGpCAT CACCCCTCAA GATATGCACA CTGCTpCCA AATAAAGCAT CAACTGTCAT 240 CTCCAGATGG GGAAGACTp pCTCCAACC AGCAGGCAGG TCCCCATCCA CTCAGACACC 300 Üt AGCACGTCCA CCTTCTCGGG CAGCACCACG TCCTCCACCT TCTGCTGGTA CACGGTGATG 360 ATGTCAGCAA AGCCGpCTG CANGACCAGC TGCCCCGTGT GCTGTGCCAT CTCACTGGCC 420 TCCACCGCGT ACACCGCTCT AGGCCGCGCA TANTGTGCAC AGAANAAATG ATGATCCAGT 480 CCCACAGCCC ACGTCCAAGA NGACTTTATC CGTCAGGGAT TCpTApCT GCAGGATGAC 540 CTGTGGTAp AApGpCGT GTCTGGGCTC AACATGCTA 579 (2) INFORMATION FOR SEQ ID NO: 148: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 249 base pairs (B) TYPE: nucleic acid 20 (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 148: TGACACCTTG TCCAGCATCT GCAAGCCAGG AAGAGAGTCC TCACCAAGAT CCCCACCCCG 60 pGGCACCAG GATCpGGAC pCCAATCTC CAGAACTGTG AGAAATAAGT ApTGTCGCT 120 AAATAAATCT pGTGGTTTC AGATATTTAG CTATAGCAGA TCAGGCTGAC TAAGAGAAAC 180 CCCATAAGAG pACATACTC ApAATCTCC GTCTCTATCC CCAGGTCTCA GATGCTGGAC 240 AAGGTGTCA 249 (2) INFORMATION FOR SEQ ID NO: 149: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 255 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 149: TGACACCpG TCCAGCATCT GCTATpTGT GACT? TTAA TAATAGCCAT TCTGACTGGT 60 GTGAGATGGT AACTCApGT GGGTpGGTC TGCATFTCTC TAATGATCAG TGATApAAG 120 ATATGCpGT TGACCACATG TATATCATCT pTGAGAAGT GTCTGpCAT 180 ATccprGCC CAcprpAA pppTATc pGTAAAr GTpMpTc cpACAGATG 240 CTGGACAAGG TGTCA 255 (2) INFORMATION FOR SEQ ID NO: 150: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 318 base pairs (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 150: TTACGCTGCA ACACTGTGGA GGCCAAGCTG GGATCACpC pCApCTAA CTGGAGAGGA 60 GGGAAGpCA AGTCCAGCAG AGGGTGGGTG GGTAGACAGT GGCACTCAGA AATGTCAGCT 120 GGACCCCTGT CCCCGCATAG GCAGGACAGC AAGGCTGTGG CTCTCCAGGG CCAGCTGAAG 180 ^^^. AACAGGACAC TGTCTCCGCT GCCACAAAGC GTCAGAGACT CCCATCTTTG AAGCACGGCC 240 pcpGGTCT TCCTGCACp CCCTGpCTG pAGAGACCT GGpATAGAC AAGGCpCTC 300 CACAGTGpG CAGCGTAA 318 (2) INFORMATION FOR SEQ ID NO: 151: 15 (¡) SEQUENCE CHARACTERISTICS: (A) LENGTH: 323 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear 20 (? ¡) DESCRIPTION OF SEQUENCE: SEQ ID NO'151 TNACGCNGCN ACNNTGTAGA GANGGNAAGG CNpCCCCAC ApNCCCCp CATNANAGAA 60 pApC ACC AAGNNTGACC NATGCCNTp ATGACTTACA TGCNNACTNC NTAATCTGTN 120 TCNNGCCpA AAAGCNNNTC CACTACATGC NTCANCACTG TNTGTGTNAC NTCATNAACT 180 GTCNGNAATA GGGGCNCATA ACTACAGAAA TGCANpCAT ACTGCTTCCA NTGCCATCNG 240 CGTGTGGCCT TNCCTACTCT TCpNTApC CAAGTAGCAT CTCTGGANTG CTTCCCCACT 300 CTCCACApG pGCAGCNAT AAT 323 (2) INFORMATION FOR SEQ ID NO: 152: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 311 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 152: TCAAGApCC ATAGGCTGAC CAGTCCAAGG AGAGpGAAA TCATGAAGGA GAGTCTATCT 60 GGAGAGAGCT GTAGTpTGA GGGpGCAAA GACTTAGGAT GGAGpGGTG GCTGTGGpA 120 GTCTCTAAGG pGATTpGT TCATAAATp CATGCCCTGA ATGCCpGCT TGCCTCACCC 180 TGGTCCAAGC CpAGTGAAC ACCTAAAAGT CTCTGTCpC pGCTCTCCA AACpCTCCT 240 GAGGATTTCC TCAGApGTC TACApCAGA TCGAAGCCAG pGGCAAACA AGATGCAGTC 300 CAGAGGGTCA G 311 (2) INFORMATION FOR SEQ ID NO: 153: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 332 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 153: CAAGApCCA TAGGCTGACC AGGAGGCTAT TCAAGATCTC TGGCAGpGA GGAAGTCTCT 60 pAAGAAAAT AGUTA CA ApTGpAAA AlTTpCTGT CpACpCAT pCTGTAGCA 120 GpGATATCT GGCTGTCCp pTATAATGC AGAGTGGGAA CTpCCCTAC CATGTiTGAT 180 AAATGpGTC CAGGCTCCAT TGCCAATAAT GTGpGTCCA AAATGCCTGT lTAGppTA 240 AAGACGGAAC TCCACCCTp GCpGGTCp AAGTATGTAT GGAATGpAT GATAGGACAT 300 AGTAGTAGCG GTGGTCAGCC TATGGAATCT TG 332 (2) INFORMATION FOR SEQ ID NO: 154: ^^ (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 345 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple 5 (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 154: TCAAGApCC ATAGGCTGAC CTGGACAGAG ATCTCCTGGG TCTGGCCCAG GACAGCAGGC 60 TCAAGCTCAG TGGAGAAGGT pCCATGACC CTCAGApCC CCCAAACCTT GGATTGGGTG 120 ACApGCATC TCCTCAGAGA GGGAGGAGAT GTANGTCTGG GCTTCCACAG GGACCTGGTA 180 ppAGGATC AGGGTACCGC TGGCCTGAGG CpGGATCAT TCANAGCCTG GGGGTGGAAT 240 GGCTGGCAGC CTGTGGCCCC ApGAAATAG GCTCTGGGGC ACTCCCTCTG pCCTANpG 300 AACpGGGTA AGGAACAGGA ATGTGGTCAN CCTATGGAAT CpGA 345 (2) INFORMATION FOR SEQ ID NO: 155: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 295 base pairs (B) TYPE: nucleic acid 20 (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 155: GACGCTTGGC CACTTGACAC ApAAACAGT TTTGCATAAT CACTANCATG TATpCTAGT 60 pGCTGTCTG CTGTGATGCC CTGCCCTGAT TCTCTGGCGT TAATGATGGC AAGCATAATC 120 AAACGCTGp CTGpAApc CAAGpATAA CTGGCApGA pAAAGCAp ATCTITCACA 180 ACTAAACTGT TCTTCATANA ACAGCCCATA pApATCAA ApAAGAGAC AATCTApCC 240 AATATCCTta ANGGCCAATA TATTTNATGT CCCTTAApA AGAGCTACTG TCCGT 295 fk (2) INFORMATION FOR SEQ ID NO: 156: 10 (i) SECU ency CHARACTERISTICS: (A) LONGITU D: 406 base pairs (B) TYPE: nucleic acid (C) FORM OF H ILO: simple (D) TOPOLOGY: linear 15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 156: twenty GACGCTTGGC CACTTGACAC TGCAGTGGGA AAACCAGCAT GAGCCGCTGC CCCCAAGGAA 60 CCTCGAAGCC CAGGCAGAGG ACCAGCCATC CCAGCCTGCA GGTAAAGTGT GTCACCTGTC 120 AGGTGGGCp GGGGTGAGTG GGTGGGGGAA GTGTGTGTGC AAAGGGGGTG TNAATGTNTA 180 TGCGTGTGAG CATGAGTGAT GGCTAGTGTG ACTGCATGTC AGGGAGTGTG AACAAGCGTG 240 CGGGGGTGTG TGTGCAAGTG CGTATGCATA TGAGAATATG TGTCTGTGGA TGAGTGCAp 300 l TGAAAGTCTG TGTGTGTGCG TGTGGTCATG ANGGTAANp ANTGACTGCG CAGGATGTGT 360 GAGTGTGCAT GGAACACTCA NTGTGTGTGT CAAGTGGCCN ANCGTC 406 (2) INFORMATION FOR SEQ ID NO: 157: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 208 base pairs (B) TYPE: nucleic acid 15 (C) THREAD FORM: single (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 157: TGACGCpGG CCACpGACA CACTAAAGGG TGpACTCAT CACTpCTTC TCTCCTCGGT 60 GGCATGTGAG TGCATCTAp CACpGGCAC TCATpGpT GGCAGTGACT GTAANCCANA 120 TCTGATGCAT ACACCAGCp GTAAAp & AA TAAATGTCTC TAATACTATG TGCTCACAAT 180 ANGGTANGGG TGAGGAGAAG GGGAGAGA 208 (2) INFORMATION FOR SEQ ID NO: 158: 25 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 547 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 158: CTTCAACCTC CpCAACCTC CTTCAACCTC CTGGApCAA ACAATCATCC CACCTCAGAC 60CTGAGACTAC AGACTCACGC CACTACATCT GGCTAAApT pGTAGAGAT 120 AGGGpTCAT CATGpGCCC TGGCTGGTCT CAAACTCCTG ACCTCAAGCA ATGTGCCCAC 180 CTCAGCCTCC CAAAGTGCTG GGApACAGG CATAAGCCAC CATGCCCAGT CCATNTTTAA 240 TC? TCCTAC CACApcpA CCACACTTTC ppATGTp AGATACATAA ATGCTTACCA 300 pATGATACA ApGCCCACA GTApAAGAC AGTAACATGC TGCACAGGp TGTAGCCTAG_360_GAACAGTAGG CAATACCACA TAGCpAGGT GTGTGGTAGA CTATACCATC TAGGpTGTG 420 TAAGpACAC pTATGCTGT pACACAATG ACAAAACCAT CTAATGATGC ATpCTCAGA 480 ATGTATCCp GTCAGTAAGC TATGATGTAC AGGGAACACT GCCCAAGGAC ACAGATApG 540 TACCTGT 547 (2) INFORMATION FOR SEQ ID NO: 159: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 203 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 159: GCTCCTCpG CCpACCAAC TCACCCAGTA TGTCAGCAAT pTATCRGCT pACCTACGA 60 AACAGCCTGT ATCCAAACAC pAACACACT CACCTGAAAA GpCAGGCAA CAATCGCCp 120 CTCATGGGTC TCTCTGCTCC AGpCTGAAC CTpCTCTp TCCTAGAACA TGCApTARG 180 TCGATAGAAG pCCTCTCAG TGC 203 (2) INFORMATION FOR SEQ ID NO: 160: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 402 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 160: TGTAAGTCGA GCAGTGTGAT GGGTGGAACA GGGpGTAAG CAGTAApGC AAACTGTAp 60 TAAACAATAA TAATAATAp TAGCATpAT AGAGCACpT ATATCTTCAA AGTACpGCA 120 AACApAYCT AApAAATAC CCTCTCTGAT TATAATCTGG ATACAAATGC ACTTAAACTC 180 AGGACAGGGT CATGAGARAA GTATGCATp GAAAGpGGT GCTAGCTATG CTrTAAAAAC 240 CTATACAATG ATGGGRAAGT TAGAGpCAG ApCTGpGG ACTGTppG TGCATpCAG 300 pCAGCCTGA TGGCAGAAp AGATCATATC TGCACTCGAT GACTYTGCp GATAACpAT 360 CACTGAAATC TGAGTGpGA TCATCACACT GCTCGACpA CA 402 (2) INFORMATION FOR SEQ ID NO: 161: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 193 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO 161: AGCATGpGA GCCCAGACAC TGACCAGGAG AAAAACCAAC CAATAGAAAC ACGCCCAGAC 60 ACTGACCAGG AGAAAAACCA ACCAATAAAA ACAGGCCCGG ACATAAGACA AATAATAAAA 120 pAGCGGACA AGGACATGAA AACAGCTAp GTAAGAGCGG ATATAGTGGT GTGTGTCTGG 180 GCTCAACATG CTA 193 (2) INFORMATION FOR SEQ ID NO: 162: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 147 base pairs (B) TYPE: nucleic acid 5 (C) THREAD FORM: single (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 162: TGpGAGCCC AGACACTGAC CAGGAGAAAA ACCAACCAAT AAAAACAGGC CCGGACATAA 60 GACAAATAAT AAAApAGCG GACAAGGACA TGAAAACAGC TApGTAAGA GCGGATATAG_120_10 TGGTGTGTGT CTGGGCTCAA CATGCTA j47 (2) INFORMATION FOR SEQ ID NO: 163: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 294 base pairs 15? (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 163: twenty TAGCATGpG AGCCCAGACA- CAAATCpTC CTTAAGCAAT AAATCATpC TGCATATGp 60 pTAAAACCA CAGCTAAGCC ATGApApC AAAAGGACTA pGTApGGG TATTpGAp 120 TGGGpcpA TCTCCCTCAC ApATCTTCA pTCTATCAT TGACCTCTTA TCCCAGAGAC 180 TCTCAAACTT pATGpATA CAAATCACAT TCTGTCTCAA AAAATATCTC ACCCACTTCT 240 CTTCTGTpC TGCGTGTGTA TGTGTGTGTG TGTGTGTCTG GGCTCAACAT GCTA 294 (2) INFORMATION FOR SEQ ID NO: 164: (i) SEQUENCE CHARACTERISTICS: (A) ITU D LENGTH: 412 base pairs (B) TYPE: nucleic acid (C) FORM OF H ILO: simple (D) TOPOLOGY: linear (? ¡) DESCRIPTION OF SEQUENCE: SEQ ID NO: 164: CGGGApGGC TpGAGCTGC AGATGCTGCC TGTGACCGCA CCCGGCGTGG AACAGAAAGC 60 CACCTGGCTG CAAGTGCGCC AGAGCCGCCC TGACTACGTG CTGCTGTGGG GCTGGGGCGT 120 GATGAACTCC ACCGCCCTGA AGGAAGCCCA GGCCACCGGA TACCCCCGCG ACAAGATGTA 180 CGGCGTGTGG TGGGCCGGTG CGGAGCCCGA TGTGCGTGAC GTGGGCGAAG GCGCCAAGGG 240 CTACAACGCG CTGGCTCTGA ACGGCTACGG CACGCAGTCC AAGGTGATCC ANGACATCCT 300 GAMCACGTG CACGACAAGG GCCAGGGCAC GGGGCCCCAAA GACGAAGTGG GCTCGGTGCT 360 GTACACCCGC GGCGTGATCA TCCAGATGCT GGACAAGGTG TCAATCACTA AT 412 (2) INFORMATION FOR SEQ ID NO: 165: (i) SEQUENCE CHARACTERISTICS: (A) ITU D LENGTH: 361 base pairs (B) TYPE: nucleic acid 15 fk (C) HI FORM: simple (D) ) TOPOLOGY: line l (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 165:GACACCp GTCCAGCATC TGCATCTGAT GAGAGCCTCA GATGGCTACC ACTAATGGCA 60 GAAGGCAAAG GAGAACAGGC ApGTATGGC AAGAAAGGAA GAAAGAGAGA GGGGAGAAAG 120 GTGCTAGGp CpTTCAACA ACCAGpCTT GATGGAACTG AGAGTAAGAG CTCAAGGCCA 180 GGTGTGGTGA CTCCAACCAG TAATCCCAAC ATpTAGGAG .GCTGAGGCAG GCAGATGTCT 240 TGACCCCATG AG1TTGTGAC CAGCCTGAAC AACATCATGA GACTCCATCT CTACAATAAT 300 TACAAAAAp AATCAGGCAT TGTGGTATGC CCTGTAGTCC CAGATGCTGG ACAAGGTGTC 360 A 361 (2) INFORMATION FOR SEQ ID NO: 166: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 427 base pairs (B) TYPE: nucleic acid 15 (C) THREAD FORM: single - • ^ (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 166: twenty TWGACTGACT CATGTCCCCT ACACCCAACT ATCpCTCCA GGTGGCCAGG CATGATAGAA 60 TCTGATCCTG ACTTAGGGGA ATATpTCp pTACTTCCC ATCpGApC CCTGCCGGTG 120 AGTpCCTGG pCAGGGTAA GAAAGGAGCT CAGGCCAAAG TAATGAACAA ATCCATCCTC 180 ACAGACGTAC AGAATAAGAG AACWTG6ACW TAGCCAGCAG AACMCAAKTG AAAMCAGAAC 240 MCpAMCTAG GATRACAAMC MCRRARATAR KTGCYCMCMC WTATAATAGA AACCAAACp 300 GTATCTAAp AAATATpAT CCACYGTCAG GGCApAGTG GTpTGATAA ATACGCpTG 360 GCTAGGApC CTGAGGpAG AATGGAARAA CAApGCAHC GAGGGTAGGG GACATGAGTC 420 AKTCTAA 427 (2) INFORMATION FOR SEQ ID NO: 167: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 500 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEC ID NOR67: twenty AACGTCGCAT GCTCCCGGCC GCCATGGCCG CGGGATAGAC TGACTCATGT CCCCTAAGAT 60 AGAGGAGACA CCTGCTAGGT GTAAGGAGAA GATGGpAGG TCTACGGAGG CTCCAGGGTG 120 GGAGTAGpC CCTGCTAAGG GAGGGTAGAC TGpCAACCT GpCCTGCTC CGGCCTCCAC 180 TATAGCAGAT GCGAGCAGGA GTAGGAGAGA GGGAGGTAAG AGTCAGAAGC pATGpGp 240 TATGCGGGGA AACGCCRTAT CGGGGGCAGC CRAGpApA GGGGACACTRTR TAGWYARTCW 300 • AGNTAGCATC CAAAGCGNGG GAGpNTCCC ATATGGpGG ACCTGCAGGC GGCCGCApA 360 GTGApAGCA TGTGAGCCCC AGACACGCAT AGCAACAAGG ACCTAAACTC AGATCCTCTG 420 CTGApACp AACATGAAp ApGTATpA pTAACAACT pGAGpATG AGGCATApA 480 pAGGTCCAT ATTACCTGGA 500 (2) INFORMATION FOR SEQ ID NO: 168: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 358 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear 20 ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 168: pCATCGCTC GGTGACTCAA GCCTGTAATC CCAGAACTp GGGAGGCCGA GGGGAGCAGA 60 TCACCTGAGG pGGGAG GAGACCAGCC TGGCCAACAT GGTGACAACC CGTCTCTGCT 120 AAAAATACAA AAApAGCCA AGCATGGTGG CATGCACpG TAATCCCAGC TACTCGGGAG 180 GCTGAGGCAG GAGAATCACT TGAGGCCAGG AGGCAGAGGT TGCAGTGAGG CAGAGGpGA 240 GATCATGCCA CTGCACTCCA GCCTGGGCAA CAGAGTAAGA CTCCATCTCA AAAAAAAAAA 300 * AAAAAAAGAA TGATCAGAGC CACAAATACA GAAAACCpG AGTCACCGAG CGATGAAA 358 (2) INFORMATION FOR SEQ ID NO: 169: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1265 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 169: twenty pCTGTCCAC ACCAATCpA GAGCTCTGAA AGAATpGTC pTAAATATC TpTAATAGT 60 AACATGTAp pATGGACCA AATTGACAp pCGACTAp TTpCCCAAA AAAAGTCAGG 120 TGAATpCAG CACACTGAGT TGGGAATpC pATCCCAGA AGWCGGCACG AGCAATpCA 180 TATpApTA AGA GApC CATACTCCGT prCAAGGAG AATCCCTGCA GTCTCCTTAA 240 AGGTAGAACA AATACpTCT CACCApGTG GGApGGACT pAAGAGGTG 300 ACTCTAAAAA AACAGAGAAC AAATATGTCT CAGpGTAp AAGCACGGAC CCATApATC 360 ATApCACp AAAAAAATGA pTCCTGTGC ACCTpTGGC AACTTCTCTT pCAATGTAG_420_10 GGAAAAACTT AGTCACCCTG AAAACCCACA AAATAAATAA AACpGTAGA TGTGGGCAGA 480 ARGTTTGGGG GTGGACApG TATGTGTpA AApAAACCC TGTATCACTG AGAAGCTGp 540 GTATGGGTCA GAGAAAATGA ATGCpAGAA GCTGpCACA TCpCAAGAG CAGAAGCAAA 600 CCACATGTCT CAGCTATAp ApApTA rpTATGCAT AAAGTGAATC ATpcpCTG 660 TApAApTC CAAAGGGTp TACCCTCTAT pAAATGCp TGAAAAACAG TGCApGACA 720 ATGGGpGAT ATppc T AAAAGAAAAA TATAApATG AAAGCCAAGA TAATCTGAAG 780 CCTGT? AT prAAAAcp prATGpcT GTGGpGATG pGpTGpr GpTG rcT 840 AppGpGG pppAcp TGTTppGT rGppGT ptGGtpoG CATACTACAT 900 GCAGTpcp TAACCAATGT CTGpTGGCT AATGTAApA AAGpGpAA pTATATGAG 960 TGCATpCAA CTATGTCAAT GGTpCTTAA TATTTApGT GTAG AGTAC TGGTAATpT 1020 pTATpACA ATATGTpAA AGAGATAACA GTpGATATG TTpCATGTG pTATAGCAG 1080 * A GpApTA pTCTATGGC ATTCCAGCGG ATATpTGGT GTpGCGAGG CATGCAGTCA 1140 ATATpTGTA CAGpAGTGG ACAGTApCA GCAACGCCTG ATAGCpCTT TGGCCpATG 1200 pAAATAAAA AGACCTGTp GGGATGTAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 1260 AAAAA 1265 (2) INFORMATION FOR SEQ ID NO: 170: (i) SEQUENCE CHARACTERISTICS: (A) LONGITU D: 383 base pairs 10 (ß) TYPE: nucleic acid (C) FORM OF H ILO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 170: TGTAAGTCGA GCAGTGTGAT GACGATApc pCTTApAA TGTGGTAAp GAACAAATGA 60 TCTGTGATAC TGATCCTGAG CTAGGAGGCG CTGpCAGp AATGGGACp CTTCGTACTC 120 ^ F TAApGATCC AGAGAACATG CTGGCTACAA CTAATAAAAC CGAAAAAAGT GAATITCTAA 180 ApppCTA CAACCApGT ATGCATGpC TCACAGCACC ACTTpGACC AATACpCAG 240 AAGACAAATG TGAAAAGGAT AATATAGpG GATCAAACAA AAACAACACA ATpGTCCCG 300 ATAApATCA AACAGCACAG CTACTTGCCT TAATpTAGA GpACTCACA TpTGTGTGG 360 AACATCACAC TGCTCGACp ACA 383 (2) INFORMATION FOR SEQ ID NO: 171 25 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 383 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 171: TGGGCACCTT CAATATCGCA AGpAAAAAT AATGpGAGT pApATACT TTTGACCTGT 60 pAGCTCAAC AGGGTGAAGG CATGTAAAGA ATGTGGACTT CTGAGGAAp pCTpTAAA 120 AAGAACATAA TGAAGTAACA TAApAC TCAAGGACTA CTpTGGpG AAGpTATAA 180 TCTAGATACC TCTACTTpT GppTGCTG pCGACAGp CACAAAGACC pCAGCAAp 240 TACAGGGTAA AATCGpGAA GTAGTGGAGG TGAAACTGAA ApTAAAAp ApCTGTAAA 300 TACTATAGGG AAAGAGGCTG AGCpAGAAT CTpTGGpG pCATGTGp CTGTGCTCp 360 ATCATCACAC TGCTCGACp ACA 383 (2) INFORMATION FOR SEQ ID NO: 172: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 699 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 172: TCGGGTGATG CCTCCTCAGG CTTGTCGpA GTGTACACAG AGCTGCTCAT GAAGCGACAG 60 CGGCTGCCCC TGGCACpCA GAACCTCpC CTCTACACp pGGTGCGCT TCTGAATCTA 120 GGTCTGCATG CTGGCGGCGG CTCTGGCCCA GGCCTCCTGG AAAGTpCTC AGGATGGGCA 180 6CACTCGTGG TGCTGAGCCA GGCACTAAAT GGACTGCTCA TGTCTGCTGT CATGGAGCAT 240 GGCAGCAGCA TCACACGCCT CTTTGTGGTG TCCTGCTCGC TGGTGGTCAA CGCCGTGCTC 300 * TCAGCAGTCC TGCTACGGCT GCAGCTCACA GCCGCCTTCT TCCTGGCCAC ApGCTCAp 360 GGCCTGGCCA TGCGCCTGTA CTATGGCAGC CGCTAGTCCC TGACAACpC CACCCTGAp 420 CCGGACCCTG TAGApGGGC GCCACCACCA GATCCCCCTC CCAGGCCpC CTCCCTCTCC 480 CATCAGCGGC CCTGTAACAA GTGCCpGTG AGAAAAGCTG GAGAAGTGAG GGCAGCCAGG 540 pApCTCTG GAGGpGGTG GATGAAGGGG TACCCCTAGG AGATGTGAAG TGTGGGTTTG 600 k GpAAGGAAA TGCpACCAT CCCCCACCCC CAACCAAGp NpCCAGACT AAAGAApAA 660 GGTAACATCA ATACCTAGGC CTGAGGAGGC ATCACCCGA 699 (2) INFORMATION FOR SEC ID N0.173: 2Q (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 701 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 173: 2b TCGGGTGATG CCTCCTCAGG CCAGATCAAA CpGGGGpG AAAACTGTGC AAAGAAATCA 60 ATGTCGGAGA AAGAATTpG CAAAAGAAAA ATGCCTAATC AGTACTAAp TAATAGGTCA 120 CApAGCAGT GGAAGAAGAA ATGpGATAT pTATGTCAG CTATpTATA ATCACCAGAG 180 TGCpAGCp CATGTAAGCC ATCTCGTAp CApAGAAAT AAGAACAAp pApCCTCG 240 GAAAGAACp pCAApTAT AGCATCpAA pGCTCAGGA TpTAAATp TGATAAAGAA 300 AGCTCCACp pGGCAGGAG TAGGGGGCAG GGAGAGAGGA GGCTCCATCC ACAAGGACAG 360 AGACACCAGG GCCAGTAGGG TAGCTGGTGG CTGGATCAGT CACAACGGAC TGACpATGC 420 CATGAGAAGA AACAACCTCC AAATCTCAGT TGCpAATAC AACACAAGCT CATpCTTGC 480 TCACGpACA TGTCCTATGT AGATCAACAG CAGGTGACTC AGGGACCCAG GCTCCATCTC 540 CATATGAGCT TCCATAGTCA CCAGGACACG GGCTCTGAAA CTGTCCTCCA TGCAGGGACA 600 CATGCCTCp CCpTCApG GGCAGAGCAA GTCACpATG GCCAGAAGTC ACACTGCAGG 660 GCAGTGCCAT CCTGCTGTAT GCCTGAGGAG GCATCACCCG A 701 (2) INFORMATION FOR SEQ ID NO: 174: 20 (¡) SEQUENCE CHARACTERISTICS: (A) LENGTH: 700 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear 25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 174: CAGGAGACAG 60 GGAAAGACAT AGATpTAAC CGGCCCCCp CAGGAGApC TGAGGCTCAG pCACpTGT 120 TGCAGTpGA ACAGAGGCAG CAAGGCTAGT GGpAGGGGC ACGGTCTCTA AAGCTGCACT 180 GCCTGGATCT GCCTCCCAGC TCTGCCAGGA ACCAGCTGCG TGGCCpGAG CTGCTGACAC 240 GCAGAAAGCC CCCTCTGGAC CCAGTCTCCT CGTCTGTAAG ATGAGGACAG GACTCTAGGA 300 * ACCCTpCCC pGGpTGGC CTCAC? TCA CAGGCTCCCA TCpGAACTC TATCTACTCT 360 TpCCTGAAA CCpGTAAAA GAAAAAAGTG CTAGCCTGGG CAACATGGCA AAACCCTGTC 420 TCTACAAAAA ATACAAAAAT TAGpGGGTG TGGTGGCATG TGCCTGTAGT CCCAGCCACT 480 TGGGAGGTGC TGAGGTGGGA GGATCACpG AGCCCGGGAG GTGGAGGpG CAGTGAGCCA 540 AGATCATGCC ACTGCACTCC AGCCTGAGTA ATAGAGTAAG ACTCTGTCTC AAAAACAACA 600 ACAACAACAG TGAGTGTGCC TCTGTTTCCG GGpGGATGG GGCACCACAT pATGCATCT 660 CTCAGATpG GACGCTGCAG CCTGAGGAGG CATCACCCGA 700 (2) INFORMATION FOR SEC ID NO: 175: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 484 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 175 : ß TATAGGGCGA ApGGGCCCG AGpGCATGN TCCCGGCCGC CATGGCCGCG GGApCGGGT 60 GATGCCTCCT CAGGCTTGTC TGCCACAAGC TACpCTCTG AGCTCAGAAA GTGCCCCTTG 120 ATGAGGGAAA ATGTCCTACT GCACTGCGAA pTCTCAGp CCATpTACC TCCCAGTCCT 180 CCpCTAAAC CAGpAATAA ApCAiTCCA CAAGTATTTA CTGApACCT GCpGTGCCA 240 GGGACTApC TCAGGCTGAA GAAGGTGGGA GGGGAGGGCG GAACCTGAGG AGCCACCTGA 300 * GCCAGCTpA TATpCAACC ATGGCTGGCC CATCTGAGAG CATCTCCCCA CTCTCGCCAA 360 CCTATCGGGG CATAGCCCAG GGATGCCCCC AGGCGGCCCA GGpAGATGC GTíXCpTGG 420 CpGTCAGTG ATGACATACA CCpAGCTGC pAGCTGGTG CTGGCCTGAG GAGGCATCAC 480 CCGA 484 (2) INFORMATION FOR SEQ ID NO: 176: 15 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 432 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear 20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 176: * TCGGGTGATG CCTCCTCAGG GCTCAAGGGA TGAGAAGTGA CpcpTCTG GAGGGACCGT 60 TCATGCCACC CAGGATGAAA ATGGATAGGG ACCCACTTGG AGGACpGCT GATATGpTG 120 GACAAATGCC AGGTAGCGGA ApGGTACTG GTCCAGGAGT TATCCAGGAT AGATTpCAC 180 CCACCATGGG ACGTCATCGT TCAAATCAAC TCpCAATGG CCATGGGGGA CACATCATGC 240 CTCCCACACA ATCGCAGTp GGAGAGATGG GAGGCAAGp TATGAAAAGC CAGGGGCTAA 300 6CCAGCTCTA CCATAACCAG AGTCAGGGAC TCpATCCCA GCTGCAAGGA CAGTCGAAGG 360 ATATGCCACC TCGGTpTCT AAGAAAGGAC AGCpAATGC AGATGAGAp AGCCTGAGGA 420 GGCATCACCC GA 432 (2) INFORMATION FOR SEQ ID NO: 177: (i) SEQUENCE CHARACTERISTICS: 15 (A) LENGTH: 788 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 177: 20 TAGCATGpG AGCCCAGACA CAGTAGCAp TGTGCCAAp TCTGGpGGA ATGGTGACAA 60 CATGCTGGAG CCAAGTGCTA ACATGCCTTG GpCAAGGGA TGGAAAGTCA CCCGTAAGGA 120 TGGCAATGCC AGTGGAACCA CGCTGCpGA GGCTCTGGAC TGCATCCTAC CACCAACTCG 180 CCCAACTGAC AAGCCCpGC GCCTGCCTCT CCAGGATGTC TACAAAApG GTGGTApGG 240 TACTGpCCT GpGGCCGAG TGGAGACTGG TGpCTCAAA CCCGGTATGG TGGTCACCTT 300 # TGCTCCAGTC AACCTTACAA CGGAAGTAAA ATCTGTCGAA ATGCACCATG AAGCTGTGAG 360 TGAAGCTCp CCTGGGGACA ATGTGGGCp CAATGTCAAG AATGTGTCTG TCAAGGATGT 420 TCGTCGTGGC AACGpGCTG GTGACAGCAA AAATGACCCA CCAATGGAAG CAGCTGGCTT 480 CACTGCTCAG GTGApATCC TGAACCATCC AGGCCAAATA AGTGCCGGCT ATGCCCCTGT 540 Ap8ApGC CACACGGCTC ACApGCATG CAAGTpGCT GAGCTGAAGG AAAAGApGA 600 TCGCCGpCT GGTAAAAAGC TGGAAGATGG CCCTAAApC pGAAGTCTG GTGATGCTGC 660 CApGpGAT ATGGpCCTG GCAAGCCCAT GTGTGpGAG AGCTTCTCAG ACTATCCACC 720 pTGGGTCGC pTGCTGpC GTGATATGAG ACAGACAGp GCGGTGGGTG TCTGGGCTCA 780 ACATGCTA 788 (2) IN FO R M ANAGEMENT FOR SEQ ID NO: 1 78: (i) S ECUENCE CHARACTERISTICS: (A) ITU D LENGTH: 786 base pairs 25 (B) TI PO: nucleic acid # (C) ) THREAD FORM: simple (D) TOPOLOGY: linear (xi) DESCRI SEQUENCE PC: SEQ ID NO: 178: TAGCATGpG AGCCCAGACA CCTGTGTTTC TGGGAGCTCT GGCAGTGGCG GApCATAGG 60 CACpGGGCT GCACpTGAA TGACACACp GGCpTApA GApCACTAG ppTAAAAA 120 ApGpGpc GpTcppc ApAAAGGp TAATCAGACA GATCAGACAG CATAAT? GC íßo * TApTAATGA CAGAAACGp GGTACATpC pCATGAATG AGCTTGCAp CTGAAGCAAG 240 AGCCTACAAA AGGCACpGT TATAAATGAA AGpCTGGCT CTAGAGGCCA GTACTCTGGA 300 GTTTCAGAGC AGCCAGTGAT TGpCCAGTC AGTGATGCCT AGpATATAG AGGAGGAGTA 360 CACTGTGCAC TCpCTAGGT GTAAGGGTAT GCAACpTGG ATCpAAAAT TCTGTACACA 420 TACACACTTT ATATATATGT ATGTATGTAT GAAAACATGA AApAGpTG TCAAATATGT 480 GTGTGTTTAG TATpTAGCT TAGTGCAACT ApTCCACAT TATpApAA ApGATCTAA 540 * GACACTpCT TGpGACACC pGAATApA ATGpCAAGG GTGCAATGTG TApCCpTA 600 GApGpAAA GCTTAApAC TATGATTTGT AGTAAApAA CppAAAAT GTATGTGAGC 660 CCpCTGTAG TGTCGTAGGG CTCTTACAGG GTGGGAAAGA TpTAATpT CCACTTGCTA 720 ATTGAACAGT ATGGCCTCAT TATATATpT GATpATAGG AGTpGTGTC TGGGCTCAAC 780 ATGCTA 786 (2) IN FO R MAC ION FOR S EC ID NO: 1 79: 25 UENCE: (A) LONGITU D: 796 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple 5 (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 179: TAGCATGpG AGCCCAGACA CTGGpACAA GACCAGACCT GCTTCCTCCA TATGTAAACA 60 # GCTTpAAAA AGCCAGTGAA CCTTpTAAT ACpTGGCAA CCTTCTpCA CAGGCAAAGA 120 ACACCCCCAT CCGCCCCpG pTGGAGTGC AGAGTpGGC pTGGpcp TGCCpGCCT 180 GGAGTATACT TCTAApCCT GpGTCCTGC ACAAGCTGAA TACCGAGCTA CCCACCGCCA 240 CCCAGGCCAG GpTCCACTC ApTApACT pATGpTCT GpCCApGC TGGTCCACAG 300 AAATAAGTp TCCTpGGAG GAATGTGAp ATACCCCTp AATpCCTCC ppGCpp 360 ppAATATC ApGGTATGT GpTGGCCCA GAGGAAACTG AAApCACCA TCATCpGAC 420 # TGGCAATCCC ApACCATGC l i l l l lAAA AAACGTAAp pTCpGCCT TACApGGCA 480 twenty GAGTAGCCCT TCCTGGCTAC TGGCTTAATG TAGTCACTCA GpTCTAGGT GGCApAGGC 540 ATGAGACCTG AAGCACAGAC TGTCpACCA CAAAAGGTGA CAAGATCTCA AACCpAGCC 600 AAAGGGCTAT GTCAGGpTC AATGCTATCT GCpCTGpC CTGCTCACTG pCTGGATIT 660 TGTccpcp CATCCCTAGC ACCAGAATIT CCCAGTCTCC CTCCCTACCT TcccpGpr 720 TAApCTAAT CTATCAGCAA AATAACTpT CAAATGTpT AACCGGTATC TCCATGTGTC 780 TGGGCTCAAC ATGCTA 796 (2) INFORMATION FOR SEQ ID NO: 180: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 488 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 180: GGATGTGCTG CAAGGCGAp AAGpGGGTA ACGCCAGGGT pTCCCAGTC ACGACGpGT 60 AAAACGACGG CCAGTGAAp GTAATACGAC TCACTATAGG GCGAApGGG CCCGACGTCG 120 CATGCTCCCG GCCGCCATGG CCGCGGGATA GCATGpGAG CCCAGACACC TGCAGGTCAT 180 pGGAGAGAT TpTCACGp ACCAGCpGA TGGTCTpp CAGGAGGAGA GACACTGAGC 240 ACTCCCAAGG TGAGGpGAA GATpCCTCT AGATAGCCGG ATAAGAAGAC TAGGAGGGAT 300 GCCTAGAAAA TGApAGCAT GCAAATpCT ACCTGCCAp TCAGAACTGT GTGTCAGCCC 360 ACApCAGCT GCpcpGTG AACTGAAAAG AGAGAGGTAT TGAGACTTp CTGATGGCCG 420 CTCTAACAp GTAACACAGT AATCTGTGTG TGTGTGGGTG TGTGTGTGTG TCTGGGCTCA 480 ACATGCTA 488 (2) INFORMATION FOR SEQ ID NO: 181: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 317 base pairs (B) TYPE: nucleic acid 20 (C) THREAD FORM: single (D) TOPOLOGY: linear ( xí) SEQUENCE DESCRIPTION: SEQ ID NO: 181 TAGCATGpG AGCCCAGACA CGGCGACGGT ACCTGATGAG TGGGGTGATG GCACCTGTGA 60 AAAGGAGGAA CGTCATCCCC CATGATApG GGGACCCAGA TGATGAACCA TGGCTCCGCG 120 TCAATGCATA pTAATCCAT GATACTGCTG ApGGAAGGA CCTGAACCTG AAGT TGTGC 180 TGCAGGTTTA TCGGGACTAT TACCTCACGG GTGATCAAAA CpCCTGAAG GACATGTGGC 240 CTGTGTGTCT AGTAAGGGAT GCACATGCAG TGGCCAGTGT GCCAGGGGTA TGGpGGTGT 300 CTGGGCTCCA CATGCTA 317 (2) INFORMATION FOR SEQ ID NO: 182: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 507 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 182: twenty # TAGCATGpG AGCCCAGACA CTGGCTGpA GCCAAATCCT CTCTCAGCTG CTCCCTGTGG 60 pTGGTGACT CAGGApACA GAGGCATCCT GTÍTCAGGGA ACAAAAAGAT pTAGCTGCC 120 AGCAGAGAGC ACCACATACA pAGAATGGT AAGGACTGCC ACCTCCTTCA AGAACAGGAG 180 TGAGGGTGGT GGTGAATGGG AATGGAAGCC TGCApCCCT GATGCATpG TGCTCTCTCA 240 AATCCTGTCT TAGTCTTAGG AAAGGAAGTA AAGTpCAAG GACGGpCCG AACTGCTTp 300 TGTGTCTGGG CTCAACATGC TATCCCGCGG CCATGGCGGC CGGGAGCATG CGACGTCGGG 360 CCCAApCGC CCTATAGTGA GTCGTApAC AApCACTGG CCGTCGTTp ACAACGTCGT 420 GACTGGGAAA ACCCTGGCGT TACCCAACTT AATCGCCpG CAGCACATCC CCCTpCCCA 480TANCGAAAAG GCCCGCA 507 (2) INFORMATION FOR SEQ ID NO: 183: 15 F (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 227 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear 20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 183: GApTACGCT GCAACACTGT GGAGGTAGCC CTGGAGCAAG GCAGGCATGG ATGCpCTGC 60 AATCCCCAAA TGGAGCCTGG TATpCAGCC AGGAATCTGA GCAGAGCCCC CTCTAApGT 120 AGCAATGATA AGpApCTC pTGpCTTC AACCTTCCAA TAGCCpGAG CpCCAGGGG 180 AGTGTCGpA ATCApACAG CCTGGTCTCC ACAGTGp & C AGCGTAA 227 (2) INFORMATION FOR SEQ ID NO: 184: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 225 base pairs (B) TYPE: nucleic acid 10 (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 184: pACGCTGCA ACACTGTGGA GCAGApAAC ATCAGACTTT TCTATCAACA TGACTGGGGT 60 TACTAAAAAG ACAACAAATC AATGGCpCA AAAGTCTAAG GAATAATpC GATACTTCAA 120 CpTATAAAA CCTGACAAAA CTATCAATCA AGCATAAAGA CAGATGAAGA ACATpCCAG 180 ATpTGGCCA ATCAGATAp pACCTCCAC AGTGpGCAG CGTAA 225 (2) INFORMATION FOR SEQ ID NO: 185: 20 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 597 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear 25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 185: GGCCCGACGT CGCATGCTCC CGGCCGCCAT GGCCGCGGGA pCGpAGGG TCTCTATCCA 60 * CTGGGACCCA TAGGCTAGTC AGAGTATpA GAGpGAGp CCTTTCTGCT TCCCAGAAp 120 TGAAAGAAAA GGAGTGAGGT GATAGAGCTG AGAGATCAGA pTGCCTCTG AAGCCTGpC 180 AAGATGTATG TGCTCAGACC CCACCACTGG GGCCTGTGGG TGAGGTCCTG GGCATCTAp 240 TGAATGAAp GCTGAAGGGG AGCACTATGC OWGGAAGGG GAACCCATCC TGGCACTGGC 300 ACAGGGGTCA CCpATCCAG TGCTCAGTGC TTCTpGCTG CTACCTGGp pCTCTCATA 360 TGTGAGGGGC AGGTAAGAAG AAGTGCCCRG TGpGTGCGA GTpTAGAAC ATCTACCAGT 420 AAGTGGGGAA GTpCACAAA GCAGCAGCp TGTpTGTGT Ap TCACCT TCAGpAGAA 480 GAGGAAGGCT GTGAGATGAA TGpAGpGA GTGGAAAAGA CGGGTAAGCT TAGTGGATAG_540_AGACCCTAAC GAATCACTAG TGCGGCCGCC pGCAGGTCG ACCATATGGG AGAGCTC 597 (2) INFORMATION FOR SEQ ID NO: 186: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 597 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single 20 (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 186: # GGCCCGAAGT TGCATGpCC CGGCCGCCAT GGCCGCGGGA pCGpAGGG TCTCTATCCA 60 CTACCTAAAA AATCCCAAAC ATATAACTGA ACTCCTCACA CCCAApGGA CCAATCCATC 120 ACCCCAGAGG CCTACAGATC CTCCTpGAT ACATAAGAAA ApTCCCCAA ACTACCTAAC 180 TATATCATp TGCAAGATp GTpTACCAA ATpTGATGG CCTTTCTGAG CTTGTCAGTG 240 TGAACCACTA pACGAACGA TCGGATApA ACTGCCCCTC ACCGTCCAGG TGTAGCTGGC 300 AACATCAAGT GCAGTAAATA pCApAAGT TITCACCTAC TAAGGTGCp AAACACCCTA 360 GGGTGCCATG TCGGTAGCAG ATCTTpGAT pGIlílIAT pCCCATAAG GGTCCTGpC 420 AAGGTCAATC ATACATGTAG TGTGAGCAGC TAGTCACTAT CGCATGACp GGAGGGTGAT 480 AATAGAGGCC TCCTpGCTG pAAAGAACT CTTGTCCCAG CCTGTCAAAG TGGATAGAGA 540 CCCTAACGAA TCACTAGTGC GGCCGCCTGC AGGTCGACCA TATGGGAGAG CTCCCAA 597 (2) INFORMATION FOR SEQ ID NO: 187: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 324 base pairs 20 (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NOR87: TCGpAGGGT CTCTATCCAC pGCAGGTAA AATCCAATCC TGTGTATATC pATAGTCTT 60 CCATATGTAG TGGpCAAGA GACTGCAGp CCAGAAAGAC TAGCCGAGCC CATCCATGTC 120 pCCACpAA CCCTGCTTTG GGpACACAT CTTAACpp CTGpCAAGT pCTCTGTGT 180 AGTpATAGC ATGAGTApG GGAWAATGCC CTGAAACCTG ACATGAGATC TGGGAAACAC 240 AAACpACTC AATAAGAAp TCTCCCATAT TpTATGATG GAAAAATpC ACATGCACAG 300 AGGAGTGGAT AGAGACCCTA ACGA 324 (2) INFORMATION FOR SEQ ID NO: 188: 10 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 178 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear 15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 188: GCGCGGGGAT TCGGGGTGAT ACCTCCTCAT GCCAAAATAC AACGTNTAAT pCACAACTT 60 GCcpccAAT pACGCApr TCAA? TGCT CTCCCCATGT Gp & GTCAc AACAAACACC 120 ApGCCCAGA AACATGTAp ACCTAACATG CACATACTCT TAAAACTACT CATCCCp 178 (2) INFORMATION FOR SEQ ID NO: 189: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 367 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear ^ ^ P (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 189: TGACACCTTG TCCAGCATCT GACACACTCT TGGCTCTTGG AAAATApGG ATAAATGAAA 60 ATGAATpCT pAGCAAGTG GTATAAGCTG AGAATATACG TATCACATAT CCTCApCTA 120 AGACACApC AGTGTCCCTG AAApAGAAT AGGACTTACA ATAAGTCTCT TCACTFTCTC 180 AATAGCTGp ApCAApGA TGGTAGGCCT TAAAAGTCAA AGAAATGAGA GGGCATGTGA 240 AAAAAAGCTC AACATCACTG ATCApAGAA AACTTCCAp CAAACCCCCA ATGAGATACC 300 ATCTCATACC AGTCAGAATG GCTApApA AAAAGTCAAA AAATAACAGA TGCTGGACAA 360 GGTGTCA 367 (2) INFORMATION FOR SEQ ID NO: 190: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 369 base pairs 15 (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 190: twenty GACACCTTGT CCAGCATCTG ACAACGCTAA CAGCCTGAGG AGATCTTTAT pApTATTT 60 AGTT? TACT CTGGCTAGGC AGATGGTGGC TAAAACApc ApTACccAT pApcApr 120 AApGpCT GCAAGGCCTA TGGATAGAGT ApGTCCAGC ACTGCTCTGG AAGCTAGGAG 180 CATGGGGATG AACAAGATAG GCTACATCCT GpCCCACAG AACpCCACT pAGTCTGGG 240 AAACAGATGA TATATACAAA TATATAAATG AApCAGGTA GTpTAAGTA CGAAAAGAAT 300 AAGAAAGCAG AGTCATGAp TANAATGCTG GAAACAGGGG CTApGCTTG AGATApGAA 360 GGTGCCCAA 369 (2) INFORMATION FOR SEQ ID NO: 191: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 369 base pairs (B) TYPE: nucleic acid 15 (C) THREAD FORM: single (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO.R91 twenty AAGAAACTAT TATCAGAGTG AACAGGCAAC 60 CTACAGAATG GGAGAAAAp pTGCAATCT ATCCATCTGA CAAAGGGCTA ATATCCAGAA 120 TCTACAAAGA ACpATACAA ATTTACAAGA AACAAACAAA CAAACAACTC CTCAAAAAGT 180 GGGTGAAGGA TGTGAACAGA CACTTCTCAA AAGAAGACAT pATGGGGCC AACAAACATA 240 TGAAAAAAAG CTCATCATCA CTGGTCACTA GATAAATGCA AATCAAAACC ACAATGAGAT 300 ACCATCTCAT TCCAGpAGA ATGGCAATCA pAAAAAGTC AGGAAACAAC AGATGCTGGA 360 CAAGGTGTC 369 (2) INFORMATION FOR SEQ ID NO: 192: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 449 base pairs (B) TYPE: nucleic acid 15 ^^^^ (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 192: TGACGCpGG CCACpGACA CTTCATCTp GCACAGAAAA ACTTCpTAC AGATpAAp 60 CAAGACTGGT CTAGTGACAG TCCTCCAGAC Al II 11 ICAT pGpCCATA TACGTGGAAT 120 pTAAAATCA TGTpCATCA GpTGAAATG ATpGGGCTG CTAATCAACA CAApGGATC 180 GACTGpCTA CTAAACAACA GGAAAATGTG TATCTG6CAG CCTGTGGAGA AACACTAAAC 240 ApGAprp cpTGccpr TACGGAcpr GpccAGCTA CATGTAATAC CAAGpCTCT 300 pAAGAGGAG AAGATGpGA TCTTCApTG TTTCTACCAG ACTGCCACCC TAGTAAATAT 360 TCTpApTA TGCTGGTAAA AAApGCCAT CCAAATAAGA TGApCATGA TACTGGTAp 420 * CCTGCTGAGT GTCAAGTGGC CAAGCGTCA 449 (2) INFORMATION FOR SEQ ID NO: 193: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 372 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple 5 (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 193: twenty * TGACGCpGG CCACpGACA CCAGGGATGT AKCAGpGAA TATAATCCTG CAApCTACA 60 TApGGCAAT pCCCATCAA ACApCTAGA AAGAGACAAC CAGGApGCT AGGCCATAAA 120 AGCTGCAATA AATAACTGGT AApGCAGTA ATCATpCAG GCCAApCAA TCCAGTpGG 180 CTCAGAGGTG CCpTGGCTG AGAGAAGAGG TGAGATATAA TGTGTpTCT TGCAACpCT 240 TGGAAGAATA ACTCCACAAT AGTCTGAGGA CTAGATACAA ACCTATpGC CApAAAGCA 300 CCAGAGTCTG pAApCCAG TACTGATAAG TGpGGAGAT TAGACTCCAG TGTGTCAAGT 360 GGCCAAGCGT CA 372 (2) IN FOR MATION FOR SEQ ID NO: 194: (i) SEQUENCE CHARACTERISTICS: (A) LONGITU D: 309 base pairs (B) TI PO: nucleic acid 15 (C) FORM OF H ILO: simple (D) ) TOPOLOGY: linear (xi) DESCR ITION OF SECUENC IA: SEQ ID NO: 194: twenty TGACGCpGG CCACpGACA CTTATGTAGA ATCCATCGTG GGCTGATGCA AGCCCpTAT 60 pAGGCpAG TGpGTGGGC ACCTTCAATA TCACACTAGA GACAAACGCC ACAAGATCTG 120 CAGAAACAp CAGpCTGAN CACTCGAATG GCAGGATAAC ppTGTGp GTAATCCpC 180 ACATATACAA AAACAAACTC TGCANTCTCA CGpACAAAA AAACGTACTG CTGTAAAATA 240 pAAGAAGGG GTAAAGGATA CCATCTATAA CAAAGTAACT TACAACTAGT GTCAAGTGGC 300 CAAGCGTCA 309 (2) INFORMATION FOR SEQ ID NO: 195: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 312 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single 15 (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 195: TGACGCpGG CCACpGACA CCCAATCTCG CACTTCATCC TCCCAGCACC TGATGAAGTA 60 twenty GGACTGCAAC TATCCCCACT TCCCAGATGA GGGGACCAAN GTACACApA GGACCCG6AT 120 GGGAGCACAG ApTGTCCGA TCCCAGACTC CAAGCACTCA GCGTCACTCC AGGACAGCGG 180 CTpCAGATA AGGTCACAAA CATGAATGGC TCCGACAACC GGAGTCAGTC CGTGCTGAGT 240 TAAGGCAATG GTGACACGGA TGCACGTCTN ACCTGTAATG GpCATCGTA AGTGTCAAGT 300 GGCCAAGCGT CA 312 * 2) INFORMATION FOR SEQ ID NO: 196: (i) SEQUENCE CHARACTERISTICS: 10 (A) LENGTH: 288 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 196: TGTATCGACG TAGTGGTCTC CTCAGCCATG CAGAACTGTG ACTCAApAA ACCTCpTCC 60 pTATGAAp ACCCAATCTC GGGTAGTGTC pTATAGTAG TGTGAGAATG GACTAATACA 120 AGTACATTp ACpAGTAAT AATAATAAAC AAATATApA CAppTGTG TATpACTAC 180 ACCATATTp pApGpAT TGTAGTGTAC ACCpCTACT TApAAAAGA AATAGGCCCG 240 AGGCGGGCAG ATCACGAGGT CAGGAGATGG AGACCACTAC GTCGATAC 288 (2) INFORMATION FOR SEQ ID NO: 197: (i) SEQUENCE CHARACTERISTICS: 25 (A) LENGTH: 289 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 197: pGGGCACCT TCAATATCAT GACAGGTGAT GTGATAACCA AGAAGGCTAC TAAGTGApA 60 ATGGGTGGGT AATGTATACA GAGTAGGTAC ACTGGACAGA GGGGTAApC ATAGCCAAGG 120 CAGGAGAAGC AGAATGGCAA AACATpCAT CACACTACTC AGGATAGCAT GCAGpTAAA 180 ACCTATAAGT AGTTTApp TGGAATpTC CACpAATAT pTCAGACTG CAGGTAACTA 240 AACTGTGGAA CACAAGAACA TAGATAAGGG GAGACCACTA CGTCGATAC 289 (2) INFORMATION FOR SEQ ID NO: 198: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 288 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 198: GTATCGACGT AGTGGTCTCC CAAGCAGTGG GAAGAAAACG TGAACCAAp AAAATGTATC 60 AGATACCCCA AAGAAAGGCG CpGAGTAAA GApCCAAGT GGGTCACAAT CTCAGATCTT 120 AAAApCAGG CTGTCAAAGA GATpGCTAT GAGGpGCTC TCAAT6ACTT CAGGCACAGT 180 CGGCAGGAGA pGAAGCCCT GGCCApGTC AAGATGAAGG AGCpTGTGC CATGTATGGC 240 AAGAAAGACC CCAATGAGCG GGACTCCTGG AGACCACTAC GTCGATAC 288 (2) INFORMATION FOR SEQ ID NO: 199: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1027 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single 15 (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 199: twenty * GCTTpTGGG AAAAACNCAA NTGGGGGAAA GGGGGNpNN TNGCAAGGGG ATAAAGGGGG 60 AANCCCAGGG pTCCCCAp CAGGGAGCTG TAAAAAGNCG GCCAGGGGAT TGTAANAGGA 120 pCAATAATA GGGGGAATGG GCCCNGAAGT TGCAAGGpC CNGCCCGCCA TGNCCGCGGG 180 ATpAGTGAC ApACGACGS TGGTAATAAA GTGGGSCCAA WAAATATpG TGATGTGAp 240 pTSGACCAG TGAACCCAp GWACAGGACC TCATpCCTY TGAGATGRTA GCCATAATCA 300 GATAAAAGRT TAGAAGTYp TCTGCACGp AACAGCATCA pAAATGGAG TGGCATCACC 360 AATpCACCC TTTGpAGCC GATACCpCC CCpGAAGGC ApCAApAA GTGACCAATC 420 GTCATACGAG. AGGGGATGGC ATGGGGApG ATGATGATAT CAGGGGTGAT ACCpCACAG 480 GTGAAAGGCA TATCCTCTTG TCTATACTGA ATACCACAAG TACCCTTTTG ACCATGTCGA 540 CTAGCAAAp TGTCTCCAAT CTGTGTWATC CCTAACAGAG CGTACCCpA ppACAAAA 600 TpATATCCT TCCTGApGA GAGpACCAT AACCTGATCC ACAATGCCCG TCTCGCTWGT 660 • TCTGAGAAAA GTGCTACAGT CTCTCpGGT ATAGCGTCTA pGGTGCTCT CCAApCATC 720 twenty pcApprc AGGCAAGGTG AACTGppG CCTATAATAA CMTCATCTCC TGATACMCGA 780 AACCCCKGGA RCTATCAAAC CATCATCATC CAGCGpCKT WATGTYMCTA AATCCCTAp 840 GCGGCCGCCT GCAGGTCAAC ATATNGGAAA ACCCCCCACC CCTTNGGAGC NTACCpGAA 900 ppCCATAT GTCCCNTAAA pANCTNGNC pANCCTGGC CNTAACCTNT TCCGGpTAA 960 ApGpTCCG CCCCCNpCC CCNCCpNNA ACCGGAAACC pAAppA ACCNGGGGp 1020 CCTATCC 1027 (2) INFORMATION FOR SEQ ID NO: 200: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 207 base pairs (B) TYPE: nucleic acid 15 (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 200: AGTGACApA CGACGCTGGC CATCpGAAT CCTAGGGCAT GAAGpGCCC CAAAGpCAG 60 CACTTGGpA AGCCTGATCC CTCTGGTGTA TCACAAAGAA TAGGATGGGA TAAAGAAAGT 120 GGACACpAA ATAAGCTATA AApATATGG TCCpGTCTA GCAGGAGACA ACTGCACAGG 180 TATACTACCA GCGTCGTAAT GTCACTA 207 (2) INFORMATION FOR SEQ ID NO: 201: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 209 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 201: TGGGCACCp CAATATCTAT TAAAAGCACA AATACTGAAG AACACACCAA GACTATCAAT 60 GAGGpACAT CTGGAGTCCT CGATATATCA GGAAAAAATG AAGTGAACAT TCACAGAGp 120 pAcpcpr GGGAACTCAA ATGCTAGAAA AGAAAAGGGT 6ccctctpc TCTGGCGTCC? ßo TGGTCCTATC CAGCGTCGTA ATGTCACTA 209 2) INFORMATION FOR SEQ ID NO: 202: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 349 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single 20 (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 202: NTACGCTGCA ACACTGTGGA GCCACTGGp pTApCCCG GCAGGpATC CAGCAAACAG 60 TCACTGAACA CACCGAAGAC CGTGGTATGG TAACCGpCA CAGTAATCGT TCCAGTCGTC 120 TGCGGGACCC CGACGAGCGT CACTGGGTAC AGACCAGAp CAGCCGGAAG AGAAAGCGCC 180 GCAGGGAGAG ACTCGAACTC CACTCCGCTG GTGAGCAGCC CCATGTpTC AACTCGAAGT 240 TCAAACGGCA pGGGpATA TACCATCAGC TGAACTTCAC ACACATCTCC pGAACCCAC 300 TGGAAATCTA TpTCpGp CCGCTCTTCT CCACAGTGp GCAGCGTAA 349 (2) INFORMATION FOR SEQ ID NO: 203: 10 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 241 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear 15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 203: TGCTCCTCp GCCTTACCAA CCCAAAGCCC ACTCTGAAAT ATGAAGTGAA TGACAAAAp 60 CAGTpTCAA CGCAATATAG TATAGpTAT CTGApcpT TGATCTCCAG GACACpTAA 120 ACAACTGCTA CCACCACCAC CAACCTAGGG ApTAGGAp CTCCACAGAC CAGAAATTAJ 180 pCTCCTTTG AGpTCAGGC TCCTCTGGGA CTCCTCTTCA TCAATGGGTG GTAAATGGCT 240 A 241 (2) INFORMATION FOR SEQ ID NO: 204: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 248 base pairs (B) TYPE: nucleic acid 5 (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 204: TAGCCApTA CCACCCATCT GCAAACCSWG ACMWWCARGR CYWGMACKYA GGCGATpGA 60 0 AGTACTGGTA ATGCTCTGAT CATGpAGp ACATAAGTGT GGTCAGTpA CAAAAApCA 120 CAGAACTAAA TACTCAATGC TATGTGpCA TGTCTGTGp TATGTGTGTG TAATGTpCA 180 ApAAGpp pTAAAAAAA AGAGATGAp TCCAAATAAG AAAGCCGTGT TGGTAAGGCA 240 AGAGGAGC 248 fifteen (2) INFORMATION FOR SEQ ID NO: 205: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 505 base pairs 20 (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 205: TACGCTGCAA CACTGTGGAG CCApCATAC AGGTCCCTAA pAAGGAACA AGTGApATG 60 CTACCTpGC ACGGpAGGG TACCGCGGCC GpAAACATG TGTCACTGGG CAGGCGGTGC 120 CTCTAATACT GCTGATGCTA GAGGTGATGT TpTGGTAAA CAGGCGGGGT AAGATpGCC 180 AGpapT TACI 111111 AACCTGTCCT TATGAGCATG CCTGTGpGG GpGACAGTG 240 GGGGTAATAA TGACpGpG GpGApGTA GATApGGGC TGpAApGT CAGpCAGTG 300 * TpTAATCTG ACGCAGGCp ATGCGGAGGA GAATGTpTC ATGpACpA TACTAACAp 360 AGpcpCTA TAGGGTGATA GApGGTCCA ApGGCTGTG AGGAGpCAG pATATGTp 420 GGGATTpp AGGTAGTGGG TGpGANCp GAACGCpTC pAApGGTG GCTGCTpTA 480 RGCCTACTAT GGGTGGTAAA TGGCT 505 (2) INFORMATION FOR SEQ ID NO: 206: (i) SEQUENCE CHARACTERISTICS 15 (A) LENGTH: 179 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 206: TAGACTGACT CATGTCCCCT ACCAAAGCCC ATGTAAGGAG CTGAGpcp AAAGACTGAA 60 GACAGACTAT TCTCTGGAGA AAAATAAAAT GGAAApGTA CpTAAAAAA AAAAAAAATC 120 GGCCGGGCAT GGTAGCACAC ACCTGTAATC CCAGCTACTA GGGGACATGA GTCAGTCTA 179 (2) INFORMATION FOR SEQ ID NO: 207: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 176 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 207: AGACTGACTC ATGTCCCCTA CCCCACCTTC TGCTGTGCTG CCGTGpCCT AACAGGTCAC 60 AGACTGGTAC TGGTCAGTGG CCTGGGGGp GGGGACCTCT ApATATGGG ATACAAATp 120 AGGAGpGGA ApGACACGA pTAGTGACT GATGGGATAT GGGTGGTAAA TGGCTA 176 (2) INFORMATION FOR SEQ ID NO: 208: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 196 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 208: AGACTGACTC ATGTCCCCTA TpAACAGGG TCTCTAGTGC TGTGAAAAAA AAAAATGCTG 60 AACApGCAT ATAACpATA pGTAAGAAA TACTGTACAA TGACTpAp GCATCTGGCT 120 AGCTGTAAGG CATGAAGGAT GCCAAGAAGT pAAGGAATA TGGGTGOTAA ATGGCTAGGG 180 GACATGAGTC AGTCTA 196 - »• - (2) INFORMATION FOR SEQ ID NO: 209: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 345 base pairs 10 (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xí) SEQUENCE DESCRIPTION: SEQ ID NO.209: GACGCTTGGC CACpGACAC CpTTApp pAAGGApC pAAGTCAp TANGTNACp 60 TGTAAGpp TCCTGTGCCC CCATAAGAAT GATAGCpTA AAAApATGC TGGGGTAGCA 120 AAGAAGATAC pCTAGCTp AGAATGTGTA GGTATAGCCA GGApCpGT GAGGAGGGGT 180 GATTTAGAGC AAApTCTTA pCTCCpGC CTCATCTGTA ACATGGGGAT AATAATAGAA 240 CTGGCpGAC AAGGpGGAA pAGTApAC ATGGTAAATA CATGTAAAAT GTpAGAATG 300 GTGCCAAGTA TCTAGGAAGT ACTTGGGCAT GGGTGGTAAA TGGCT 345 (2) INFORMATION FOR SEQ ID NO: 210: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 178 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 210: GACGCTTGGC CACpGACAC TAGAGTAGGG pTGGCCAAC TTTpCTATA AAGGACCAGA 60 GAGTAAATAT pCAGGCTp GTGGGpGTG CAGTCTCTCT TGCAACTACT CAGCTCTGCC 120 ApGTAGCAT AGAAATCAGC CATAGACAGG ACAGAAATGA ATGGGTGGTA AATGGCTA 178 (2) INFORMATION FOR SEQ ID NO: 211: (i) SEQUENCE CHARACTERISTICS: 15 (A) LENGTH: 454 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 211: 20 TGGGCACCp CAATATCTAT CCAGCGCATC TAAApCGCT ppTCTTGA ITAAAAApT 60 CACCACTTGC TGTTTpGCT CATGTATACC AAGTAGCAGT GGTCTGAGGC CATGCTTGp 120 ppGApCG ATATCAGCAC CGTATAAGAG CAGTGCTpG GCCApAAp TATCTTCAp 180 GTAGACAGCA TAGTGTAGAG TGGTATCTCC ATACTCATCT GGAATATpG GATCAGTGCC 240 ATGpCCAGC AACApAACG CACApCATC pCCTGGCAT TGTACGGCCT pGTCAGAGC 300 TGTCCTCTp pGpGTCAA GGACApAAG pGACATCGT CTGTCCAGCA CGAGTpTAC 360 TACpCTGAA pCCCApGG CAGAGGCCAG ATGTAGAGCA GTCCTCTTp GCpGTCCCT 420 i _ * ^ CTTGpCACA TCAGTGTCCC TGAGCATAAC GGAA 454 2) IN FORMATION FOR SEC ID NO: 212: (i) CHARACTERISTICS OF SECUENC IA: (A) LONGITU D: 337 base pairs (B) TYPE: nucleic acid (C) FORM OF HI LO: simple 15 (D) TOPOLOGY: line l ^? (xi) SEQUENCE DESCRIPTION: SEC I D NO.212: twenty ^^ ~ TCCGpATGC CACCCAGAAA ACCTACTGGA GpACTTAp AACATCAAGG CTGGAACCTA 60 pTGCCTCAG TCCTATCTGA pCATGAGCA CATGGpAp ACTGATCGCA pGAAAACAT 120 TGATCACCTG GGTpcpTA pTATCGACT GTGTCAT6AC AAGGAAACp ACAAACTGCA 180 ACGCAGAGAA ACTApAAAG GTApCAGAA ACGTGAAGCC AGCAApGp TCGCAApCG 240 GCAppGAA AACAAApTG CCGTGGAAAC TpAApTGT TCTTGAACAG TCAAGAAAAA 300 # CApApGAG GAAAApAAT ATCACAGCAT AACGGAA 337 (2) INFORMATION FOR SEQ ID NO: 213: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 715 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single 15 (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 213: twenty TCGGGT6ATG CCTCCTCAGG CATCTTCCAT CCATCTCTTC AAGApAGCT GTCCCAAATG 60 ppTCCpC TCpcpTAC TGATAAATp GGACTCCpC pGACACTGA TGACAGCTp 120 AGTATCCpC pGTCACCp GCAGACpTA AACATAAAAA TACTCApGG ppAAAAGG 180 AAAAAAGTAT ACApAGCAC TApAAGCp GGCCpGAAA CAppCTAT CTpTApAA 240 ATGTCGGpA GCTGAACAGA ApCA TTA CAATGCAGAG TGAGAAAAGA AGGGAGCTAT 300 ATGCATpGA GAATGCAAGC ApGTCAAAT A CATTíTA AATGCTpCT TAAAGTGAGC 360 ACATACAGAA ATACApAAG ATApAGAAA GTGTTTpGC pGTGTACTA CTAApAGGG 420 AAGCACCTTG TATAGpCCT CpCTAAAAT TGAAGTAGAT pTAAAAACC CATGTAATTT 480 AApGAGCTC TCAGpCAGA TpTAGGAGA AppAACAG GGApTGGp pGTCTAAAT 540 pTGTCMp TNpTAGpA ATCTGTATAA TTGTATAAAT GTCAAACTGT AIGTACTCCG ßoo TTpCATGCT GCTATGAAAG AAATACCCAN GACAGGGpA pTATAAANG GAAAGANGp 660 (2) INFORMATION FOR SEQ ID NO: 214: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 345 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 214: GGGApCGGG TGATGCCTCC 60 TCAGGCCCAC pGGGCCTGc T? TCCCAAA TGGCAGCTCC TCTGGACATG CCApCCTTC 120 TCCCACCTGC CTGApcpc ATATGpGGG TGTCCCTGp pTCTGGTGC TATTTCCTGA 180 CTGCTGpCA GCTGCCACTG TCCTGCAAAG CCTGCCTTp TAAATGCCTC ACCApCCTT 240 CATpG rC pAAATATGG GAAGTGAAAG TGCCACCTGA GGCCGGGCAC AGTGGCTCAC 300CCAGCACTp GGGAGCCTGA GGAGGCATCA CCCGA 345 (2) INFORMATION FOR SEQ ID NO: 215: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 429 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single 15 (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 215: ATCCTTCTGA CCT? TGGGT pTAAGCAGG AGGTGTCAGA AAAGpACCA CAGGGATAAC 180 TGGCTTGTGG CGGCCAAGCG pCATAGCGA CGTCGCTpT TGATCCTTCG ATGTCGGCTC 240 pCCTATCAT TGTGAAGCAG AApCACCAA GCGpGGAp GpCACCCAC TAATAGGGAA 300 CGTGAGCTGG GpTAGACCG TCGTGAGACA GGpAGpiT ACCCTACTGA TGATGTGTKG 360 pGCCATGGT AATCCTGCTC AGTACGAGAG GAACCGCAGG pCASACAp TGGTGTATGT 420 GCpGCCTT 429 : 216: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 593 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID NO: 216: TGACACCTAT GTCCNGCATC TGpCACAGT pCCACAAAT AGCCAGCCTT TGGCCACCTC 60 TCTCTCCTGA GGTATACAAG TATATCAGGA GGTGTATACC pCTCTTCTC pCCCCACCA 120 AAGAGAACAT GCAGGCTCTG GAAGCTGTCT TAGGAGCCTT TGGGCTCAGA ATpCAGAGT 180 CpGGGTACC pGGATGTGG TCTGGAAGGA GAAACATTGG CTCTGGATAA GGAGTACAGC 240 CGGAGGAGGG TCACAGAGCC CTCAGCTCAA GCCCCTGTGC CTTAGTCTAA AAGCAGCTH 300 GGAT6AGGAA GCAGGpAAG TAACATACGT AAGCGTACAC AGGTAGAAAG TGCTGGGAGT 360 CAGAApGCA CAGTGTGTAG GAGTAGTACC TCAATCAATG AGGGCAAATC AACTGAAAGA 420 - AGAAGACCNA pAATGAAp GCpANGGGG AAGGATCAAG GCTATCATGG AGATCTpCT 480 2Q AGGAAGApA pGpTANAA pATGAAAGG ANTAGGGCAG GGACAGGGCC AGAAGTANAA 540 GANAACApG CCTATANCCC pGTCpGCA CCCAGATGCT GGACAAGGTG TCA 593 (2) INFORMATION FOR SEQ ID NO: 217: (i) SEQUENCE CHARACTERISTICS: 25 (A) LENGTH: 335 base pairs (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEC ID NO: 217: TGACACCTTG TCCAGCATCT GACGTGAAGA TGAGCAGGTC AGAGGAGGTG TCCTGGApT 60 CCTGGpCTG TGGGCTCCGT GGCAATGAAT TCTTCTGTGA AGTGGATGAA GACTACATCC 120 AGGACAAAp TAATCpACT GGACTCAATG AGCAGGTCCC TCACTATCGA CAAGCTCTAG_180_* ACATGATCp GGACCTGGAG CCTGATGAAG AACTGGAAGA CAACCCCAAC CAGAGTGACC 240 TGApGAGCA GGCAGCCGAG ATGCTpATG GApGATCCA CGCCCGCTAC ATCCpACCA 300 ACCGTGGCAT CGCCCAGATG CTGGACAAGG TGTCA 335 (2) INFORMATION FOR SEQ ID NO: 218: 1-5 (i) SEQUENCE CHARACTERISTICS: * (A) LENGTH: 248 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear 23 (? ¡) DESCRIPTION OF SEQUENCE: SEQ ID NO: 218: TCAAAGACTA 60 TGTATGAAAT GGGACTGTAA GTACAGAGGG AAGGGTGGCC CpATCGCCA GAAGpGGTA 120 GATGCGTCCC CCTCATGAAA TGpCTGTCA CTGCCCGACA pTGCCGAAT TACTGAAAp 180 CCGTAGAAp AGTGCAAAp CTAACGpGT TCATCTAAGA pATGGpCC ATGpTCTAG_240_TAC? TTA 248 (2) INFORMATION FOR SEQ ID NO: 219: (i) SEQUENCE CHARACTERISTICS: 10 (A) LENGTH: 530 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID N0.219: TGACGCpGG CCACpGACA CAAGTAGGGG ATAAGGACAA AGACCCATNA GGTGGCCTGT 60 * CAGCCpTTG pACTGpGC pCCCTGTCA CCACGGCCCC CTCTGTAGGG GTGTGCTGTG 120 CTCTGTGGAC ApGGTGCAT pTCACACAT ACCApCTCT pCTGCTTCA CAGCAGTCCT 180 GAGGCGGGAG CACACAGGAC TACCpGTCA GATGANGATA ATGATGTCTG GCCAACTCAC 240 CCCCCAACCT TCTCACTAGT TATANGAAGA GCCANGCCTA NAACCTTCTA TCCTGNCCCC 300 pGCCCTATG ACCTCATCCC TGpCCATGC CCTApCTGA pTCTGGTGA ACTpGGAGC 360 AGCCTGGTp NTCCTCCTCA CTCCAGCCTC TCTCCATACC ATGGTANGGG GGTGCTCTTC 420 CACNCAAANG GTCAGGTGTG TCTGGGGAAT CCTNANANCT GCCNGGAGp TCCNANGCAT 480 TCpAAAAAC CpcpGCCT AATCANATNG TGTCCAGTGG CCAACCNTCN 530 (2) INFORMATION FOR SEQ ID NO: 220: (i) SEQUENCE CHARACTERISTICS: (A) LONGITU D: 531 base pairs (B) TI PO: nucleic acid (C) HI FORM: simple (D) TOPOLOGY 'linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 220: TCTTCTAAAG GCCTGA? CA GAG? GTGGA 60 AAA? CTCCC AGTGTCAGGG A? GTCAGGA ACAGGGCTGC TCCTGTGCTC ACT? ACCTG 120 CTGTGTGGCT GCTGGAAAAG GAGGGAAGAG GAATGGCTGA ITG? ACCTA ATGTCTCCCA ISO 5 GTT? TCATA pcpcpGG ATCCTCTTCT CTGACAACTG pcccppG GTcpcpcT 240 TCpGCTCAG AGAGCAGGTC TCpTAAAAC TGAGAAGGGA GAATGAGCAA ATGApAAAG 300 % AAAACACACT TCTGAGGCCC AGAGATCAAA TApAGGTAA ATACTAAACC GCpGCCTGC 360 TGTGGTCACT pTCTCCTCT pCACATGCT CTATCCCTCT ATCCCCCACC TApCATATG 420 GCTpTATCT GCCAAGpAT CCGGCCTCTC ATCAACCpC TCCCCTAGCC TACTGGGGGA 480 TATCCATCTG GGTCTGTCTC TGGTGTApG GTCTCAAGTG GCCAAGCGTC A 531 (2) INFORMATION FOR SEQ ID NO: 221: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 530 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single 20 (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 221: ApGACGCp GGCCACp & CACCCGCCTG CCTGCAATAC TGGGGCAAGG GCCpCACTG 60 CpTCCTGCC ACCAGCTGCC ACTGCACACA GAGATCAGAA ATGCTACCAA CCAAGACTGT 120 TGGTCCTCAG CCTCTCTGAG GAGAAAGAGC AGAAGCCTGG AAGTCAGAAG AGAAGCTAGA 180 TCGGCTACGG CCTTGGCAGC CAGCpCCCC ACCTGTGGa ATAAAGTCGT GaTGGCTTA 240 ACAATGGGGG CACCTCCTGA GAAACACAp GpAGGCAAT TCGGCGTGTG pCATCAGAG 300 CATATpAa CAAACCTCGA TAGTGCAGCC TACTATCaC TApGCTCCT ACGCTGCAAA 360 -? - CCTGAACAGC ATGGGACTGT ACTGAATACT GGAAGCAGCT GGTGATGGTA CpApTGTG 420 TATCTAAAa CAGAGAAGGT ACAGTAAGAA TATGGTATa TAAACpAa GGGACCGCCA 480 TCCTATATGC AGTCTGpGT GACCAAAATG TGTCAAGTGG CCAAGCGTCA 530 (2) INFORMATION FOR SEQ ID NO: 222: 15 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 578 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 222: ACCTGGpCA 60 CTGAAAGGCG aTCTCCCTC CCCGCGTCGC CCTGAAGCAG GGGGAGGACT TCGCCCAGCC 120 AAGGCAGpG TATGAGTTp AGCTGCGGCA CpCGAGACC TCTGAGCCCA CCTCCpCAG 180 GAGCCpCCC CGApAAGGA AGCCAGGGTA AGGApCCTT CCTCCCCCAG ACACCACGAA 240 CAAACCACCA CCCCCCCTAT TCTGGCAGCC CATATACATC AGAACGAAAC AAAAATAAa 300 ? ^ k AATAAACNAA AACCAAAAAA AAAAGAGAAG GGGAAATGTA TATGTCTGTC aTCCTGpG 360 CpTAGCCTG TCAGCTCCTA NAGGGCAGGG ACCGTGTCp CCGAATGGTC TGTGCA6CGC 420 CGACTGCGGG AAGTATCGGA GGAGGAAGCA GAGTCAGCAG AAGpGAACG GTGGGCCCGG 480 CGGCTCpGG GGGCTGGTGT TGTACpCGA GACCGCpTC GCTTTpGTC TTAGApTAC 540 GT TGCTCp TGGAGTGGGA NACCACTACN TCNATACA 578 (2) INFORMATION FOR SEQ ID NO: 223: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 578 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single 20 (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 223: TGTATCGACG TAGTGGTCTC CTCpGCAAA GGACTGGCTG GTGAATGGp TCCCTGAAp 60 ATGGACTTAC CCTAAAaTA TCTTATaTC ApACCAGp GCAAAATAp AGAATGTGp 120 GTCACTGTp apTGApC CTAGAAGGp AGTCTTAGAT ATGpACTp AACCTGTATG 180 CTGTAGTGCT pGAATGaT ppTGpTG ppTGp TGCCCAACCT GTCAApATA 240 GCTGCpAGG TCTGGACTGT CCTGGATAAA GCTGpAAAA TApCACCAG TCCAGCCATC 300 pACAAGCTA ApAAGTCAA CTAAATGCTT CCTTGppG CaGACpGT TATGTCAATC 360 CTCAATpCT GGGpapr TGGGTGCCCT AAATCTTAGG GTGTGAcpr cpAGaTcc 420 TGTAAaTCC ApCCCAAGC AAGaCAACT TaaTAATA CTpCCAGAA Gp pGCT 480 GAAGCCpTC CpaCCCAG CGGAGCAACT TGATpTCTA CAACpCCCT aTCAGAGCC 540 ACAAGAGTAT GGGATATGGA GACaCTACG TCGATAa 578 (2) INFORMATION FOR SEQ ID NO: 224: 15 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 345 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear 20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 224: CaCTCCCAG 60 GTGGATcpr pcpTATAC pAcpap AGGTpcTCT TApcAAGAA GTGTAGTGGT 120 AAAAGTCTp TCAATCTAa TGGpAAATA ATGATAGCCT GGGAAATAAA TAGAAATpT 180 pcpraTc rAGGpGA ATAAAGAAAC AGAAAAAATA GAAaTACTG AAAATAATCT 240 AAGpCCAAC aTAGAAGAA CTGCA6AA6A AATGAAGAAA GTGATGATGA THAGATm 300 GATApGAp TAGAAGAaC AGGAGGAGAC aCTACGTCG ATAa 345 (2) INFORMATION FOR SEQ ID NO: 225: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 347 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 225: twenty TGTATCGACG TAGTGGTCTC CAAACTGAGG TATGTGTGCC ACTAfíCACAC AAAGCCTTCC 60 AACAGGGACG aGG OGG CAGpTAAAG GGAATCTGp TCTAAApAA pTC CCTT 120 CTCTAAGTAT TCTpCCTAA AACTGATCAA GGTGTGAAGC CTGTGCTCp TCCCAACTCC 180 CCpTGACAA OGCCpCAA CTAACACAAG AAAAGGaTG TCTGAaCTC pCCTGAGTC 240 TGACTCTGAT ACGpGpCT GATGTCTAAA GAGCTCCAGA ACACCAAAGG GACAApCAG 300 * AATGCTGGTG TATAACAGAC TCCAATGGAG ACaCTACGT CGATAa 347 (2) INFORMATION FOR SEQ ID NO: 226: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 281 base pairs (B) TYPE: nucleic acid 15 (C) THREAD FORM: single (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 226: twenty AGGNGNGGGA NTGTATCGAC CTAGTGCTCT CCCAACAGTC TGT p G TCTGCAGGTG 60 TCAGTGTTp GGACAATGAG GCACapGT cpApGA CTCCTCAGCT CTAAATGCTG 120 AAApAAATC pGTaTaC AAGTCTGGAA pCCTGATGA GGTTpACAA AGTATpTGG 180 ATCAATACTC CAACAAATCA GAAAGCaGA AAGAGGATCC TTTCAATAp GaGAACaC 240 GAGTGGApT AaaCCTa GGAGACCACT ACGTCGATAC A 281 * (2) INFORMATION FOR SEQ ID NO: 227: (i) SEQUENCE CHARACTERISTICS: 10 (A) LENGTH: 3646 base pairs (B) TYPE: nucleic acid (C) THREAD FORM: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 227: fifteen twenty # GGGAAAaCT TCCTCCaGC CTTGTAAGGG pGGAGCCCT CTCCAGTATA TGCTGaGAA 60 TTTpCTCTC GGTpCTaG AGGApATGG AGTCCGCCp AAAAAAGGCA AGCTCTGGAC 120 ACTCTGCAAA GTAGAATGGC CAAAGTpGG AGpGAGTGG CCCCpGAAG GGTaCTGAA 180 CCTaCAAp GpCAAGCTG TGTGGCGGGT TGpACTGAA ACTCCCGGCC TCCCTGATa 240 GTpCCCTAC ApGATCAAT GGCTGAGTp GGTCAGGAGC ACCCCTTCCG TGGCTCaCT 300 TG c T TaTAApp ACCTCCAAGG TCCTCCTGAG CCAGACCGTG ppcGCCTC 360 «GACCCTCAGC CGGpCGGCT CGCCCTGTAC TGCCTCTCTC TGAAGAA6AG GAGAGTCTCC 420 CTCACCCAGT CCaCCGCCT TAAAACCAGC CTACTCCCTT AGGGTaTCC aTGTCTCCT 480 fifteen twenty CGGCTATGTC CCCTGTAGGC TaTOCCa pGCCTCTTG GpGCAACCG TGGTGGGAGG 540 AACTAGCCCC TCTACTACa CTGAGAGAGG aCAAGTCCC TCTGGGTGAT GAGTGCTCa 600 CCCCCpCCT GGpTATGTC CCTTCpTCT ACpCTGACT TGTATAApG GAAAACCaT 660 AATCCTCCCT TCTCTGAAAA GCCCCAGGCT pGACCTCAC TGATGGAGTC TGTACTCTGG 720 ACAapGGC CaCCTGGGA TGACTGTCAA CAGCTCCTIT TGACCCTpT aCCTCTGAA 780 * aGAGGGAAA GTATCCAAAG AGAGGCCAAA AAGTACAACC TaaTOAC CAATAGGCCG 840 GAGGAGGAAG CTAGAGGAAT AGT pAa GACCCAApG GGACCTAAp GGGACCCAAA 900 pTCTCAAGT GGAGGGAGAA CTpTGACGA TTTCaCCGG TATCTCCTCG TGGGTApCA 960 GGGAGCTGCT CAGAAACCTA TAAACpGTC TAAGGCGACT GAAGTCGTCC AGGGGaTGA 1020 TaGTCAc GGAGTGG? T TAGAGCACCT CCAGGAGGCT TATCAGATp Aaccccpr íoßo TaCCTGG GCCCCCGAAA ATAGCaTGC TCpAApTG GaTTTGTGG CTCAGGCAGC 1140 CCCAGATAGT AAAAGGAAAC TCCAAAAACT AGAGGGATTT TGCTGGAATG AATACCAGTC 1200 AGCTpTAGA GATAGCCTAA AAGGTmTG AaGTCAAGA GGpGAAAAA CAAAMCAAG 1260 CAGCTCAGGC AGCTGAAAAA AGCaCTGAT AAAGaTCCT GGAGTATaG AGpTACTGT 1320 TAaT GCC TCATpaCT TCCCCTCCa aTGGTGTp AAATCaGCT AaCTACTTC 1380 CTGACTCAAA CTCaCTAp CCTGpaTG ACTGTCAGGA ACTGpGGAA ACTACTGAAA 1440 CTGGCCGACC TGATCTTCAA AATGTGCCCC TAGGAAAGGT GGATGCCACC ATGpaaG 1500 AaGTAGaG CpCCTCGAG AAGOaCTAC GAAAGGCCGG TGCAGCTGp ACaTGGAGA 1560 CAGATGTGp GTGGGCTCAG GCTpACCAG OAAaCCTC AGaCAAAAG GCTGAApa 1620 TCGCCCTaC TCAGGCTCTC CGATGGGGTA AGGATApAA COTTV CT GACAGCAGGT 1680 ACGCCTpGC TACTGTGaT GTACGTGGAG CaTCTACa GGAGCGTGGG CTACTCACCT 1740 CAGaGGTGG CTGTAATCa CTGTAAAGGA aTOAAAGG AAAAaCGGC TGpGCCCGT 1800 GGTAACCAa AAGCTWTC AGCAGCTCAA aTGaGTGT GACTpCAGT aCGCCTCTA 1860 AAcpGCTGC caaGTCTc ctpcaoG COGATCTGC CTGACAATCC CGaTACTa 1920 ACAGAAGAAG AAAACTGGCC TCAGAACTa GAGCCAATAA AAATCAGGAA GGpGGTGa 1980 pcpccrra CTCTAGAATC paTACCCC GAActcp &G GAAAAc rA ATCAGTCACC 2040 TAaGTCTAC aCCaTTTA GGAGGAGCAA AGCTACCTa GCTCCTCCGG AGCCGTpTA 2100 AaYcccca TC? OAAGC CTAAaaTC AAGCAGCTCT CCGGTGaa ACCTGCGCCC 2160 AGGTAAATGC CAAAAAAGGT CCTAAACCa GCCaGGCa CCGTCTCCAA GAAAACTaC 2220 GaGAAAA GTGGGAAAp ac TAaG AAGTAAAACC AaCCGGGCT GGGTACAAAT 2280 ACCpCTAGT ACTGGTAaC ACCTTCTCTG aTGGACTa AGaiTTGCT ACCAAAAACG 2340 AAACTGTCAA TATGGTAGp AAGppTAC TCAATGAAAT aTCCCTCa aTGGGCTGC 2400 CTGlTTGCa TAGGGTCTa TAATGaCCG GCCpCGCCT TGTCTATAGT 1TAGTCAGTC 2460 AGTAAGGCGT TAAAapCA ATGGAAGCTC apGTGCCT ATCGACCCa aGCTCTGGG 2520 CAAGTAGAAC GaTGAACTG CACCCTAAAA AAaCTCpA CAAAApAAT CpAGAAACC 2580 GGTGTAAAp GTGTAAGTCT CCTTCCTpA GCCCTACTTA GAGTAAGGTG CACCCCpAC 2640 TGGGCTGGGT TCTTACCTp TGAAATaTG TATGGGAGGG TGCTGCCTAT CTTGCCTAAG 2700CCCAApGGC AAAAATATa OAACTAAp TApACAGTA CCTACAGTCT 2760 CCCCAACAGG TACAAaTAT aTCCTGCa CTTCTTCaG GAACCaTCC CAATCCAAp 2820 CCTGAACAGA CAGGGCCCTG C papC CCGCCAGGTG ACCTGpGp TGpAAAAAG 2880 pCCAGAGAG AAGGACTCCC TCCTGCTTGG AAGAGACCTC AaCCGT T CaTGC 2940 * ACGGCTCTGA AGGTGaTGG apCCTGCG TGGApaTC ACTCCCGaT CAAAAAGGCC 3000 AACAGAGCCC AACTAGAAAC ATGGGTCCCC AGGGCTGGCT CAGGCCCCp AAAACTGCAC 3060 CTAAGpGGG TGAAGCap AapAApC pTCpAA ppCTAAAA CAATGaTAG_3120_CpCTGTCAA ACTTATGTAT CTTAAaCTC AATATAACCC CCpGpATA ACTGAGGAAT 3180 CAATaTpG ApCCCCCAA AAAaOAGT GGGGAATGTA GTGTCCAACC TGGTTpTAC 3240 TAACccTGp pTAacTCT cccrpccp TAATaar GcpGprcc AccTG pG 3300 ACTCTcccp AGCTAA GC Gca TG CTcaTcpG GCTCTGTCAC TGGCAGCCGC 3360 pCCTCAAGG ACpAACpG TGCAAGCTa CTCCCAGaC ATCCAAGAAT GCAApAACT 3420 , 20 GATAAaTAC TGTGGCAAGC TATATCCGa GpCCCAGGA ApCCTCCAA p Ta AG 3480 CCCCTCTACC CpCAGCAAC acaCCCTG ATCAGTaGC AGCaTCAGC ACCGAGGCAA 3540 GGCCCTCaC CAGOAAAAG ApCTGACTC ACTGAAaCT TGGATaTCA pAGTATTIT 3600 TAGCAGTAAA GH I H U I I CppTCTp CT I H U ICT CGTGCC 3646 25

Claims (17)

1. CLAIMS 1. An isolated DNA molecule, comprising: (a) a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3 - SEQ ID NO: 77 and SEQ ID NOS: 142, 143 , 146-152, 154-166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-227; (b) a variant of said nucleotide sequence containing one or more substitutions, deletions, insertions and / or modifications of nucleotides and no more than 20% of the nucleotide positions, so that the antigenic and / or immunogenic properties of the polypeptide encoded by the nucleotide sequence are retained; or (c) a nucleotide sequence encoding an epitope of a polypeptide encoded by at least one sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3 -SEC ID NO: 77 and SEQ ID NOS: 142, 143, 146-152, 154-166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-227.
2. 2. An isolated DNA molecule encoding an epitope of a polypeptide, wherein the polypeptide is encoded by a nucleotide sequence that: (a) hybridizes to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO. : 3 - SEQ ID NO: 77 and SEQ ID NOS: 142, 143, 146-152, 154-166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216 , 218, 219, 221-227 under strict conditions; and - (b) is at least 80% identical to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3 - SEQ ID NO: 77 and SEQ ID NOS: 142, 143, 146-152 , 154-166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-227; 5 and wherein the RNA corresponding to the nucleotide sequence is expressed at a higher level in human breast tumor tissue than in normal breast tissue.
3. 3. An isolated DNA molecule that encodes an epitope of a * polypeptide, wherein the polypeptide is encoded by: (a) a nucleotide sequence transcribed from the sequence of SEC I D NO: 141; or (b) a variant of the nucleotide sequence containing one or more substitutions, deletions, insertions and / or nucleotide modifications in no more than 20% of the nucleotide positions, so that the antigenic and / or immunogenic properties of the polypeptide encoded by the nucleotide sequence are retained.
4. 4. An isolated DNA or AR N molecule comprising a nucleotide sequence complementary to a DNA molecule 20 according to one of the claims 1 -3.
5. 5. A recombinant expression vector comprising a DNA molecule according to any of claims 1 -3.
6. 6. A host cell transformed or transfected with the expression vector according to claim 5.
7. 7. A polypeptide comprising an amino acid sequence encoded by a DNA molecule according to any of claims 1-3.
8. A polypeptide according to claim 7, wherein the polypeptide comprises an epitope of an amino acid sequence encoded by at least one nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3 - SEQ ID NO: 77 and SEQ ID NOS: 142, 143. 146-152, 154- * 166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 10 218, 219, 221 -227
9. 9. A monoclonal antibody that binds to a polypeptide according to claim 7.
10. 10. A method for determining the presence of breast cancer in a patient comprising detecting, within a sample Biological, at least one polypeptide according to claim 7, and thus determine the presence of breast cancer in the patient.
11. 1 1. A method for determining the presence of breast cancer in a patient comprising detecting, within a sample Biological, at least one polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86 and SEQ ID NOS: 144, 145, 153, 167, 1 77, 193, 199, 205, 208 , 215, 217, 220, and sequences that hybridize to it under strict conditions.
12. 12. The method of claims 10 or 11, wherein the biological sample is a portion of a breast tumor. The method of claim 10, wherein the detection step comprises contacting the biological sample with a The monoclonal antibody according to claim 9. 14. The method of claim 1, wherein the detection step comprises contacting the biological sample with a monoclonal antibody that binds to a polypeptide encoded by * a nucleotide sequence selected from the group consisting of 10 SEC I D NO: 78-86 and SEQ ID NOS: 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, and sequences for hybridizing them under stringent conditions. 15. A method for determining the presence of breast cancer in a patient comprising detecting, within a sample A biological molecule, an RNA molecule encoding at least one polypeptide according to claim 7, and from which the presence of breast cancer in the patient is determined. 16. A method for determining the presence of breast cancer in a patient comprising detecting, within a sample Biological, at least one AR N molecule encoding a polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86 and SEQ ID NOS: 144, 145, 153, 167, 177, 193 , 199, 205, 208, 215, 217, 220, and sequences that hybridize thereto under stringent conditions; and determining from them the presence of breast cancer in the patient. The method of claim 15 or 16, wherein the biological sample is a portion of a breast tumor. 18. The method of claim 15, wherein the detection step comprises: (a) preparing cDNAs of RNA molecules within the biological sample; and (b) specifically amplifying cDNA molecules that are capable of encoding at least a portion of a polypeptide according to claim 7, and thus determining the presence of breast cancer in the patient. The method of claim 16, wherein the detection step comprises: (a) preparing a cDNA of RNA molecules within the fP &, biological sample; and (b) specifically amplifying cDNA molecules that are capable of encoding at least a portion of a polypeptide encoded by a nucleotide sequence selected from group 20 consisting of SEQ ID NO: 78-86 and SEQ ID NOS: 144, 145 , 153. 167, 177, 193, 199, 205, 208, 215, 217, 220, and sequences that hybridize thereto under strict conditions; and thus determine the presence of breast cancer in the patient. * 20. A polypeptide according to claim 7, for use within a method for detecting the presence of breast cancer in a patient. 21. A polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86 and SEC I D NOS: 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, and sequences that hybridize to them under strict conditions; and to be used within a method to detect the presence of * breast cancer in a patient. 22. A method for monitoring the progression of breast cancer in a patient, comprising: (a) detecting an amount, in a biological sample, of at least one polypeptide according to claim 7 at a first point in time; 15 (b) repeating step (a) at a subsequent point in time; and (c) comparing the amounts of polypeptides detected in steps (a) and (b) and monitoring the progression of breast cancer in the patient. 23. A method for monitoring the progression of breast cancer in a patient, comprising: (a) detecting in a biological sample an amount of at least one polypeptide at a first point in time, the polypeptide being encoded by a sequence of nucleotides selected from the group consisting of SEQ ID NO: 78-86 and SEQ ID NOS: 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, and sequences that hybridize to the same under strict conditions; (b) repeating step (a) at a subsequent point in time; and (c) comparing the amounts of polypeptides detected in the steps (a) and (b) and thus monitoring the progression of breast cancer in the patient. 24. The method of claim 22 or 23, wherein the < Biological sample is a portion of a breast tumor. The method of claim 22, wherein the detection step comprises contacting a portion of the biological sample with a monoclonal antibody according to claim 9. 26. The method of claim 23, wherein the step of of detection comprises contacting the biological sample with a 15 monoclonal antibody that binds to a polypeptide encoded by "t- a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86 and SEQ ID NOS: 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, and sequences for hybridizing thereto, under stringent conditions. 27. The method of any of claim 20 or 22, wherein the polypeptide comprises an epitope of an amino acid sequence encoded by at least one nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO. : 3 - SEQ ID NO: 77 and SEQ ID NOS: 142, 143, 146-152, 154-166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216 , 218, 219, 221-227. 28. A method for monitoring the progression of breast cancer in a patient comprises: (a) detecting an amount, in a biological sample, of at least one RNA molecule encoding a polypeptide according to claim 7 in a first point in time. (b) repeating step (a) at a subsequent point in time; and (c) comparing the amounts of RNA molecules detected in steps (a) and (b) and thus monitoring the progression of breast cancer in the patient. The method of claim 28, wherein the detection step comprises: (a) preparing cDNAs of RNA molecules within the biological sample; and (b) specifically amplifying cDNA molecules that are capable of encoding at least a portion of a polypeptide according to claim 7. 30. A method for monitoring the progression of breast cancer in a patient, comprising: (a) detecting an amount within a biological sample of at least one RNA molecule at a point in time, the AR N molecule encoding a polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86 and SEQ ID NOS: 144, 145, 1 53, 167, 177, 193, 199, 205, 208, 215, 217, 220, and sequences that hybridize thereto under stringent conditions; (b) repeating step (a) at a subsequent point in time; and (c) comparing the amounts of RNA molecules detected in steps (a) and (b) and thus monitoring the progression of breast cancer in the patient. 31. A pharmaceutical composition, comprising a polypeptide according to claim 7 and a physiologically acceptable carrier. 32. A pharmaceutical composition for inhibiting the development of breast cancer, comprising a polypeptide and a physiologically acceptable carrier, the polypeptide being encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86 and SEQ ID NO. NOS: 144, 145, 153, 167. 177, 193, 199, 205, 208, 215, 217, 220, and sequences to hybridize them under strict conditions. 33. A vaccine, comprising a polypeptide according to claim 7 and an immune response enhancer. 34. A vaccine, comprising a DN-molecule according to any of claims 1 -3. 35. A vaccine, comprising a recombinant expression vector comprising an A DN molecule according to any of claims 1-3. 36. A vaccine for inhibiting the development of breast cancer, comprising a polypeptide and an immune response enhancer, r a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86 and SEQ ID NOS: 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, and sequences that hybridize thereto under stringent conditions. 37. A diagnostic kit comprising: (a) one or more monoclonal antibodies according to claim 9; and (b) a detection reagent. 38. A diagnostic kit comprising: (a) one or more monoclonal antibodies that bind to a polypeptide encoded by a nucleotide sequence selected from the group consisting of sequences provided in SEQ ID NO: 78-86 and SEQ ID NOS : 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220; and 15 (b) a detection reagent. iF ^ 39. The equipment of any of claims 37 or 38, wherein the monoclonal antibodies are immobilized on a solid support. 40. A diagnostic kit comprising a first polymerase chain reaction primer and a second polymerase chain reaction primer, the first and second primers each comprising at least about 10 contiguous nucleotides of an RNA molecule of according to claim 4. ico comprising a first polymerase chain reaction primer and a second polymerase chain reaction primer, the first and second primers each comprising at least about 10 contiguous nucleotides of an RNA molecule encoding a polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86 and SEQ ID NOS: 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, * 217, 220. 10 42. A diagnostic kit comprising at least one of oligonucleotides, the oligonucleotide probe comprising at least 15 contiguous nucleotides of a DNA molecule according to claim 4. 43. A team of diagnosis comprising at least one 15 oligonucleotide probe, the oligonucleotide probe comprising at least about 15 contiguous oligonucleotides of a DNA sequence selected from the group consisting of SEQ ID NO: 78-86 and SEQ ID NOS: 144, 145, 153, 167, 177, 193, 199, 205, 208, 215 , 217, 220.